

CURRICULUM VITAE

Name: José BASELGA, M.D.

Date of birth: July 3rd, 1959

Place of birth: Barcelona, Spain

Nationality: Spanish

Office Address: Oncology Service
Vall d'Hebron University Hospital
Psg. Vall d'Hebron, 119-129
08035 Barcelona, Spain

Telephone Number: +34 932 746 085

Fax Number: +34 932 746 059

E-mail: jbaselga@vhio.net

Licensed physician:

1994 New York State Medical License # 195,159 (inactive)

1994 Barcelona Medical License # 18,199

Education:

1976-1982 School of Medicine - Universitat Autònoma de Barcelona. Barcelona, Spain.

Certificates:

1985 Educational Commission for Foreign Medical Graduates Certificate, USA.

1989 Board Certified in Internal Medicine. American Board of Internal Medicine, USA.

1991 Board Certified in Medical Oncology. American Board of Internal Medicine, USA.

1992 Ph.D. Cum Laude and Extraordinary Award. Universitat Autònoma de Barcelona ('School of Medicine'). Barcelona, Spain.

Postdoctoral Training:

- 1983-1984 Mandatory Military Service, Army Physician, Department of Medicine, Spanish Army, Spanish Army Hospital of Melilla. North Africa, Spain.
- 1984-1986 Residency, Department of Medicine, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona. Barcelona, Spain.
- 1986-1987 Internship, Department of Medicine, State University of New York, Health Sciences Center at Brooklyn. New York, USA.
- 1987-1989 Residency, Department of Medicine, State University of New York, Health Sciences Center at Brooklyn. New York, USA.
- 1989-1992 Fellowship, Medical Oncology, Memorial Sloan-Kettering Cancer Center. New York, USA.
- 1992-1994 Special Fellow, Department of Medicine, Memorial Sloan-Kettering Cancer Center. New York, USA.

Positions and Appointments:

- 1994-1996 Clinical Assistant Physician, Breast / Gynecology Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center. New York, USA.
- 1994-1996 Instructor of Medicine, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College. New York, USA.
- 1996- Professor of Medicine, Universitat Autònoma de Barcelona. Barcelona, Spain.
- 1996- Chairman, Medical Oncology Service, Vall d'Hebron University Hospital. Barcelona, Spain.
- 1996- Director, Medical Oncology, Hematology and Radiation Oncology Department, Vall d'Hebron University Hospital. Barcelona, Spain.
- 2007- Director, Vall d'Hebron Institute of Oncology (V.H.I.O.), Vall d'Hebron University Hospital. Barcelona, Spain.

Awards and Prizes:

- 1989 First Prize. Annual Research Competition for Residents, Department of Medicine. State University of New York, Health Sciences Center at Brooklyn.
- 1990-1991 Lederle Scholar in Clinical Oncology. Memorial Sloan-Kettering Cancer Center
- 1992 Travel Award. American Society of Clinical Oncology (ASCO).
- 1992-1993 Young Investigator Award. American Society of Clinical Oncology (ASCO).
- 1992-1994 Clinical Scholar Grant in Biomedical Research. Sloan-Kettering Institute.
- 1994- 1997 Career Development Award. American Society of Clinical Oncology (ASCO).
- 1999 Young Investigator Award. American Association for Cancer Research (AACR).
- 2002- 2006 Bristol-Myers Squibb Unrestricted Cancer Grant Award.

- 2003 Honorary Membership Award. The European Society for Therapeutic Radiology and Oncology (ESTRO).
- 2004 Waun Ki Hong Visiting Professorship. UTMD Anderson Cancer Center.
- 2004 Distinguished Alumni Award. 29th Annual Alumni Society Meeting. Memorial Sloan-Kettering Cancer Center.
- 2004 Elected Member. American Society of Clinical Investigation (ASCI).
- 2005 Annual Award. European Society of Medical Oncology (ESMO).
- 2005 Professional Excellence Award in Biomedicine Research. Barcelona College of Physicians.
- 2006 City Award “La Clau de la Ciutat de Barcelona” (*“The Key to the City of Barcelona”*).
- 2006 Michael Clavel Lecture Award. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
- 2006 San Salvatore Prize 2006. San Salvatore Foundation.
- 2007 American- Italian Cancer Foundation (AICF) Prize for Scientific Excellence in Medicine.
- 2008 Civil Order of Health. Category: Commander with Plaque. Ministry of Health. Government of Spain.
- 2008 American Association for Cancer Research (AACR)-Rosenthal Family Foundation Award.
- 2008 Statesman Award. American Society of Clinical Oncology (ASCO).
- 2008 Rey Jaime I Award in Medical Research. Fundación Premios Rey Jaime I.

Current Institutional Responsibilities:

- 1996- Chairman, Medical Oncology Service, Vall d’Hebron University Hospital. Barcelona, Spain.
- 1996- Director, Medical Oncology, Hematology and Radiation Oncology Department, Vall d’Hebron University Hospital. Barcelona, Spain.
- 2000- Member, Board of Directors of the Vall d’Hebron Research Institute, Vall d’Hebron University Hospital. Barcelona, Spain.
- 2007- Director, Vall d’Hebron Institute of Oncology (V.H.I.O.), Vall d’Hebron University Hospital. Barcelona, Spain.

Scientific and Medical Societies:

American Society of Clinical Oncology - ASCO www.asco.org

- Member: 1990-
- Board of Directors. Member: 2003-2006
- Committees:
 - International Affairs Committee. Member: 2003-2006
 - Educational Committee. Member: 2003-2006

- Strategic Planning Committee. Member: 2003-2006
- Grant Selection Committee. Member: 2005-2006
- Annual Meetings:
 - Subcommittee Breast Cancer. Member: 2001-2003
 - Subcommittee Breast Cancer. Chair: 2003
 - Subcommittee Developmental Therapeutics. Member: 2005-2006

American Association for Cancer Research - AACR www.aacr.org

- Member: 1990-
- Council of Scientific Advisors. Member: 2006-
- Board of Directors. Member: 2009-2012
- Committees:
 - Clinical Cancer Research Committee. Member: 2002-2005
 - Pezcoller Foundation - AACR International Award for Cancer Research. Selection Committee. Member: 2004, 2005
 - Dorothy P. Landon - AACR Prize Committee for Translational Research. Selection Committee. Member: 2006, 2008
 - International Affairs Committee. Member: 2007-2010
 - Special Conferences Committee. Member: 2007-2010
 - Landon Foundation - AACR Innovator Award for International Collaboration in Cancer Research. Scientific Review Committee. Chairperson: 2009
- Annual Meetings:
 - 92nd AACR Annual Meeting. Scientific Committee. Member: 2001
 - 94th AACR Annual Meeting. Educational Committee. Member: 2003
 - 96th AACR Annual Meeting. Program Sub-Committee, Experimental Therapeutics Section. Chair: 2005
 - 96th AACR Annual Meeting. Clinical Cancer Research Committee. Member: 2005
 - 97th AACR Annual Meeting. Program Committee. Co-Chair: 2006
 - 98th AACR Annual Meeting. Program Sub-Committee, Experimental Therapeutics Section. Member: 2008
 - 99th AACR Annual Meeting. Program Committee, Experimental and Molecular Therapeutics Section and Mechanisms of Drug Action Subcommittee. Member: 2008

- 100th AACR Annual Meeting. Education Committee. Member: 2009
- 101st AACR Annual Meeting. Program Committee. Co-Chair: 2010
- Other Meetings:
 - 11th Symposium on New Drugs in Cancer Therapy. International Organizing Committee. Member: 2000
 - International Conference on Molecular Targets and Cancer Therapeutics. Scientific Committee. Member: 2001
 - AACR Oncogenomics Conference. Program Committee. Member: 2005
 - AACR Special Conference: Drugging the Genome. Co-Chair: 2006
 - AACR-NCI-EORTC Molecular Targets Conference. Scientific Committee. Member: 2008
 - 8th AACR-Japanese Cancer Association International Conference. Organizing Committee. Member: 2010
 - AACR's Translational Cancer Medicine Conference Series. 3rd Joint American-Israeli Conference on Cancer. Program Committee. Member: 2008
 - AACR Centennial Conference on Translational Cancer Medicine 2008: Advances in Biology Driven Cancer Clinical Trials. Organizing Committee. Member: 2008
 - AACR Translational Cancer Medicine 2010 Conference. Program Committee. Member: 2010

European Society for Medical Oncology - ESMO www.esmo.org

- Member: 1996-
- President: 2008-2009
- Committees:
 - Young Medical Oncologists (YMO) Working Group. President: 2004-2008
- Bi-Annual Congresses:
 - 25th European Society for Medical Oncology Congress. Scientific Committee. Member: 2000
 - 27th European Society for Medical Oncology Congress. Scientific Committee. Member: 2002
 - 29th European Society for Medical Oncology Congress. Scientific Committee. Member and Chairman: 2004
 - 31st European Society for Medical Oncology Congress. Scientific Committee. Member and Chairman: 2006

- 33rd European Society for Medical Oncology Congress
Congress. President: 2008
- Other Congresses:
 - 2009 IMPAKT Breast Cancer Conference. Co-Chair: 2009
 - 2010 IMPAKT Breast Cancer Conference. Co-Founder: 2010

European Cancer Organization – ECCO www.ecco.com

- Board of Directors. Member: 2008-2009. Re-elected: 2010-2011
- Bi-Annual Congresses:
 - The European Cancer Conference – ECCO 12. Scientific Committee (Science / Basic Medicine). Member: 2003
 - The European Cancer Conference – ECCO 13. Scientific Committee. Chairman: 2005
 - The European Cancer Conference – ECCO 14. Vice-president: 2007
 - Joint European Cancer Conference (ECCO) 15 34th European Society for Medical Oncology Congress (ESMO) Multidisciplinary Congress. Organising and Executive Scientific Program Committees. Member: 2009
- Other Congresses:
 - 3rd European Breast Cancer Conference – EBCC 3. National Organizer Committee. President: 2002
 - 4th European Breast Cancer Conference – EBCC 4. Scientific Committee. Member: 2004
 - 7th European Breast Cancer Conference – EBCC 7. Executive Scientific, Organising and National Organizer Committees. Member: 2010

European Organization for Research and Treatment of Cancer – EORTC www.eortc.be

- Board of Directors. Member: 2003-2006

International Agency for Research on Cancer – IARC www.iarc.fr

- Scientific Committee. Member: 2004-2009

Spanish Cooperative Breast Cancer Group – SOLTI www.gruposolti.org

- Member: 1996-
- Scientific Committee. President: 2000-2009

- President: 2009-

Sociedad Española de Oncología Médica – SEOM www.seom.org

- Member: 1996-

Centro Nacional de Investigaciones Oncológicas – CNIO www.cnio.es

- Scientific Advisory Board. Member: 2000-2003
- Board of Directors. Member: 2004-2009

European Commission - Research Management www.ec.europa.eu

- Expert Assessor
- Genomics and Biotechnology for Health (combating cancer). Expressions of Interest. Member: 2002

Fundació Privada d'Estudis i Recerca Oncològica – FERRO www.fero.org

- President: 2000-2007

Fundación Príncipe de Asturias www.fundacionprincipedeasturias.org

- *Príncipe de Asturias Award* in the category of Scientific Investigation. Member of the Jury: 2004, 2005, 2006

Institut National Du Cancer, France www.e-cancer.fr

- International Advisory Board. Member: 2005-2007

American College of Physicians www.acponline.org

- Member: 1990-

The American Society of Breast Disease www.asbd.org

- Member: 1999-

Ludwing Institute for Cancer Research – LICR www.licr.org

- Scientific Advisory Committee. Member: 2006-

American-Italian Cancer Foundation – AICF www.aicfonline.org

- Board of Directors. Member: 2008-
- Scientific Advisory Board. Member: 2008-

San Antonio Breast Cancer Symposium – SABCS www.sabcs.org

- Program Planning Committee. Member: 2008

Editorial Board:

Annals of Oncology. Associate Editor: 1999-2002
Annals of Oncology. Editorial Advisory Board. Member: 2002-
Cancer Cell. Editorial Advisory Board. Member: 2002-
Clinical Cancer Research. Editorial Advisory Board. Member: 1995-
Clinical Cancer Research. Senior Editor: 2009-
Investigational New Drugs. Editorial Advisory Board. Member: 2001-
Journal of Clinical Oncology. Editorial Advisory Board. Member: 2001-2005, 2006-2009
Cancer Prevention Research. Editorial Advisory Board. Member: 2008-
Nature Reviews Cancer. Advisor of the Highlights Section.
Journal of the National Cancer Institute. Ad-hoc reviewer.
Cancer Research. Ad-hoc reviewer.
International Journal of Cancer. Ad-hoc reviewer.
European Journal of Cancer. Ad-hoc reviewer.
Cancer. Ad-hoc reviewer.
New England Journal of Medicine. Ad-hoc reviewer.
Cell. Ad-hoc reviewer.

Invited Lectures:

- 12/93 MD Anderson Cancer Center. Head and Neck Conference. Presenter: “Studies with Anti-EGF Receptor Monoclonal Antibodies in Lung Cancer”. Houston, Texas, USA.
- 06/94 UCSF Esther Zollar Breast Conference Research Lecture. Presenter: “Growth Factor Receptors as Targets in Breast Cancer Therapy”. San Francisco, California, USA.
- 06/94 Pacific Medical Center. Geraldine Brush Cancer Center. Presenter: “Studies with Anti-Growth Factor Receptor Monoclonal Antibodies against Human Breast Cancer Xenografts”. San Francisco, California, USA.
- 09/94 6th Breast Cancer Working Conference. Presentation EORTC: “Anti-Her2/ Monoclonal Antibody Studies in Breast Cancer”. Amsterdam, Holland.
- 12/94 Yale Cancer Center. Speaker at the Yale Cancer Center Grand Rounds on “Growth Factor Receptors as Targets in Cancer Therapy”. New Haven, Connecticut, USA.
- 04/95 University of Virginia Health Sciences Center. Speaker at Cancer Center Seminar

- Series: "Growth Factor Receptors as Targets for Cancer Therapy". Charlottesville, Virginia, USA.
- 05/95 Institute Curie. Speaker: "Therapy of Breast Cancer with Monoclonal Antibodies against HER2/Neu and the EGF Receptor". Paris, France.
- 05/95 Spring Meeting. Cancer and Leukemia Group B, Breast Committee. Speaker: "Growth Factor Receptors as Targets for Breast Cancer Therapy". Providence, Rhode Island, USA.
- 06/95 International Symposium: Changes in the Treatment of Breast Cancer. European Society of Medical Oncology. Speaker: "Growth Factor Receptors as Targets for Breast Cancer Therapy". Madrid, Spain.
- 06/95 Postgraduate Course in Breast Cancer. Memorial Sloan-Kettering Cancer Center and the European School of Oncology. Speaker: Monoclonal Antibody Based Treatment Strategies . New York, USA.
- 10/95 Cancer Therapy and Research Center. Drug Development Education Series. Speaker: "Growth Factor Receptors as Targets for Breast Cancer Therapy". San Antonio, Texas, USA.
- 10/95 5th Annual Solid Tumor Symposium. Speaker: "Current Approaches in the Management and Screening of Breast and Ovarian Cancers". New York Medical College. Valhalla, New York, USA.
- 02/96 VI Jornadas Invernales de Actualización en Oncología. Speaker: "Cáncer de Mama de alto riesgo: Quimioterapia Altas Dosis" (*High Risk Breast Cancer: High Dosage Chemotherapy*). Hospital Miguel Servet. Unidad de Oncología Médica. Formigal, Spain.
- 09/96 German Breast Cancer Society Congress. Speaker: "Therapy of Breast Cancer with Anti-HER/neu Monoclonal Antibodies". Göttingen, Germany.
- 09/96 II International Symposium - Changes in the Treatment of Breast Cancer. Speaker: "Growth Factor Receptor Overexpression and Chemosensitivity in Breast Cancer". Buenos Aires, Argentina.
- 11/96 International Symposium on Breast Cancer, Advances in Biology and Therapy. Lecturer: "Antibodies to Growth Factors and Receptors". Hospital Clinic Universitari. Valencia, Spain.
- 12/96 The Taxol Mini Symposium, San Antonio Breast Cancer Symposium. Lecturer: "Therapeutic Implications of the Relationship between HER2 Overexpression and Paclitaxel Sensitivity". The University of Texas. San Antonio, Texas, USA.
- 02/97 VI Simposio Internacional sobre Biología y Utilidad Clínica de los Marcadores Tumoraes. Speaker: "Therapeutic Implications of the Relationship between C-erbB-2 Overexpression and Paclitaxel Sensitivity". Hospital Clínic i Provincial. Barcelona, Spain.
- 03/97 5th Course on Advanced Medical Oncology. Advanced Breast Cancer. Cátedra y Servicio de Oncología Médica. Hospital Universitario San Carlos. Facultad de Medicina. Universidad Complutense. Madrid, Spain.
- 03/97 Basic Oncology for Medical Cancer Specialists. Annals of Oncology (Spanish Edition). Lecturer: "Implicaciones Diagnósticas y Terapéuticas de la Telomerasa en

- Cáncer” (*Diagnostic Implications and Telomerase in Cancer Therapy*). Almagro, Ciudad Real, Spain.
- 06/97 2nd International Symposium: Changes in the Treatment of Breast Cancer. European Society of Medical Oncology. Speaker: “Monoclonal Antibodies Interfering with Signal Transduction Pathways in the Therapy of Breast Cancer”. Madrid, Spain.
- 09/97 Breast Cancer in the Next Millennium. Speaker: “A Comprehensive Forum: Therapeutic Implications of HER2 Overexpression in Breast Cancer”. Morristown Memorial Hospital. Morristown, New Jersey, USA.
- 09/97 European School of Oncology. Spanish Area. Speaker: “Chemotherapy Intensive”. Barcelona, Spain.
- 10/97 Sessions Clínico-Científiques de L’Institut Català d’Oncologia. Lecturer: “Implicacions Terapeútiques de l’Expressió elevada de l’Oncogen HER2/Neu en el Càncer de Mama” (*Therapeutic Implication of HER2/Neu in Breast Cancer*). Ciutat Sanitària i Universitària de Bellvitge. Barcelona, Spain.
- 10/97 2nd Congress European Society of Gynecology. Speaker: Results of HER2/Neu (C-ErbB-2) Antibody Treatment in Metastatic Breast Cancer . Göttingen, Germany.
- 11/97 European School of Oncology. Advanced Courses on Medical Treatment of Breast Cancer. Speaker: The Use of Chemotherapy in Woman with Locally Advanced or Metastatic Breast Cancer . Budapest, Hungary.
- 11/97 European School of Oncology. Advanced Courses on Medical Treatment of Breast Cancer. Speaker: “The Use of Chemotherapy in Woman with Locally Advanced or Metastatic Breast Cancer”. Warsaw, Poland.
- 02/98 1st Symposium on Breast Cancer Updates. Lecturer: “Tendencias Actuales y Experiencia con Taxol” (*Present Tendencias and Experience with Taxol*). Baiona, Pontevedra, Spain.
- 03/98 Instituto Nazionale per lo Studio e la Cura dei Tumori: “Gli Anticorpi Monoclonali in Terapia Oncologica: Mito o Realtà?”. Speaker: “HER2/Neu as a Target for Breast Cancer Therapy”. Milan, Italy.
- 03/98 6th Course Theoretic and Practical on Medical Oncology Progress. Speaker: “Cáncer de Mama Avanzado” (*Advanced Breast Cancer*). Hospital Universitario de San Carlos. Facultad de Medicina. Universidad Complutense de Madrid, Spain.
- 03/98 The Fox Chase Cancer Center and Free University Hospital Paclitaxel Investigators’ Workshop and Consensus Conference. Chairman: “Bladder, Head and Neck, Esophageal Cancer”. Presenter: “Phase I-II trial of paclitaxel/cisplatin/gemcitabine in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium”. St. Thomas, Virgin Islands, USA.
- 04/98 1st International Forum on Breast Cancer Treatment. Presenter: “Docetaxel: Overview and Future Directions”. New York, USA.
- 11/98 MD Anderson Cancer Center. The Women’s Cancer Research Group. Lecturer: “The Epidermal Growth Factor Receptor and HER2 as Targets for Breast Cancer Therapy” and “Biosynthesis of Growth Factors: Transforming Growth Factor α as a Model”. Houston, Texas, USA.
- 03/99 Instituto Nazionale per lo Studio e la Cura dei Tumori: New drugs in Breast Cancer . Speaker: Controlled Clinical Trials in Ovarian and Breast Cancer . Milan, Italy.

- 01/00 Vanderbilt University Cancer Center. Speaker Division Seminar: “Basic Science and Clinical Aspects of Growth factor Receptor-Targeted Approaches: Herceptin and Beyond”. Nashville, Tennessee, USA.
- 02/00 2nd International Symposium on Molecular Biology of Breast Cancer. Lecturer: “The EGF Receptor Family as Targets for Breast Cancer Therapy”. Lillehammer, Norway.
- 09/00 2nd Annual Lynn Sage Breast Cancer Symposium. Presenter: “Update on Herceptin”. Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
- 09/00 2nd European Breast Cancer Conference. Speaker: “C-erb-B2/Neu and Prediction of Response to Taxanes and Anthracyclines” and “Monoclonals, Antibody-Toxins and Other Receptor Targeted Approaches”. Brussels, Belgium.
- 10/00 3rd Symposium: “Revisiones en Cáncer” (*Reviews on Cancer*). Speaker: “Terapia Anti-HER2, Combinaciones con Quimioterapia y Perspectivas Futuras” (*AntiHER2 Therapy, Chemotherapy Combinations and Future Perspectives*). Madrid, Spain.
- 10/00 25th ESMO Congress. Chairman of the Educational Session: “Therapeutic Antibodies in Oncology”; Lecturer: “Monoclonal Antibodies Directed at Growth factor Receptors”. Hamburg, Germany.
- 01/01 3rd Annual Symposium of the Belgium Society of Medical Oncology. Heuson Memorial Lecture: “Growth Factors as Targets for Cancer Therapy”. Brussels, Belgium.
- 02/01 11th International Congress on Anti-Cancer Treatment. Educational Lecture: “Targeting the Epidermal Growth Factor Receptor”. Paris, France.
- 02/01 7th International Conference – Adjuvant Therapy of Primary Breast Cancer. Speaker: “Integration of Taxol-Herceptin into the Adjuvant Setting”. St. Gallen, Switzerland.
- 03/01 Current Topics in Breast Cancer Research-IV. Speaker: “Antibodies to HER2 and EGFR-update on Early Clinical Studies”. Moller Centre. Churchill College. Cambridge, United Kingdom.
- 03/01 I Dieci Anni Dell’Oncologia Medica Di Pisa. Lecturer: “New Perspectives in Medical Oncology”. St. Chiara Hospital. Pisa, Italy.
- 04/01 Encuentros en Oncología. Lecturer: “Inhibidores RAS Farnesil Transferasa” (*RAS Farnesol Inhibitors Transferase*). Segovia, Spain.
- 05/01 2001 ASCO Annual Meeting. Co-Chair and Invited Discussant: “Integrated Symposium Targeting the EGF Receptor: A Clinical Reality”. San Francisco, California, USA.
- 06/01 6th Madrid Breast Cancer Conference on Changes in the Treatment of Breast Cancer. Speaker: “Monoclonal Antibody-Directed Cytotoxic Therapy in Breast Cancer”. Madrid, Spain.
- 08/01 Breast Cancer Think Tank of National Cancer Institute. Speaker: “Clinical trials with Iressa, an EGFR TK Inhibitor”. Chantilly, Virginia, USA.
- 10/01 ASCO-NCI Scientific Symposium on Molecular Oncology for the Clinical Oncologist. Speaker: “Clinical Development of Molecularly Targeted Agents”. Boston, Massachusetts, USA.

- 10/01 The European Cancer Conference - ECCO 11. Speaker: "Controversies in the HER2 Positive Patient: How to Best Identify?". Lisbon, Portugal.
- 06/02 5th Pan-European Cancer Symposium: A New Era in the Management of Breast Cancer: Improving Outcome by Targeted Treatment. Speaker: "Emerging Role of Receptor-Based Therapy in Breast Cancer". Prague, Czech Republic.
- 02/02 6th Symposium: Reviews on Cancer. Invited Speaker. "Anticuerpos Monoclonales frente a Receptores de Tirosina-Quinasa (Anti-EGFR)" (*Monoclonal Antibodies Facing Tyrosine-Kinase Receptors*) (Anti-EGFR). Madrid, Spain.
- 02/02 CNIO Symposium on Basic and Translational Cancer Research. Molecular Pathology and Pharmacogenomics. Lecturer: "Clinical Trials in the XXI Century". Madrid, Spain.
- 02/02 5th Course on Medical Oncology. Nuevas Dianas Terapéuticas (*New Therapeutic Targets*). Speaker: "Anticuerpos monoclonales anti-EGFR y anti-HER2" (*Monoclonal Antibodies Anti-EGFR y Anti-HER2*). Madrid, Spain.
- 02/02 12th International Congress on Anti-Cancer Treatment. Speaker: "EGF/EGFR". Paris, France.
- 03/02 3rd European Breast Cancer Conference. Chair in Opening Ceremony; Lecturer: "Tyrosine Kinase Inhibitors"; Chair: "A New Look at Breast Cancer Heterogeneity". Barcelona, Spain.
- 04/02 93rd AACR Annual Meeting. Speaker: "EGF Receptor as a Target: Preclinical and Clinical Studies". San Francisco, California, USA.
- 04/02 Symposium at Radiation Research Meeting (EGFR): Molecular Inhibition of EGFR: From Lab to Clinic. Invited Speaker: "EGFR Inhibition Combined with Chemotherapy". Reno, Nevada, USA.
- 06/02 2nd European Spring Oncology Conference (ESOC-2). Invited Lecturer. "Clinical Results Studies with EGFR Inhibitors" and "Pharmacodynamic and Molecular Studies for Patients Selection and Monitoring Responses with Molecular targeted Agents". Málaga, Spain.
- 06/02 European Association for Cancer Research (EACR) - Asociación Española de Investigación sobre el Cáncer (ASEICA). Chairman of the Translational Research Symposium. Granada, Spain.
- 07/02 Gordon Research Conferences: Chemotherapy of Experimental/Clinical Cancer. Lecturer: "Targeting the Epidermal Growth Factor Receptor Family: Current Status and Challenges". New London, New Hampshire, USA.
- 09/02 1st Annual Symposium on Anty-Receptor Signaling in Human Neoplasia. Co-chair and Invited Speaker: "Pharmacodynamic Assays in Trials with Anti-EGFR Therapies". Chicago, Illinois, USA.
- 10/02 27th ESMO Congress. Invited Lecturer at the ESMO Young Medical Oncologists Forum in Collaboration with the Flims Alumni Clum. Lecturer: "Education in Modern Medical Oncology"; ESMO/ASCO Joint Symposium "Novel Targeted Treatment: Is it promise being realised?". Lecturer: "Current Status of Anty-Tyrosine Kinase Receptor Therapies". Nice, France.
- 11/02 ASCO Molecular Therapeutics Symposium. Presenter: "Receptor Tyrosine Kinase Inhibitors: Biological Overview". San Diego, California, USA.

- 11/02 14th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Speaker: “EGF-Receptor Targeting - Clinical Achievements” and “Strategies to Optimise Anti-Receptor Therapies”. Frankfurt, Germany.
- 12/02 25th Annual San Antonio Breast Cancer Symposium. Certified Symposium Biologic Therapies. Lecturer: “Current Therapeutic Challenges”. San Antonio, Texas, USA.
- 02/03 14th International Congress on Anti-Cancer Treatment. Educational Lecture: “New Anti-EGFR Strategies”. Paris, France.
- 02/03 5th Symposium on Cancer Reviews: Cancer Medical Treatment. Lecturer: “Tratamiento Neoadyuvante del Cáncer de Mama: Experiencia Europea” (*Neoadjuvant Treatment of Breast Cancer: The European Experience*). Madrid, Spain.
- 03/03 8th International Conference – Primary Therapy of Early Breast Cancer. Invited Lecturer: “Biological Targets in Breast Cancer Therapeutics” and “Future Directions in the Treatment of Early Breast Cancer”. St. Gallen, Switzerland.
- 03/03 Jornada de Oncología. Invited lecturer: “Nuevas Dianas Terapéuticas” (*New Therapeutic Targets*). Santiago de Compostela, Spain.
- 03/03 V Aniversario Encuentros en Oncología. Invited Lecturer: “Cáncer de Mama” (*Breast Cancer*). Madrid, Spain.
- 04/03 3rd Scientific Symposium. Fundación Lilly. Invited Lecturer: “Tyrosine Kinase Inhibitors”. Madrid, Spain.
- 06/03 2003 ASCO Annual Meeting. Co-Chair and Invited Lecturer : “The Epidermal Growth Factor as a Therapeutic Target”. Chicago, Illinois, USA.
- 06/03 Clinical Cancer Research in Europe Symposium. Invited Lecturer: “Advances in Molecular Targeted Therapies”. Milan, Italy.
- 06/03 IX Congreso Sociedad Española de Oncología Médica (SEOM). Invited Lecturer: “La Investigación en Oncología” (*Oncology Investigation*). Tenerife, Spain.
- 06/03 5th International Congress: Perspectives in Colorectal Cancer-PICC 2003. Invited Lecturer: “Signal Transduction Inhibition”. Barcelona, Spain.
- 07/03 Encuentro de Cánceres de Próstata, Mama y Ovario. Tumores Hormo-Dependientes. Universidad Internacional Menéndez y Pelayo. Invited Lecturer: “Terapias Biológicas” (*Biological Therapies*). Santander, Spain.
- 07/03 94th AACR Annual Meeting. Invited Lecturer: “Tyrosine Kinase Specific Therapy: Molecular Mechanisms and Drug Development”. Washington DC, USA.
- 08/03 Second Annual Symposium on Anti-Signaling Strategies in Human Neoplasia (CBCE). Co-Chair and Invited Lecturer: “Biochemical Pharmacodynamics”. Chicago, Illinois, USA.
- 08/03 1st Nordic Course in Molecular Oncology. Speaker: “Clinical Studies on Tyrosine Kinases as Cancer Drug Targets”. Copenhagen, Denmark.
- 09/03 FLASCA-ASCO Meeting. Invited Lecturer: “Update on Anti-Epidermal Growth Factor Receptor Therapies in Cancer”. Córdoba, Argentina.
- 09/03 The European Cancer Conference - ECCO 12. Chair and Invited Lecturer: “EGFR Therapies in Other Tumour Types”. Copenhagen, Denmark.
- 10/03 2nd International Symposium on Signal Transduction Modulators in Cancer Therapy-NDDO Research Foundation Cancer Therapy Conferences Series. Chair of

- the Plenary Session and Invited Lecturer: “Anti EGFR Antibodies: An Overview”. Amsterdam, Holland.
- 01/04 Cancer Complexity 2004 Symposium. Invited Lecturer: “Complexity and Intervention Strategies II”. Institut Gustave-Roussy. Villejuif, France.
- 02/04 CNIO Symposium on Molecular Taxonomy of Cancer. Invited Lecturer: “Pharmacodynamic Endpoints and Patient Selection with Targeted Therapies”. Madrid, Spain.
- 02/04 VI Simposio de Revisiones en Cáncer. Invited Lecturer: “Limitaciones de los Tratamientos Dirigidos contra el EGFR en el Tratamiento del Cáncer de Colon, Pulmón, Cabeza y Cuello” (*‘Limitations of Directed Treatments against EGFR in the Treatment of Cancer of the Colon, Lung, Head and Neck’*). Madrid, Spain.
- 02/04 Inspiration for Life: Optimising Survival in Breast Cancer. Chair and Invited Lecturer: “HER-Targeted Therapies: Using Tumour Biology to Guide Drug Development”. Prague, Czech Republic.
- 02/04 Vanderbilt University Cancer Center. Division Seminar. Speaker: “Pharmacodynamic Endpoints with Molecular Targeted Agents”. Nashville, Tennessee, USA.
- 03/04 2004 EGFR Summit. Co-chair and Invited Lecturer: “Single Agent Studies in Colorectal, Head and Neck and other Cancers”. Miami, Florida, USA.
- 03/04 4th European Breast Cancer Conference. Chair and Invited Lecturer: “Optimal Management of the Patient with an Her2 Overexpressing Tumour” and “Receptor Targeted Therapies”. Hamburg, Germany.
- 03/04 95th AACR Annual Meeting. Keynote Speaker: “Pharmacodynamic Approaches to Targeted Therapy Optimization”; Chair at Educational Session and Invited Speaker: “New Directions in ErbB Directions Targeting” and “Small Molecule Tyrosine Kinase Inhibitors: Is the Glass Half Empty or Half Full? . Orlando, Florida, USA.
- 05/04 Science Forum “Gefitinib”: The Developing Science. Chair and Invited Lecturer: “Other EGFR Related Approaches”. London, United Kingdom.
- 05/04 Molecular Targeted Therapy of Cancer. Chair and Invited Lecturer: “Targeting EGFR - A Promising Clinical Therapeutic Approach”. Barcelona, Spain.
- 05/04 I Reunión Nacional de Grupos Cooperativos (SEOM). Invited Lecturer: “Relevancia de la Investigación Clínica en Oncología” (*‘Relevance on Clinical Investigation on Oncology’*). Madrid, Spain.
- 06/04 2004 ASCO Annual Meeting. Chair of the Educational Session: “How Valid Are Biologic Correlates in Clinical Studies?”; Invited Lecturer and Poster Discussant. New Orleans, Louisiana, USA.
- 06/04 3rd European Spring Oncology Conference (ESOC-3). Invited Lecturer: “Clinical Development of mTor Targeted Drugs CCI-779 and RAD001”. Marbella, Spain.
- 06/04 FECS-AACR-ASCO Workshop Methods in Clinical Cancer Research. Keynote Speaker: “Translational Medicine” and Chair of the Session: “Efficacy Studies and Ethical Considerations”. Flims, Switzerland.
- 06/04 Teknon - Col.legi Oficial de Farmacèutics Barcelona: Cicle Conferències Reflexions sobre la Salut. Invited Lecturer: “Tractament del Càncer al 2004:

- Avanços i Reptes” (*Cancer Treatment in 2004: Advances and Challenges*).
Barcelona, Spain.
- 07/04 II Seminario de Oncología para la Industria Farmacéutica. Invited Lecturer:
“Importancia de la Investigación en Oncología Médica” (*The importance of the
Medical Oncology Investigation*). Guadalajara, Spain.
- 07/04 Waun Ki Hong Visiting Professorship Award. Invited Lecturer: “Pharmacodynamic
Approaches to Targeted Therapy Optimization”. Houston, Texas, USA.
- 07/04 2nd Inter-American Breast Cancer Conference. Invited Lecturer and Chair of the
Session: “Targeted Therapies in Breast Cancer-Part II”. Cancun, Mexico.
- 09/04 Appropriate Dose-Optimal Results -Scientific Course-. Chairman and Lecturer:
“The Dose-dense Concept Needs to Take New Drugs Adapted to Tumour Biology
in Account”. Barcelona, Spain.
- 09/04 3rd Annual Symposium on Anti-Signaling Strategies in Human Neoplasia. Co-Chair
and Chair of the Session: “Molecular and Signaling Profiling in Patient Selection and
Monitoring”; Lecturer: “Pharmacodynamic Endpoints of Target Inhibition and
Biological Activity in Clinical Trials with AntiSignaling Agents”. Barcelona, Spain.
- 09/04 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer
Therapeutics. Chair of plenary session and Poster Discussant. Geneve, Switzerland.
- 10/04 CNIO. Master en Oncología Molecular. Invited Lecturer: “Concepto de Oncología
Molecular y su Nivel de Desarrollo Actual” (*Concept of Molecular Oncology and
its Actual Developer Level*). Madrid, Spain.
- 10/04 Cancer Colloquium “Freedom to Discover”. Invited Lecturer. New Jersey, USA.
- 10/04 XI Santiago Ramón y Cajal Medical Lecture organised by the Queen Sofía Spanish
Institute of New York with the presence of Her Majesty Queen Sofía of Spain.
Conference: “Advances in the Treatment of Cancer in the Genomic Era: Evolution
or Revolution?”. Barcelona, Spain.
- 10/04 2nd International EGFR Symposium. Co-Chair. Sevilla, Spain.
- 10/04 The European Society for Therapeutic Radiology and Oncology (ESTRO 23).
Invited Lecturer: “Pharmacodynamic Endpoints in the Clinical Development of
Molecularly Targeted Agents”. Amsterdam, Holland.
- 11/04 29th ESMO Congress. Lecturer: “Critical Issues in Molecular Targeted Therapies”.
Viena, Austria.
- 11/04 6th International Workshop on Pharmacodynamics of Anticancer Agents. Invited
Lecturer: “Pharmacodynamics of EGFR-Targeting Drugs”. Venice, Italy.
- 11/04 The 29th Annual Alumni Society Meetings. Invited Lecturer: “EGFR Inhibitors:
Current Status”. New York, USA.
- 11/04 Colloquium. El Futur de la Medicina: del Desencís a l’Esperança. Invited Lecturer:
“Esperances del Futur amb els Avenços de la Medicina” (*Future Hopes and
Progress in Medicine*). Barcelona, Spain.
- 11/04 XXXI Symposium Internacional Oncología Mamaria. Keynote Lecturer: “Terapia
con Anticuerpos Monoclonales”(*Monoclonal Antibody Therapy*). Barcelona,
Spain.

- 12/04 Colloquium: “Presente y Futuro de la Investigación Biomédica en los Hospitales Universitarios” (*Present and Future of the Biomedical Research in the University Hospitals*). Participant. Sevilla, Spain.
- 12/04 27th Annual San Antonio Breast Cancer Symposium. Poster Discussant. San Antonio, Texas, USA.
- 01/05 9th International Conference - Primary Therapy of Early Breast Cancer 2005. Invited Lecturer: “Novel Biological Therapeutic Targets”. St. Gallen, Switzerland.
- 02/05 16th International Congress on Anti-Cancer Treatment. Lecturer: “New Targeted Therapies”. Paris, France.
- 02/05 Keystone Symposium. Invited Lecturer: “Mechanisms of Action of EGFR-Inhibitory Antibodies and Small Molecules”. Santa Fe, New Mexico, USA.
- 03/05 3rd International Symposium on Targeted Anticancer Therapies (TAT 2005). Invited Lecturer: “Antibodies Directed Against the HER Family of Receptors”. Amsterdam, Holland.
- 03/05 VI Encuentros en Oncología. Invited Lecturer: “Drug Development in the Genomic Age”. Segovia, Spain.
- 03/05 Teknon - Col.legi Oficial de Farmacèutics Barcelona: Ciclo de Conferencias Diálogos para la Salud. Invited Lecturer: “Avances en el Tratamiento de Cáncer de Mama” (*Advances in Breast Cancer Treatment*). Barcelona, Spain.
- 05/05 87th American Radium Society (ARS). Keynote Speaker. Barcelona, Spain.
- 05/05 2005 ASCO Annual Meeting. Poster Discussant and Presenter of Educational Sessions. Orlando, Florida, USA.
- 06/05 6th Breast Cancer Conference: Changes in the Treatment of Breast Cancer. Invited Lecturer: “The Role of Small Molecules TKI”. Madrid, Spain.
- 06/05 X Congreso Nacional de la Sociedad Española de Oncología Médica (SEOM) . Chair of Educational Session “Mama II: Enfermedad Avanzada” (*Breast II: Advanced Illness*). Zaragoza, Spain.
- 07/05 World Congress on Lung Cancer. Session: “Targeted therapies I”. Co-Chair and Discussant; Session: “Current issues in translational research and targeted therapies”. Co-Chair of the Session and Lecturer: “Biotherapies and molecular targeted therapies in the adjuvant setting”. Barcelona, Spain.
- 09/05 AACR Special Conference in Advances in Breast Cancer Research: Genetics, biology and clinical applications. Lecturer: “Pharmacodynamic Endpoints in the Clinical Development of Molecularly Targeted Agents in Breast Cancer”. La Jolla, California, USA.
- 10/05 58th Annual Symposium on Fundamental Cancer Research. M. D. Anderson Cancer Center. Speaker: “Biomarker Development for Targeted Agents Directed at the PI3K/AKT/mTOR Pathway”. Houston, Texas, USA.
- 10/05 The European Cancer Conference - ECCO 13. Speaker: “Basic Science/Medicine” and “Breast Cancer”. Paris, France.
- 10/05 AECC -Foro- Debate sobre Cáncer. Lecturer: “Logros y decepciones en la batalla contra el cáncer” (*Achievements and Deceptions on the Battle against Cancer*). Madrid, Spain.

- 11/05 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Speaker: "Optimizing therapies for Inhibiting Kinase Receptors". Philadelphia, New Jersey, USA.
- 12/05 28th Annual San Antonio Breast Cancer Symposium. Speaker: "Biomarker Strategies" and "Disease Progression Following Adjuvant Trastuzumab". San Antonio, Texas, USA.
- 01/06 AACR Special Conference in Cancer Research: Drugging the Cancer Genome: Developing Rational Combination Therapies for Multigene Cancers. Co-chair of the Conference and Speaker: "Incorporation of Tumor Pharmacodynamic Endpoints in the Development of Molecular Targeted Agents". Rancho Mirage, California, USA.
- 02/06 5th International Congress on Breast Cancer: From Gene to Cure. Speaker: "Her2-Neu". Amsterdam, Holland.
- 03/06 5th European Breast Cancer Conference. Presidential Symposium Speaker: "Novel Approaches to Targeting the ErbB Pathway in Breast Cancer". Nice, France.
- 03/06 Jornadas Ciencia y Sociedad. Lecturer: "Arrinconando el cáncer" (*Cornering Cancer*). Madrid, Spain.
- 04/06 97th AACR Annual Meeting . Chair and Organizer Special Session Plenary: "Breakthroughs in Clinical Research"; Speaker: "EGFR Inhibitors in the Treatment of Cancer: Current Status and Emerging Strategies". Washington DC, USA.
- 06/06 4th European Spring Oncology Conference (ESOC-IV). Co-chair: "Determinants of Response to ErbB Receptor Inhibitors" and Speaker: "Lapatinib in Breast Cancer: Place for Hope". Marbella, Spain.
- 07/06 19th European Association for Cancer Research (EACR) Meeting. Presentation of the prestigious Mike Price Lecture: "Targeted Therapy". Budapest, Hungary.
- 08/06 ASCO Development in Molecular Therapeutics in Breast Cancer Conference. Session: "Growth Factors and GF Receptors as Therapeutic Targets". Co-Chair of the Session and Speaker: "The HER Family". Aspen, Colorado, USA.
- 09/06 International Breast Cancer Symposium. Speaker: "Optimal Use of Herceptin in Breast Cancer Adjuvant Therapy". Taipei, Taiwan.
- 09/06 The 7th International Conference of the Asian Clinical Oncology Society (ACOS) and CSCO-ASCO-ESMO Joint Symposium. Speaker: "Genetic Profiling of Breast Cancer". Beijing, China
- 09/06 Closing Ramón y Cajal Lectures. "Del Laboratorio al Paciente: la Promesa de la Medicina Molecular en la Lucha contra el Cáncer" (*From the Laboratory to the Patient: The Promise of Molecular Medicine in the Fight against Cancer*). Barcelona, Spain.
- 09/06 31st ESMO Congress. Press Officer of the Congress. Young Oncologist Masterclass. Co-Chair Session and Speaker: "Practical Examples Based on Published Papers" and "How to Write a Translational Research Paper. The Editor's Point of View"; Special Symposium "Management of Advanced Breast Cancer in 2006: Evolving Options". Chair Symposium and Lecturer: "Evolving Landscape in Advanced Breast Cancer: from Genomic Signatures to Novel Agents"; Controversy Session, Pro-Speaker: "Should We Use Gene Signatures to Guide Treatment Decisions Today?. The Example of Breast Cancer"; Presidential Symposium, Discussant:

- “Trastuzumab plus Anastrozole Prolongs Progression-Free Survival in Postmenopausal Women with HER2-Positive, Hormone-Dependent Metastatic Breast Cancer (MBC)”. Istanbul, Turkey.
- 10/06 Cancer Colloquium and Distinguished Achievement Award Ceremony. “Mechanism of Trastuzumab Resistance in HER2 Positive Breast Cancer”. New Jersey, USA.
- 11/06 18th EORTC-NCI-AACR Symposium. Michael Clavel Lecturer: “Targeted Therapies”; Plenary Session: “Antibody versus Small Molecule Inhibitors of Receptor Tyrosine Kinases”. Speaker: “Combination of Monoclonal Antibodies and Tyrosine Kinase Inhibitors with the Same Target”. Prague, Czech Republic.
- 11/06 VII Congress of the Italian Association of Medical Oncology (AIOM). Special session " New Frontiers of the Therapies of Breast Cancer ". Lecturer: " Update on Her2 Targeting in Breast Cancer". Milan, Italy.
- 11/06 CNIO Symposium on Molecular Markers in Cancer Therapy. Keynote Lecture: “Incorporating Molecular Markers in Early Clinical Trials with Targeted Agents”. Madrid, Spain.
- 12/06 29th Annual San Antonio Breast Cancer Symposium. Speaker: “Trastuzumab Resistant Metastatic Disease : Current Options and Future Targets”. San Antonio, Texas, USA.
- 03/07 German Breast Group Annual Meeting. Keynote Lecture: “From Bench to Bedside- Current Understanding of Her2-Positive Disease”. Frankfurt, Germany.
- 04/07 98th AACR Annual Meeting. Speaker: " Receptor Tyrosine Kinase Inhibitors" and "Small Molecules Versus Monoclonal Antibodies in Her2 Amplified Breast Cancer". Los Angeles, California, USA.
- 06/07 2007 ASCO Annual Meeting. ASCO Extended Education Session: Career Choices: “Options in Academia, Private Practice, Industry and Government”. Roundtable Facilitator: “Mentors in Academia”. Chicago, Illinois, USA.
- 06/07 XV Reunió Anual de Col·legis i Associacions Professionals adheritis. Lecturer: "Recerca Biomèdica. Promeses i Oportunitats" (*Biomedical Research. Promises and Oportunities*). Barcelona, Spain.
- 06/07 VII Madrid Breast Cancer Conference. Symposium: “Targeted Therapy: Present and Future”. Co-Chair of the Symposium and Lecturer: “Novel Targeted Agents in the Treatment of Breast Cancer”. Madrid, Spain.
- 06/07 I Jornada Técnica de la Estrategia en Cáncer del Sistema Nacional de Salud. Chair of the Roundtable: “Epidemiología, Práctica Clínica e Investigación" (*Practical, Clinical and Investigative Epidemiology*). Madrid, Spain.
- 07/07 ESMO Conference Lugano (ECLU). ESMO Young Oncologists Masterclass I.: "Practical Aspects for a Successful Career in Oncology". Speaker: "How can ESMO Help Young Oncologists and How Young Oncologists can Help ESMO"; 6th ESMO Patient Seminar. Co-Chair of the session: "Latest Developments in Breast Cancer"; Breast Controversy Session: “Will Molecular Diagnostics Become Part of Routine Clinical Practice?”. “Pro” Speaker "Yes" Argument. Lugano, Switzerland.
- 07/07 Harvard Breast Cancer Conference. Jean H. Lubrano Distinguished Visiting Scholar Lecture: "The New Generation of Targeted Therapies for Breast Cancer". Boston, Massachusetts, USA.

- 09/07 The 2007 Breast Cancer Symposium. Lecturer: "Other Anti-HER2 Agents". San Francisco, California, USA.
- 09/07 European Cancer Conference - ECCO 14. Keynote Lecturer: "Approaches to Targeted Therapy Optimization: The Epidermal Growth Factor Receptor Family as a Model System"; Scientific Symposium: "Advances in New Drugs for Breast Cancer". Chair of the Symposium and Lecturer: "The Pros and Cons of Signal Transduction Inhibitors in Breast Cancer". Barcelona, Spain.
- 10/07 Severo Ochoa Lecture organised by the Queen Sofía Spanish Institute of New York with the presence of Her Majesty Queen Sofía of España y los Hospitales Ruber. "Cancer, su Tratamiento. Realidades y esperanzas" (*Cancer, its treatment: Realities and Hopes*). Madrid, Spain.
- 10/07 XI Congreso Nacional Congreso Sociedad Española de Oncología Médica (SEOM). Presidential Session. Lecturer: "Avances en Cáncer de Mama 2007: de Firmas Genómicas a Nuevas Terapias" (*Advances in Breast Cancer 2007: from Genomic Signatures to New Therapies*). Madrid, Spain.
- 10/07 MD Anderson Breast Cancer Research Program Lecture Series. Lecturer: "Novel anti-HER2 Strategies in the Treatment of Cancer". Houston, Texas, USA.
- 10/07 AACR Special Conference. Advances in Breast Cancer Research: Genetics, Biology and Clinical Applications. Speaker: Mechanisms of Trastuzumab Resistance in HER2 Positive Breast Cancer". San Diego, California, USA.
- 11/07 I Symposium Esteve de Cáncer de Mama. Chair of the symposium and Lecturer: "Terapia Hormonal en el Cáncer de Mama. Nuevas combinaciones" (*Hormonal therapy in Breast Cancer. New combinations*) Barcelona, Spain.
- 11/07 American Italian Cancer Foundation Research Symposium. Co-lecturer: "Inhibition of the EGF Receptor Family as Cancer Therapy". New York, USA.
- 11/07 34th Symposium Internacional "Avances y Controversias en Ginecología Oncológica" de la Fundación Santiago Dexeus. Lecturer: "Nuevos fármacos en la terapia del cáncer de ovario" (*New Drugs in the Therapy of Ovarian Cancer*). Barcelona, Spain.
- 12/07 Institut Claudius Regaud. Invited lecturer: "New approaches in the therapy of breast cancer". Toulouse, France.
- 12/07 The Euro-Region Academic-Industrial Partnering Conference. Keynote lecture: "New challenges in oncology". Toulouse, France.
- 12/07 30th Annual San Antonio Breast Cancer Symposium. Co-moderator SABCS General Session VI; Symposium "European and US Perspectives on Current Clinical Trials, Clinical Practice, and Treatment Guidelines"; Co-Presenter: "Defining the Role of Targeted Therapies in Breast Cancer: How and When Should These Agents be Incorporated?". San Antonio, Texas, USA.
- 04/08 99th AACR Annual Meeting. Speaker: "The mTOR Pathway as a Cancer Target: Pharmacodynamic measurements of mTOR inhibition"; 32nd Annual AACR-Rosenthal Family Foundation Award Lecture: "New directions in targeting the HER receptor family: A voyage to the center of the cell". San Diego, USA.

- 04/08 The 6th European Breast Cancer Conference (EBCC-6). Lecturer: Keynote Symposium on Challenges in breast cancer molecular targeting: "Targeting HER family". Berlin, Germany.
- 05/08 13th Taiwan Joint Cancer Conference. Lecturer: "Novel approaches with targeted therapy in breast cancer: Anti-HER2 agents and beyond". Taipei, Taiwan.
- 06/08 2008 ASCO Annual Meeting. Education session: Picking the winners through biomarker enrichment: Could this be the end of phase III trials? Lecture: "Translational endpoints of today and tomorrow". Chicago, Illinois, USA.
- 06/08 V European Spring Oncology Conference. Lecturer: "Emerging Kinase Targets: "mTOR/PI3K Small Molecules Inhibitors" and Targeted Agent-based Combination Strategies: "Combining Endocrine Therapy and (other) Targeted Therapies", Marbella, Málaga, Spain.
- 07/08 AACR Centennial Conference Translational Cancer Medicine 2008: "Cancer Clinical Trials and Personalized Medicine". Lecturer: "Combinatorial Approaches with Signal Transduction Inhibitors". Monterey, California, USA.
- 09/08 33rd ESMO Congress. Lecturer: "Understanding and Preparing a Paper on Translational Research. How to Write a Translational Research Paper"; "Novel Agents in the Era of Targeted Therapy- What have we Learned and How has our Practice Changed?". Stockholm, Sweden.
- 10/08 XXIX Reunión Nacional de la Sección de Ginecología Oncológica y Patología Mamaria de la SEGO. Lecturer: "Nuevas Dianas Terapéuticas en el Cáncer de Mama" (*New Therapeutic Targets in Breast Cancer*). Barcelona, Spain.
- 10/08 2008 ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer. Lecturer: "Overview: EGFR Pathway". Florida, USA.
- 11/08 AACR Centennial Conference Translational Cancer Medicine 2008: "Bridging the Lab and the Clinic in Cancer Medicine". Lecturer: "Biomarker Driven Clinical Trials with Molecular Targeted Agents". Jerusalem, Israel.
- 11/08 New York University Medical Grand Rounds. 15th Belsky Memorial Lecture: "Advances in the Therapy of HER2 Positive Breast Cancer". New York, USA.
- 11/08 The Institute of Cancer Research Distinguished Lecture. "New Directions in Targeting the HER Receptor Family: A Voyage to the Center of the Cell". London, UK.
- 12/08 31st Annual San Antonio Breast Cancer Symposium. Lecturer: Novel Anti-HER2 Strategies in the Therapy of Breast Cancer . San Antonio, Texas, USA.
- 01/09 British Breast Group Meeting. Lecturer: New Approaches to Anti-HER2 Therapy . West Midlands, UK.
- 02/09 20th International Congress on Anti-Cancer Treatment (ICACT). Presidential Lecture: Targeting the PI3K Pathway in Cancer . Paris, France.
- 02/09 Foundation Ipsen Seminar: Molecular Targets of Cancer Therapy. Lecturer: Emerging Molecular Targets in Breast Cancer: HER2 and beyond ". Jaipur, India.
- 03/09 11th International Conference Primary Therapy of Early Breast Cancer - Evidence, Controversies and Consensus. Lecturer: "Review of New Targeted Drugs: Crawling toward the Adjuvant Setting". St. Gallen, Switzerland.
- 03/09 15th Scientific Symposium of the Lilly Foundation. Lecturer: "Targeting HER2 in

- Breast Cancer- Novel Therapies and Mechanisms of Resistance". Madrid, Spain.
- 04/09 100th AACR Annual Meeting. Speaker: "Novel Strategies in the Therapy of HER2-Positive Breast Cancer". Denver, USA.
- 05/09 IMPAKT 2009 Breast Cancer Conference. Lecturer: "Is Dormancy Targetable?.The Clinician: A Point of View"; Discussant: Pathways for PI3Kinase Session. Brussels, Belgium.
- 05/09 Champalimaud Foundation Cancer Symposium 2009. Speaker: "Emerging Molecular Targets in Breast Cancer: HER2 and Beyond". Lisbon, Portugal.
- 06/09 The Institute of Cancer Research Centenary Conference. Lecturer: "Targeting PI3 Kinase in the Clinic". London, UK.
- 06/09 VIII Madrid Breast Cancer Conference. Lecturer:"Pertuzumab, a Her2 Dimerization Inhibitor, as a Novel Anti-Her2 Therapy of Breast Cancer";"The Role of M-TOR/PI3K Inhibitors in the Treatment of Breast Cancer". Madrid, Spain.
- 08/09 European Society of Cardiology Congress 2009. Lecturer: "Cardiotoxic anti-cancer treatments"; "Cardiotoxicity of new anticancer agents". Barcelona, Spain.
- 09/09 Fundación Premios "Rey Jaime I". Distinguished Lecture Rey Jaime I Awards: "New Therapeutic Targets in Breast Cancer". Barcelona, Spain.
- 09/09 Joint ECCO 15 – 34th ESMO Multidisciplinary Congress. Co-Chair: Scientific Symposium "Resistance Mechanism to EGFR and HER2 Inhibitors and Strategies to Overcome them"; Lecturer: "An Overview of Resistance to Anti-EGFR/HER2 Agents"; Discussant: Presidential Session V Best of 2009. Berlin, Germany.
- 10/09 XI Congress of the Italian Association of Medical Oncology (AIOM). Chair: "AIOM incontra ESMO". Milan, Italy.
- 10/09 Institute Gustave Roussy. Lecturer: "Targeting HER2 Resistance in Breast Cancer". Villejuif, France.
- 10/09 XII Congreso Nacional de la Congreso Sociedad Española de Oncología Médica (SEOM). Presidential Lecture: "Dianas Moleculares Emergentes en el Tratamiento del Cáncer de Mama" (*Emerging Molecular Therapies in the Treatment of Breast Cancer*). Barcelona, Spain.
- 11/09 The 14th Annual Scientific Symposium of Hong Kong Cancer Institute. Speaker: "Novel directions in the therapy of HER2 positive breast cancer". Hong Kong, Republic of China.
- 11/09 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital. Invited lecturer: "Emerging Molecular Targets in Breast Cancer: HER2 and beyond". Baltimore, USA.
- 12/09 32nd Annual San Antonio Breast Cancer Symposium. Presenter General Session: SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC) ; Moderator Poster Discussion Her2 Targeting and Resistance . San Antonio, Texas, USA.
- 01/10 Institute of Medical Biology. Distinguished Lecturer: Targeting the PI3K pathway as cancer therapeutics . Singapore, Singapore.

Publication list:

1. Martinez Perez J, Baselga J, Monso E, Fernandez JM. "Value of the electrophysiologic study of the diaphragm in the diagnosis of phrenic paralysis". *Med Clin (Barc)*. 1985 Apr 30;84(16):674.
2. Casper ES, Baselga J, Smart TB, Magill GB, Markman M, Ranhosky A. "A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma". *Cancer Chemother Pharmacol*. 1991;28(1):51-4.
3. Baselga J. "Sarcoma of soft tissue". *Med Clin (Barc)*. 1991 Jan 12;96(1):16-7.
4. Baselga J, Reich L, Doherty M, Gulati S. "Fat embolism syndrome following bone marrow harvesting". *Bone Marrow Transplant*. 1991 Jun;7(6):485-6.
5. Atlas I, Mendelsohn J, Baselga J, Fair WR, Masui H, Kumar R. "Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha". *Cancer Res*. 1992 Jun 15;52(12):3335-9.
6. Baselga J, Kris MG, Scher HI, Phillips M, Heelan RT. "Phase II trial of gallium nitrate in previously treated patients with small cell lung cancer". *Invest New Drugs*. 1993 Feb;11(1):85-6.
7. Baselga J, Krown SE, Telzak EE, Filippa DA, Straus DJ. "Acquired immune deficiency syndrome-related pulmonary non-Hodgkin lymphoma regressing after zidovudine therapy". *Cancer*. 1993 Apr 1;71(7):2332-4.
8. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, McIntosh J, Kurie J, Dmitrovsky E. "Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung". *Cancer Res*. 1993 May 15;53(10 Supplement):2379-85.
9. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH, Jr., Mendelsohn J. "Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies". *J Natl Cancer Inst*. 1993 Aug 18;85(16):1327-33.
10. Fan Z, Baselga J, Masui H, Mendelsohn J. "Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts". *Cancer Res*. 1993 Oct 1;53(19):4637-42.
11. Baselga J, Maerz WJ, Moy D, Miller WH, Jr., Castro L, Reuter VE, Yao TJ, Masui H, Dmitrovsky E. "Over-expression of transforming growth factor alpha antagonizes the anti-tumorigenic but not the differentiation actions of retinoic acid in a human teratocarcinoma cell". *Oncogene*. 1993 Dec;8(12):3257-63.

12. Baselga J, Mendelsohn J. "The epidermal growth factor receptor as a target for therapy in breast carcinoma".
Breast Cancer Res Treat. 1994 Jan;29(1):127-38.
13. Miller WH, Jr., Maerz WJ, Kurie J, Moy D, Baselga J, Lucas DA, Grippo JF, Masui H, Dmitrovsky E. "All-trans-retinoic acid and hexamethylene bisacetamide (HMBA) regulate TGF-alpha and Hst-1/kFGF expression in differentiation sensitive but not in resistant human teratocarcinomas".
Differentiation. 1994 Jan;55(2):145-52.
14. Baselga J, Mendelsohn J. "Receptor blockade with monoclonal antibodies as anti-cancer therapy".
Pharmacol Ther. 1994 Oct;64(1):127-54.
15. Ciardiello F, Damiano V, Bianco C, di Isernia G, Ruggiero A, Caraglia M, Tagliaferri P, Baselga J, Mendelsohn J, Bianco AR, Tortora G. "Cooperative antiproliferative effects of 8-chloro-cyclic AMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells".
Clin Cancer Res. 1995 Feb;1(2):161-7.
16. Seidman AD, Reichman BS, Crown JP, Yao TJ, Currie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P. "Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response".
J Clin Oncol. 1995 May;13(5):1152-9.
17. Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao TJ, Lepore J, Gilewski T, Currie V, Crown J, Hakes T, Baselga J, Sklarin N, Moynihan ME, Tong W, Egorin M, Kearns C, Springgs D, Norton L. "Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer".
J Clin Oncol. 1995 Oct;13(10):2575-81.
18. Seidman AD, Hudis CA, Fennelly D, Raptis G, Baselga J, Norton L. "Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer".
Semin Oncol. 1995 Oct;22(5 Supplement 12):108-16.
19. Hudis CA, Seidman AD, Baselga J, Raptis G, Lebwohl D, Gilewski T, Currie V, Moynihan ME, Sklarin N, Fennelly D, et al. "Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes".
Semin Oncol. 1995 Dec;22(6 Supplement 15):18-23.
20. Hudis CA, Seidman AD, Crown JP, Balmaceda C, Freilich R, Gilewski TA, Hakes TB, Currie V, Lebwohl DE, Baselga J, Raptis G, Gollub M, Robles M, Bruno R, Norton L. "Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer".
J Clin Oncol. 1996 Jan;14(1):58-65.
21. Hudis C, Seidman A, Raptis G, Fennelly D, Gilewski T, Baselga J, Theodoulou M, Sklarin N, Moynihan M, Surbone A, Currie V, Lebwohl D, Uhlenhopp M, Crown J, Norton L. "Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience".
Semin Oncol. 1996 Feb;23(1 Supplement 1):58-64.

22. Baselga J, Mendelsohn J, Kim YM, Pandiella A. "Autocrine regulation of membrane transforming growth factor-alpha cleavage". *J Biol Chem*. 1996 Feb 9;271(6):3279-84.
23. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. "Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer". *J Clin Oncol*. 1996 Mar;14(3):737-44.
24. Zamora-Leon SP, Golde DW, Concha, II, Rivas CI, Delgado-Lopez F, Baselga J, Nualart F, Vera JC. "Expression of the fructose transporter GLUT5 in human breast cancer". *Proc Natl Acad Sci U S A*. 1996 Mar 5;93(5):1847-52.
25. Ribas A, Albanell J, Bellmunt J, Sole-Calvo LA, Bermejo B, Gallardo E, Vidal R, Vera R, Eres N, Carulla J, Baselga J. "Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity". *J Clin Oncol*. 1996 May;14(5):1573-80.
26. Seidman AD, Hochhauser D, Gollub M, Edelman B, Yao TJ, Hudis CA, Francis P, Fennelly D, Gilewski TA, Moynahan ME, Currie V, Baselga J, Tong W, O'Donoghue M, Salvaggio R, Auguste L, Spriggs D, Norton L. "Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer". *J Clin Oncol*. 1996 Jun;14(6):1877-84.
27. Bellmunt J, Eres N, Ribas A, Casado S, Albanell J, Baselga J. "Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis". *Cancer Chemother Pharmacol*. 1997;40(3):273-6.
28. Seidman AD, Hudis CA, Raptis G, Baselga J, Fennelly D, Norton L. "Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience". *Oncology (Williston Park)*. 1997 Mar;11(3 Supplement 2):20-8.
29. Baselga J, Seidman AD, Rosen PP, Norton L. "HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications". *Oncology (Williston Park)*. 1997 Mar;11(3 Supplement 2):43-8.
30. Baselga J, Mendelsohn J. "Type I receptor tyrosine kinases as targets for therapy in breast cancer". *J Mammary Gland Biol Neoplasia*. 1997 Apr;2(2):165-74.
31. Bellmunt J, Ribas A, Eres N, Albanell J, Almanza C, Bermejo B, Sole LA, Baselga J. "Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma". *Cancer*. 1997 Nov 15;80(10):1966-72.
32. Hudis C, Riccio L, Holmes F, Seidman A, Baselga J, Currie V, Fennelly D, Gilewski T, Moynahan M, Raptis G, Sklarin N, Surbone A, Uhlenhopp M, Maickel

- N, Yao TJ, Hellmann S, Usakewicz J, Hortobagyi G, Norton L. "Phase II study of semisynthetic paclitaxel in metastatic breast cancer".
Eur J Cancer. 1997 Nov;33(13):2198-202.
33. Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW, Baselga J. "PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner".
Clin Cancer Res. 1997 Nov;3(11):2099-106.
34. Agus DB, Gambhir SS, Pardridge WM, Spielholz C, Baselga J, Vera JC, Golde DW. "Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters".
J Clin Invest. 1997 Dec 1;100(11):2842-8.
35. Ribas A, Albanell J, Sole-Calvo LA, Gallardo E, Bellmunt J, Vera R, Vidal R, Carulla J, Baselga J. "Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma".
Cancer. 1998 Mar 1;82(5):878-85.
36. Hudis C, Riccio L, Seidman A, Baselga J, Currie V, Fennelly D, Gilewski T, Lebwohl D, Moynahan M, Raptis G, Surbone A, Sklarin N, Yao TJ, Keefe D, Norton L. "Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel".
Cancer Invest. 1998;16(2):67-71.
37. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. "Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/Neu overexpressing human breast cancer xenografts".
Cancer Res. 1998 Jul 1;58(13):2825-31.
38. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. "Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/Neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment".
J Clin Oncol. 1998 Aug;16(8):2659-71.
39. Maerz WJ, Baselga J, Reuter VE, Mellado B, Myers ML, Bosl GJ, Spinella MJ, Dmitrovsky E. "FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas".
Oncogene. 1998 Aug 13;17(6):761-7.
40. Merlos-Suarez A, Fernandez-Larrea J, Reddy P, Baselga J, Arribas J. "Pro-tumor necrosis factor-alpha processing activity is tightly controlled by a component that does not affect notch processing".
J Biol Chem. 1998 Sep 18;273(38):24955-62.
41. Seidman AD, Hudis CA, Albanell J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J, Norton L. "Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer".
J Clin Oncol. 1998 Oct;16(10):3353-61.

42. Felip E, Massuti B, Camps C, Benito D, Isla D, Gonzalez-Larriba JL, Lopez-Cabrerizo MP, Salamanca O, Puerto-Pica J, Moyano A, Baselga J, Rosell R. "Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: comparison of two Phase II trials".
Clin Cancer Res. 1998 Nov;4(11):2723-8.
43. Hudis C, Seidman A, Baselga J, Raptis G, Lebwahl D, Gilewski T, Moynahan M, Sklarin N, Fennelly D, Crown JP, Surbone A, Uhlenhopp M, Riedel E, Yao TJ, Norton L. "Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy".
J Clin Oncol. 1999 Jan;17(1):93-100.
44. D'Andrea G, Fennelly D, Norton L, Baselga J, Gilewski T, Hudis C, Moynahan ME, Raptis G, Sklarin N, Surbone A, Theodoulou M, Templeton MA, Yao TJ, Seidman AD. "Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer".
Clin Cancer Res. 1999 Feb;5(2):275-9.
45. Urena JM, Merlos-Suarez A, Baselga J, Arribas J. "The cytoplasmic carboxy-terminal amino acid determines the subcellular localization of proTGF-(alpha) and membrane type matrix metalloprotease (MT1-MMP)".
J Cell Sci. 1999 Mar;112 (Pt 6):773-84.
46. Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J. "Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells".
Cancer Res. 1999 Mar 15;59(6):1196-201.
47. Fernandez-Larrea J, Merlos-Suarez A, Urena JM, Baselga J, Arribas J. "A role for a PDZ protein in the early secretory pathway for the targeting of proTGF-alpha to the cell surface".
Mol Cell. 1999 Apr;3(4):423-33.
48. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. "Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer".
Semin Oncol. 1999 Aug;26(4 Supplement 12):78-83.
49. Albanell J, Baselga J. "The ErbB receptors as targets for breast cancer therapy".
J Mammary Gland Biol Neoplasia. 1999 Oct;4(4):337-51
50. Baselga J. "New horizons: gene therapy for cancer".
Anticancer Drugs. 1999 Nov;10 Supplement 1:S39-42.
51. Albanell J, Baselga J. "Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer".
Drugs Today (Barc). 1999 Dec;35(12):931-46.
52. Baselga J, Pfister D, Cooper MR, Cohen R, Burtneess B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J. "Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin".

- J Clin Oncol. 2000 Feb;18(4):904-14.
53. Albanell J, Baselga J. "Systemic therapy emergencies".
Semin Oncol. 2000 Jun;27(3):347-61.
54. Bellmunt J, Guillem V, Paz-Ares L, Gonzalez-Larriba JL, Carles J, Albanell J, Tabernero JM, Cortes-Funes H, Baselga J. "Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer".
Eur J Cancer. 2000 Jul;36 Supplement 2:17-25.
55. Bellmunt J, Guillem V, Paz-Ares L, Gonzalez-Larriba JL, Carles J, Batiste-Alentorn E, Saenz A, Lopez-Brea M, Font A, Nogue M, Bastus R, Climent MA, de la Cruz JJ, Albanell J, Banus JM, Gallardo E, Diaz-Rubio E, Cortes-Funes H, Baselga J. "Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group".
J Clin Oncol. 2000 Sep 15;18(18):3247-55.
56. Baselga J. "Clinical trials of single-agent trastuzumab (Herceptin)".
Semin Oncol. 2000 Oct;27(5 Supplement 9):20-6.
57. Baselga J. "Current and planned clinical trials with trastuzumab (Herceptin)".
Semin Oncol. 2000 Oct;27(5 Supplement 9):27-32.
58. Baselga J. "New therapeutic agents targeting the epidermal growth factor receptor".
J Clin Oncol. 2000 Nov 1;18(21 Supplement):54S-9S.
59. Baselga J. "Monoclonal antibodies directed at growth factor receptors".
Ann Oncol. 2000;11 Supplement 3:187-90.
60. Borrell-Pages M, Fernandez-Larrea J, Borroto A, Rojo F, Baselga J, Arribas J. "The carboxy-terminal cysteine of the tetraspanin L6 antigen is required for its interaction with SITAC, a novel PDZ protein".
Mol Biol Cell. 2000 Dec;11(12):4217-25.
61. Baselga J, Averbuch SD. "ZD1839 ('Iressa') as an anticancer agent".
Drugs. 2000;60 Supplement 1:33-40; discussion 41-2.
62. Mendelsohn J, Baselga J. "The EGF receptor family as targets for cancer therapy".
Oncogene. 2000 Dec 27;19(56):6550-65.
63. Baselga J. "Clinical trials of single-agent trastuzumab (Herceptin)".
Eur J Cancer. 2001 Jan;37 Supplement 1:S18-24.
64. Baselga J. "Clinical trials of Herceptin(R) (trastuzumab)".
Eur J Cancer. 2001 Jan;37 Supplement 1:18-24.
65. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2".
N Engl J Med. 2001 Mar 15;344(11):783-92.
66. Baselga J, Tabernero JM. "Weekly docetaxel in breast cancer: applying clinical data to patient therapy".
Oncologist. 2001;6 Supplement 3:26-9.
67. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. "Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells".

- Cancer Res. 2001 Jun 15;61(12):4744-9.
68. Baselga J, Albanell J. "Mechanism of action of anti-HER2 monoclonal antibodies". Ann Oncol. 2001;12 Supplement 1:S35-41.
 69. Baselga J. "Phase I and II clinical trials of trastuzumab". Ann Oncol. 2001;12 Supplement 1:S49-55.
 70. Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Rosello J, Nicholson RI, Mendelsohn J, Baselga J. "Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments". Cancer Res. 2001 Sep 1;61(17):6500-10.
 71. Baselga J. "Is circulating HER-2 more than just a tumor marker?" Clin Cancer Res. 2001 Sep;7(9):2605-7.
 72. Baselga J. "Targeting the epidermal growth factor receptor: a clinical reality". J Clin Oncol. 2001 Sep 15;19(18 Supplement):41S-44S.
 73. Baselga J. "The EGFR as a target for anticancer therapy--focus on cetuximab". Eur J Cancer. 2001 Sep;37 Supplement 4:S16-22.
 74. Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, Baselga J, Caligiuri MA. "Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells". Eur J Immunol. 2001 Oct;31(10):3016-25.
 75. Baselga J, Albanell J, Molina MA, Arribas J. "Mechanism of action of trastuzumab and scientific update". Semin Oncol. 2001 Oct;28(5 Supplement 16):4-11.
 76. Albanell J, Rojo F, Baselga J. "Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839". Semin Oncol. 2001 Oct;28(5 Supplement 16):56-66.
 77. Bellmunt J, de Wit R, Albanell J, Baselga J. "A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer". Eur J Cancer. 2001 Nov;37(17):2212-5.
 78. Merlos-Suarez A, Ruiz-Paz S, Baselga J, Arribas J. "Metalloprotease-dependent protransforming growth factor-alpha ectodomain shedding in the absence of tumor necrosis factor-alpha-converting enzyme". J Biol Chem. 2001 Dec 21;276(51):48510-7.
 79. Baselga J. "Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials". Oncology. 2001;61 Supplement 2:14-21.
 80. Albanell J, Baselga J. "Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect". J Natl Cancer Inst. 2001 Dec 19;93(24):1830-2.
 81. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J. "Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition".

- J Clin Oncol. 2002 Jan 1;20(1):110-24.
82. Baselga J. "Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing".
Ann Oncol. 2002 Jan;13(1):8-9.
83. Molina MA, Saez R, Ramsey EE, Garcia-Barchino MJ, Rojo F, Evans AJ, Albanell J, Keenan EJ, Lluch A, Garcia-Conde J, Baselga J, Clinton GM. "NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer".
Clin Cancer Res. 2002 Feb;8(2):347-53.
84. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC. "Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery".
Clin Cancer Res. 2002 Apr;8(4):1172-81.
85. Diaz-Rubio E, Evans TR, Tabemero J, Cassidy J, Sastre J, Eatock M, Bisset D, Regueiro P, Baselga J. "Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors".
Ann Oncol. 2002 Apr;13(4):558-65.
86. Baselga J. "Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes".
J Clin Oncol. 2002 May 1;20(9):2217-9.
87. Baselga J, Norton L. "Focus on breast cancer".
Cancer Cell. 2002 May;1(4):319-22.
88. Baselga J, Albanell J. "Targeting epidermal growth factor receptor in lung cancer".
Curr Oncol Rep. 2002 Jul;4(4):317-24
89. Bellmunt J, Cos J, Cleries R, Perez M, Ribas A, Eres N, Murio JE, Margarit C, Baselga J. "Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer".
Cancer Invest. 2002;20(5-6):673-85.
90. Baselga J. "Why the epidermal growth factor receptor? The rationale for cancer therapy".
Oncologist. 2002;7 Supplement 4:2-8.
91. Baselga J. "A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand-dependent ErbB2 receptor heterodimerization".
Cancer Cell. 2002 Aug;2(2):93-5.
92. Bellmunt J, Albanell J, Paz-Ares L, Climent MA, Gonzalez-Larriba JL, Carles J, de la Cruz JJ, Guillem V, Diaz-Rubio E, Cortes-Funes H, Baselga J. "Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine".
Cancer. 2002 Aug 15;95(4):751-7.
93. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM. "Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial".

- J Clin Oncol. 2002 Sep 15;20(18):3815-25.
94. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL. "PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization". Nat Med. 2002 Oct;8(10):1145-52.
 95. Baselga J, Hammond LA. "HER-targeted tyrosine-kinase inhibitors". Oncology. 2002;63 Supplement 1:6-16.
 96. Baselga J, Albanell J. "Epithelial growth factor receptor interacting agents". Hematol Oncol Clin North Am. 2002 Oct;16(5):1041-63.
 97. Baum M, Buchanan M, Baselga J, Cataliotti L, Jassem J, Piccart M. "The future of breast cancer research in danger". Eur J Cancer. 2002 Nov;38(17):2210-3.
 98. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J. "Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types". J Clin Oncol. 2002 Nov 1;20(21):4292-302.
 99. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ. "A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy". Ann Oncol. 2003 Jan;14(1):29-35.
 100. Motzer RJ, Amato R, Todd M, Hwu WJ, Cohen R, Baselga J, Muss H, Cooper M, Yu R, Ginsberg MS, Needle M. "Phase II trial of anti-epidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma". Invest New Drugs. 2003 Feb;21(1):99-101.
 101. Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J. "TACE is required for the activation of the EGFR by TGF-alpha in tumors". EMBO J. 2003 Mar 3;22(5):1114-24.
 102. Anido J, Matar P, Albanell J, Guzman M, Rojo F, Arribas J, Averbuch S, Baselga J. "ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells". Clin Cancer Res. 2003 Apr;9(4):1274-83.
 103. Arteaga CL, Baselga J. "Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice". Clin Cancer Res. 2003 May;9(5):1579-89.
 104. Baselga J. "A review of EGFR targeted therapy". Clin Adv Hematol Oncol. 2003 Apr;1(4):218-9.
 105. Kuenen BC, Tabernero J, Baselga J, Cavalli F, Pfanner E, Conte PF, Seeber S, Madhusudan S, Deplanque G, Huisman H, Scigalla P, Hoekman K, Harris AL.

- "Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma".
Clin Cancer Res. 2003 May;9(5):1648-55.
106. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J. "Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]".
J Clin Oncol. 2003 Jun 15;21(12):2237-46.
107. LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Feyereislova A, Heyes A, Averbuch SD, Ochs J, Baselga J. "Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors".
Clin Cancer Res. 2003 Jun;9(6):2040-8.
108. Borroto A, Ruiz-Paz S, de la Torre TV, Borrell-Pages M, Merlos-Suarez A, Pandiella A, Blobel CP, Baselga J, Arribas J. "Impaired trafficking and activation of tumor necrosis factor-alpha-converting enzyme in cell mutants defective in protein ectodomain shedding".
J Biol Chem. 2003 Jul 11;278(28):25933-9.
109. Boyle P, Autier P, Bartelink H, Baselga J, Boffetta P, Burn J, Burns HJ, Christensen L, Denis L, Dicato M, Diehl V, Doll R, Franceschi S, Gillis CR, Gray N, Griecute L, Hackshaw A, Kasler M, Kogevinas M, Kvinnsland S, La Vecchia C, Levi F, McVie JG, Maisonneuve P, Martin-Moreno JM, Bishop JN, Oleari F, Perrin P, Quinn M, Richards M, Ringborg U, Scully C, Siracka E, Storm H, Tubiana M, Tursz T, Veronesi U, Wald N, Weber W, Zaridze DG, Zatonski W, zur Hausen H. "European Code Against Cancer and scientific justification: third version (2003)".
Ann Oncol. 2003 Jul;14(7):973-1005.
110. Baselga J. "Skin as a surrogate tissue for pharmacodynamic end points: is it deep enough?".
Clin Cancer Res. 2003 Jul;9(7):2389-90.
111. Mendelsohn J, Baselga J. "Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer".
J Clin Oncol. 2003 Jul 15;21(14):2787-99.
112. Bellmunt J, de Wit R, Albiol S, Tabernero J, Albanell J, Baselga J. "New drugs and new approaches in metastatic bladder cancer".
Crit Rev Oncol Hematol. 2003 Aug;47(2):195-206.
113. Baselga J, Llombart-Cussac A, Bellet M, Guillem-Porta V, Enas N, Krejcy K, Carrasco E, Kayitalire L, Kuta M, Lluch A, Vodvarka P, Kerbrat P, Namer M, Petruzalka L. "Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients".

- Ann Oncol. 2003 Sep;14(9):1383-90.
114. Felip E, Rosell R, Domine M, Santome L, Garrido P, Font A, Carrato A, Terrasa J, Vadell C, Mane JM, Baselga J. "Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study".
Ann Oncol. 2003 Oct;14(10):1549-54.
115. Bianchi G, Albanell J, Eiermann W, Vitali G, Borquez D, Vigano L, Molina R, Raab G, Locatelli A, Vanhauwere B, Gianni L, Baselga J. "Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer".
Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5944-51.
116. Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, Tillner J, Kovar A, Braun AH, Trarbach T, Seeber S, Harstrick A, Baselga J. "Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor".
J Clin Oncol. 2004 Jan 1;22(1):175-84.
117. Villanueva de la Torre T, Bech-Serra JJ, Ruiz-Paz S, Baselga J, Arribas J. "Inactivating mutations block the tumor necrosis factor-alpha-converting enzyme in the early secretory pathway".
Biochem Biophys Res Commun. 2004 Feb 20;314(4):1028-35.
118. Baselga J. "Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?".
J Clin Oncol. 2004 Mar 1;22(5):759-61.
119. Arteaga CL, Baselga J. "Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?".
Cancer Cell. 2004 Jun;5(6):525-31.
120. Baselga J, Arribas J. "Treating cancer's kinase 'addiction'".
Nat Med. 2004 Aug;10(8):786-7.
121. Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, Anton A, Laurent C, Mayordomo JI, Estaun N, Losa I, Guillem V, Garcia-Conde J, Tisairé JL, Baselga J. "A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer".
Ann Oncol. 2004 Sep;15(9):1358-65.
122. Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzman M, Rodriguez S, Arribas J, Palacios J, Baselga J. "Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting".
Clin Cancer Res. 2004 Oct 1;10(19):6487-501.
123. Tabernero J, Salazar R, Casado E, Martinelli E, Gomez P, Baselga J. "Targeted therapy in advanced colon cancer: the role of new therapies".
Ann Oncol. 2004;15 Supplement 4:iv55-62.
124. Yarden Y, Baselga J, Miles D. "Molecular approach to breast cancer treatment".

- Semin Oncol. 2004 Oct;31(5 Supplement 10):6-13.
125. Baselga J, Gianni L, Geyer C, Perez EA, Riva A, Jackisch C. "Future options with trastuzumab for primary systemic and adjuvant therapy".
Semin Oncol. 2004 Oct;31(5 Supplement 10):51-7.
126. Herbst RS, Fukuoka M, Baselga J. "Gefitinib--a novel targeted approach to treating cancer".
Nat Rev Cancer. 2004 Dec;4(12):956-65.
127. Hidalgo A, Tabernero J, Rojo F, Marimon I, Andreu J, Baselga J. "Feasibility of CT scan-guided Tru-Cut serial liver biopsies to evaluate pharmacodynamic endpoints in patients with liver metastasis treated with experimental drugs".
Abdom Imaging. 2005 Jan-Feb;30(1):65-8.
128. Camps C, Felip E, Sanchez JM, Massuti B, Artal A, Paz-Ares L, Carrato A, Alberola V, Blasco A, Baselga J, Astier L, Voi M, Rosell R. "Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer".
Ann Oncol. 2005 Apr;16(4):597-601.
129. Tabernero J, Rojo F, Marimon I, Voi M, Albanell J, Guix M, Vazquez F, Carulla J, Cooper M, Andreu J, Van Vreckem A, Bellmunt J, Manne V, Manning JA, Garrido C, Felip E, Del Campo JM, Garcia M, Valverde S, Baselga J. "Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors".
J Clin Oncol. 2005 Apr 10;23(11):2521-33.
130. Baselga J, Arteaga CL. "Critical update and emerging trends in epidermal growth factor receptor targeting in cancer".
J Clin Oncol. 2005 Apr 10;23(11):2445-59.
131. Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P. "Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule".
J Clin Oncol. 2005 Apr 1;23(10):2162-71.
132. Arribas J, Baselga J. "Who will benefit from treatment against EGFR?".
Lancet Oncol. 2005 May;6(5):257-8.
133. Miller KD, Trigo JM, Wheeler C, Barge A, Rowbottom J, Sledge G, Baselga J. "A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer".
Clin Cancer Res. 2005 May 1;11(9):3369-76.
134. Boyle P, Ariyaratne M, Bartelink H, Baselga J, Berns A, Brawley OW, Burns H, Davidov M, Dinshaw KA, Dresler C, Eggermont AM, Gajurel D, Gordina G, Gray N, Kakizoe T, Karki BS, Kasler M, Kerr DJ, Khayat D, Kiselev A, Khuhaprema T, Klocker H, Levshin V, Martin-Moreno JM, McVie JG, Mendelsohn J, Napalkov NP, Ngoma TA, Park JG, Philip T, Potschke-Langer M, Poudal HN, Rajan B, Ringborg U, Rodger A, Seffrin JR, Shanta V, Shrestha MM, Thomas R, Tursz T, de

- Valeriola D, Veronesi U, Wiestler OD, Zaridze D, Zatonski W, Zeng YX. "Curbing tobacco's toll starts with the professionals: World No Tobacco Day." *Lancet*. 2005 Jun 11-17;365(9476):1990-2.
135. Baselga J. "Does epidermal growth factor receptor status predict activity of cetuximab in colorectal cancer patients?". *Nat Clin Pract Oncol*. 2005 Jun;2(6):284-5
136. Baselga J, Albanell J, Ruiz A, Lluch A, Gascon P, Guillem V, Gonzalez S, Sauleda S, Marimon I, Tabernero JM, Koehler MT, Rojo F. "Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer". *J Clin Oncol*. 2005 Aug 10;23(23):5323-33.
137. Spano JP, Milano G, Baselga J. "EGFR/VEGF signalling pathway in colorectal cancer: the way we are!". *Bull Cancer*. 2005 Aug;92(Spec no):S3-4.
138. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, Gascon P, Amellal N, Harstrick A, Eckardt A. "Phase II multicenter study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck". *J Clin Oncol*. 2005 Aug 20;23(24):5568-77.
139. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E. "Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study". *J Clin Oncol*. 2005 Sep 1;23(25):5960-72.
140. Baselga J, Cortes J. "Epidermal growth factor receptor pathway inhibitors". *Cancer Chemother Biol Response Modif*. 2005;22:205-23.
141. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD. "Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer". *N Engl J Med*. 2005 Oct 20;353(16):1659-72.
142. Tabernero J, Macarulla T, Ramos FJ, Baselga J. "Novel targeted therapies in the treatment of gastric and esophageal cancer". *Ann Oncol*. 2005 Nov;16(11):1740-8.
143. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA. "Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials". *J Clin Oncol*. 2005 Nov 1;23(31):8081-92.

144. Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Llombart Cussac A, Bozhok A, Martinez-Agullo A, Greco M, Byakhov M, Lopez Lopez JJ, Mansutti M, Valagussa P, Bonadonna G. "Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy".
Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8715-21.
145. Saez R, Molina MA, Ramsey EE, Rojo F, Keenan EJ, Albanell J, Lluch A, Garcia-Conde J, Baselga J, Clinton GM. "p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer".
Clin Cancer Res. 2006 Jan 15;12(2):424-31.
146. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N. "mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt".
Cancer Res. 2006 Feb 1;66(3):1500-8.
147. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. "Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck".
N Engl J Med. 2006 Feb 9;354(6):567-78.
148. Wu FY, Wang SE, Sanders ME, Shin I, Rojo F, Baselga J, Arteaga CL. "Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity".
Cancer Res. 2006 Feb 15;66(4):2162-72.
149. Calvo E, Baselga J. "Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors".
J Clin Oncol. 2006 May 10;24(14):2158-63.
150. Baselga J. "Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in the treatment of cancer? A mutation-driven question".
J Clin Oncol. 2006 May 20;24(15):2225-6.
151. Baselga J. "Targeting tyrosine kinases in cancer: the second wave".
Science. 2006 May 26;312(5777):1175-8.
152. Bech-Serra JJ, Santiago-Josefat B, Esselens C, Saftig P, Baselga J, Arribas J, Canals F. "Proteomic identification of desmoglein 2 and activated leukocyte cell adhesion molecule as substrates of ADAM17 and ADAM10 by difference gel electrophoresis".
Mol Biol Cell. 2006 Jul;26(13):5086-95.
153. Anido J, Scaltriti M, Bech Serra JJ, Santiago Josefat B, Todo FR, Baselga J, Arribas J. "Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation".
EMBO J. 2006 Jul 12;25(13):3234-44.
154. Mendelsohn J, Baselga J. "Epidermal growth factor receptor targeting in cancer".
Semin Oncol. 2006 Aug;33(4):369-85.
155. Rojo F, Tabernero J, Albanell J, Van Cutsem E, Ohtsu A, Doi T, Koizumi W, Shirao K, Takiuchi H, Ramon Cajal S, Baselga J. "Pharmacodynamic studies of

- gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma".
J Clin Oncol. 2006 Sep 10;24(26):4309-16. Erratum in: J Clin Oncol. 2006 Dec 10;24(35):5620.
156. Baselga J, Perez EA, Pienkowski T, Bell R. "Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer".
Oncologist. 2006;11 Suppl 1:4-12.
157. Scaltriti M, Baselga J. "The epidermal growth factor receptor pathway: a model for targeted therapy".
Clin Cancer Res. 2006 Sep 15;12(18):5268-72.
158. Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J, Ramon y Cajal S. "Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer".
Cancer. 2006 Oct 15;107(8):1801-11
159. Rojo F, Najera L, Lirola J, Jimenez J, Guzman M, Sabadell MD, Baselga J, Ramon y Cajal S. "4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis".
Clin Cancer Res. 2007 Jan 1;13(1):81-9.
160. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez Rovira P, Piccart-Gebhart MJ. "2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial".
Lancet. 2007 Jan 6;369(9555):29-36.
161. Bruna A, Darken RS, Rojo F, Ocana A, Penuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, Seoane J. "High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene".
Cancer Cell. 2007 Feb;11(2):147-60.
162. Sessa C, Cresta S, Cerny T, Baselga J, Rota Caremoli E, Malossi A, Hess D, Trigo J, Zucchetti M, D'Incalci M, Zaniboni A, Capri G, Gatti B, Carminati P, Zanna C, Marsoni S, Gianni L. "Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors".
Ann Oncol. 2007 Mar;18(3):561-8.
163. Bellmunt J, Paz-Ares L, Cuello M, Cecere F, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz J, Taron M, Rosell R, Baselga J. "Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy".
Ann Oncol. 2007 Mar;18(3):522-8.
164. Piccart M, Goldhirsch A, Wood W, Pritchard K, Baselga J, Reaby L, Kossler I, Kyriakides S, Norton L, Coates A. "Keeping faith with trial volunteers".
Nature. 2007 Mar 8;446(7132):137-8.

165. Cortes J, Baselga J. "Targeting the microtubules in breast cancer beyond taxanes: the epothilones".
Oncologist. 2007 Mar;12(3):271-80.
166. Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J, Di Cosimo S, Matias-Guiu X, Ramon y Cajal S, Arribas J, Baselga J. "Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer".
J Natl Cancer Inst. 2007 Apr 18;99(8):628-38.
167. Vermorken J. B., Trigo J., Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A and Baselga J. "An open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck failing platinum-based therapy".
J Clin Oncol. 2007 Jun 1;25(16):2171-7.
168. Curran D, Giralt J, Harari P M, Kian Ang K, Cohen R B, Kies M S, Jassem J, Baselga J, Rowinsky E K, Bonner J A, Amellal N and Comte S. "Quality of Life in Head and Neck Cancer Patients Following Treatment with High-dose Radiotherapy Alone or in Combination with Cetuximab".
J Clin Oncol. 2007 Jun 1;25(16):2191-7.
169. Prat A, Baselga J. "Biologic therapy: current and future applications in oncology"
Med Clin (Barc). 2007 Jun 30;129(5):184-93.
170. Di Cosimo S, Baselga J. "Pharmacodynamic endpoints in primary breast cancer".
Ann Oncol. 2007 Jul;18 Supplement 9:ix21-3.
171. Thomas E, Tabernero J, Fournier M, Conte P, Fumoleau P, Lluch A, Vahdat L T, Bunnell C A, Burris H A, Viens P, Baselga J, Rivera E, Guarneri V, Poulart V, Klimovsky J, Lebwohl D and Martin M. "Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer".
J Clin Oncol. 2007 Aug 10;25(23):3399-406.
172. Khambata-Ford S, Garrett Ch R, Meropol N J, Basik M, Harbison C T, Wu S, Wong T W, Huang X, Takimoto C H, Godwin A K, Tan B R, Krishnamurthi S S, Burris III H A, Poplin E A, Hidalgo M, Baselga J, Edwin A Clark E A and Mauro D J. "Expression of epiregulin and amphiregulin and K-RAS mutation status are associated with disease control in metastatic colorectal cancer patients treated with cetuximab".
J Clin Oncol. 2007 Aug 1;25(22):3230-7.
173. Armengol G, Rojo F, Castellvi J, Iglesias C, Cuatrecasas M, Pons B, Baselga J, Ramon Y Cajal S. "4E-Binding Protein 1: A Key Molecular "Funnel Factor" in Human Cancer with Clinical Implications".
Cancer Res. 2007 Aug 15;67(16):7551-5.
174. Baselga J, Tabernero J. " Combined Antiangiogenesis and Antiepidermal Growth Factor Receptor Targeting in the Treatment of Cancer: Hold Back, We Are Not There Yet".
J Clin Oncol. 2007 Oct 10;25(29):4516-8.

175. Folprecht G, Tabernero J, Köhne CH, Zacharchuk C, Paz-Ares L, Rojo F, Quinn S, Casado E, Salazar R, Abbas R, Lejeune C, Marimón I, Andreu J, Ubbelohde U, Cortes-Funes H, Baselga J. "Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer". *Clin Cancer Res.* 2008 Jan 1;14(1):215-223.
176. Prat A, Parera M, Peralta S, Perez-Benavente MA, Garcia A, Gil-Moreno A, Martinez-Palones JM, Roxana I, Baselga J, Del Campo JM. "Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer". *Ann Oncol.* 2008 Feb;19(2):327-31.
177. Twelves C, Trigo JM, Jones R, De Rosa F, Rakhit A, Fettner S, Wright T, Baselga J. "Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study". *Eur J Cancer.* 2008 Feb;44(3):419-26.
178. Baselga J, Rothenberg ML, Tabernero J, Seoane J, Daly T, Cleverly A, Berry B, Rhoades SK, Ray CA, Fill J, Farrington DL, Wallace LA, Yingling JM, Lahn M, Arteaga C, Carducci M. " TGF-beta signalling-related markers in cancer patients with bone metastasis". *Biomarkers.* 2008 Mar;13(2):217-36.
179. Baselga J, Rosen N. " Determinants of Resistance to anti-epidermal growth factor receptor agents. *J Clin Oncol.* 2008 Apr 1;26(10):1582-4.
180. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J. "Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors". *J Clin Oncol.* 2008 Apr 1;26(10):1603-10.
181. Awada A, Albanell J, Canney PA, Dirix LY, Gil T, Cardoso F, Gascon P, Piccart MJ, Baselga J. "Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study". *Br J Cancer.* 2008 May 6;98(9):1500-7.
182. Felip E, Rojo F, Reck M, Heller A, Klughammer B, Sala G, Cedres S, Peralta S, Maacke H, Foernzler D, Parera M, Möcks J, Saura C, Gatzemeier U and Baselga J. "A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy". *Clin Cancer Res.* 2008 Jun 15;14(12):3867-74.
183. Untch M, Gelber RD, Jackisch C, Procter M, Baselga J, Bell R, Cameron D, Bari M, Smith I, Leyland-Jones B, de Azambuja E, Wermuth P, Khasanov R, Feng-Yi F, Constantin C, Mayordomo JI, Su CH, Yu SY, Lluch A, Senkus-Konefka E, Price C,

- Haslbauer F, Sahui TS, Srimuninnimit V, Colleoni M, Coates AS, Piccart-Gebhart MJ, Goldhirsch A; for the HERA Study Team. " Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial".
Ann Oncol. 2008 Jun;19(6):1090-6.
184. Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J. "Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies".
Cancer. 2008 Jun 15;112(12):2710-9.
185. Baselga J, Senn HJ; European Society for Medical Oncology. "The perspective and role of the medical oncologist in cancer prevention: a position paper by the European Society for Medical Oncology".
Ann Oncol. 2008 Jun;19(6):1033-5.
186. ESMO, Baselga J. "Creating a stronger front against cancer: ESMO and ECCO join forces".
Ann Oncol. 2008 Aug;19(8):1367-8.
187. Prat A, Baselga J. "The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2".
Nat Clin Pract Oncol. 2008 Sep;5(9):531-42.
188. Boyle P, Anderson BO, Andersson LC, Ariyaratne Y, Auleley GR, Barbacid M, Bartelink H, Baselga J, Behbehani K, Belardelli F, Berns A, Bishop J, Brawley O, Burns H, Clanton M, Cox B, Currow D, Dangou JM, de Valeriola D, Dinshaw K, Eggermont A, Fitzpatrick J, Forstmane M, Garaci E, Gavin AT, Kakizoe T, Kasler M, Keita N, Kerr D, Khayat D, Khleif S, Khuhaprema T, Knezevic T, Kubinova R, Mallath M, Martin-Moreno J, McCance D, McVie JG, Merriman A, Ngoma T, Nowacki M, Orgelbrand J, Park JG, Pierotti M, Ashton LP, Puska P, Escobar CV, Rajan B, Rajkumar T, Ringborg U, Robertson C, Rodger A, Roovali L, Santini LA, Sarhan M, Seffrin J, Semiglazov V, Shrestha BM, Soo KC, Stamenic V, Tamblyn C, Thomas R, Tuncer M, Tursz T, Vaitkiene R, Vallejos C, Veronesi U, Wojtyla A, Yach D, Yoo KY, Zatonski W, Zaridze D, Zeng YX, Zhao P, Zheng T. "Need for global action for cancer control".
Ann Oncol. 2008 Sep;19(9):1519-21.
189. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP. "Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer".
J Clin Invest. 2008 Sep;118(9):3065-74.
190. Rao S, Starling N, Cunningham D, Benson M, Wotherspoon A, Lüpfer C, Kurek R, Oates J, Baselga J, Hill A. " Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer".
Br J Cancer. 2008 Sep 16;99(6):868-74.
191. Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, Freed E, Ligon AH, Vena N, Ogino S, Chheda MG, Tamayo P, Finn S, Shrestha Y, Boehm JS, Jain S, Bojarski E, Mermel C, Barretina J, Chan JA, Baselga J, Tabernero J, Root DE,

- Fuchs CS, Loda M, Shivdasani RA, Meyerson M, Hahn WC. "CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity".
Nature. 2008 Sep 25;455(7212):547-51.
192. Baselga J. "Novel agents in the era of targeted therapy: what have we learned and how has our practice changed?"
Ann Oncol. 2008 Sep;19 Suppl 7:vii281-8.
193. O'Brien PJ, Ramanathan R, Yingling JM, Baselga J, Rothenberg ML, Carducci M, Daly T, Adcock D, Lahn M. "Analysis and variability of TGFbeta measurements in cancer patients with skeletal metastases".
Biologics. 2008 Sep;2(3):563-9.
194. Serra V, Markman B, Scaltriti M, Eichhorn P, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, and Baselga J. "NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits growth of cancer cells with activating PI3K mutations"
Cancer Res. 2008 Oct 1;68(19):8022-30.
195. Vilar E, Scaltriti M, Balmaña J, Saura C, Guzman M, Arribas J, Baselga J and Tabernero J. " Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. "
Br J Cancer. 2008 Nov 18;99(10):1607-12.
196. Eichhorn P, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen R, Valero V, Seoane J, Bernards R and Baselga J. "Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235."
Cancer Res. 2008 Nov 15;68(22):9221-30.
197. Domingo E, Suriñach JM, Murillo J, Duran M, Suriñach J, Baselga J, de Sevilla TF. "Prognostic factors in the diagnostic work-up of cancer patients in an internal medicine department: does age matter?".
Int J Clin Pract. 2008 Nov;62(11):1723-9.
198. Di Cosimo S, Baselga J. "Targeted therapies in breast cancer: Where are we now?."
Eur J Cancer. 2008 Dec;44(18):2781-90.
199. Carracedo A, Baselga J, Pandolfi PP. "Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors."
Cell Cycle. 2008 Dec 15;7(24):3805-9.
200. Cortes J, DiCosimo S, Climent MA, Cortés-Funes H, Lluch A, Gascón P, Mayordomo JI, Gil M, Benavides M, Cirera L, Ojeda B, Rodríguez CA, Trigo JM, Vazquez J, Regueiro P, Dorado JF, Baselga J; Spanish Breast Cancer Cooperative Group SOLTI. "Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study."
Clin Cancer Res. 2009 Jan 1;15(1):307-14.
201. Prat A, Parera M, Adamo M, Peralta S, Perez-Benavente MA, Garcia A, Gil-Moreno A, Martinez-Palones JM, Baselga J, del Campo JM. "Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels."

- Ann Oncol. 2009 Feb;20(2):294-7.
202. Baselga J, Zambetti M, Llombart-Cussac A, Manikhas G, Kubista E, Steger G, Biakhov M, Khasanov R, Machson A, Tjulandin S, Ludwig H, Verrill M, Ciruelos E, Egyhazi S, Xu L, Zerba K, Lee H, Clark E, Galbraith S. "Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer."
J Clin Oncol. 2009 Feb 1;27(4):526-34.
203. Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, Smith DJ, Landolfi S, Ramon y Cajal S, Arribas J, Baselga J. "Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity."
Oncogene. 2009 Feb 12;28(6):803-14.
204. Lennon S, Barton C, Banken L, Gianni L, Marty M, Baselga J and B Leyland-Jones. "The Utility of Serum HER2 Extracellular Domain (ECD) Assessment in Clinical Decision Making: Pooled Analysis of Four Trials of Trastuzumab in Metastatic Breast Cancer."
J Clin Oncol. 2009 Apr 1;27(10):1685-93.
205. Peñuelas S, Anido J, Prieto-Sánchez RM, Folch G, Barba I, Cuartas I, García-Dorado D, Poca MA, Sahuquillo J, Baselga J, Seoane J. "TGFβ increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma."
Cancer Cell. 2009 Apr 7;15(4):315-27.
206. Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Llombart Cussac A, Bozhok A, Martinez-Agullo A, Greco M, Byakhov M, Lopez Lopez J J, Mansutti M, Valagussa P and Bonadonna G. "Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate and Fluorouracil, as Adjuvant or Primary Systemic Therapy: Results of a Randomized Phase III European Cooperative Trial in Operable Breast Cancer (ECTO)."
J Clin Oncol. 2009 May 20;27(15):2474-81.
207. Baselga J, Semiglazov V, Van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W and Rugo HS. "Phase II randomized neoadjuvant study of the mTOR inhibitor everolimus (RAD001) in combination with letrozole versus placebo and letrozole in patients with ER+ breast cancer."
J Clin Oncol. 2009 Jun 1;27(16):2630-7.
208. Pedersen K, Angelini PD, Laos S, Bach-Faig A, Cunningham MP, Ferrer-Ramón C, Luque-García A, García-Castillo J, Parra-Palau JL, Scaltriti M, Ramón y Cajal S, Baselga J, Arribas J. "A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis."
Mol Cell Biol. 2009 Jun;29(12):3319-31.
209. Baselga J, Swain SM. "Novel anticancer targets: revisiting ERBB2 and discovering ERBB3."
Nat Rev Cancer. 2009 Jul;9(7):463-75.

210. Di Cosimo S, Baselga J. "Phosphoinositide 3-kinase mutations in breast cancer: a "good" activating mutation?". *Clin Cancer Res*. 2009 Aug 15;15(16):5017-9.
211. Pomerantz MM, Ahmadiyeh N, Jia L, Herman P, Verzi MP, Doddapaneni H, Beckwith CA, Chan JA, Hills A, Davis M, Yao K, Kehoe SM, Lenz H-J, Haiman CA, Yan C, Henderson BE, Frenkel B, Barretina J, Bass A, Tabernero J, Baselga J, Regan MM, Manak JR, Shivdasani R, Coetzee GA, Freedman ML. "The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer". *Nat Genet*. 2009 Aug;41(8):882-4.
212. Markman B, Atzori F, Pérez-García J, Tabernero J, Baselga J. "Status of PI3K inhibition and biomarker development in cancer therapeutics". *Ann Oncol*. 2009 Aug 27.
213. Garcia-Castillo J, Pedersen K, Angelini PD, Bech-Serra JJ, Colome N, Cunningham MP, Parra Palau JL, Canals F, Baselga J, Arribas J. "HER2 carboxy terminal fragments regulate cell migration and cortactin phosphorylation". *J Biol Chem*. 2009 Sep 11;284(37):25302-13.
214. Chandarlapaty S, Scaltriti M, Angelini P, Ye Q, Guzman M, Hudis C.A, Norton L, Solti D.B, Arribas J, Baselga J, Rosen N. "Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth". *Oncongene*. 2009 Oct 26.
215. Ellis MJ, Lin L, Crowder R, Tao Y, Hoog J, Snider J, Davies S, Deschryver K, Evans DB, Steinseifer J, Bandaru R, Liu W, Gardner H, Semiglazov V, Watson M, Hunt K, Olson J, Baselga J. "Phosphatidylinositol-3-kinase Alpha catalytic subunit kinase domain mutations impart a favorable prognosis on estrogen receptor positive breast cancer through a mechanism that is independent of responsiveness to endocrine treatment". *Breast Cancer Res Treat*. 2009 Oct 21.
216. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. "Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival". *Lancet Oncol*. 2009 Nov 6.
217. Cedrés S, Prat A, Martínez P, Pallisa E, Sala G, Andreu J, Del Campo JM, Quispe I, Baselga J, Felip E. "Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib". *Lung Cancer*. 2009 Nov; 66(2):257-61.
218. Lennon S, Barton C, Banken L, Gianni L, Marty M, Baselga J, Leyland-Jones B. "Reply to S.M. Ali et al". *Clin Cancer Res*. 2009 Nov 16.
219. Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, Esteva FJ, Buzdar AU, Chen H, Eksambi S, Hortobagyi GN, Baselga J, Gonzalez-Angulo

- AM. "Loss of HER2 Amplification Following Trastuzumab-based Neoadjuvant Systemic Therapy and Survival Outcomes".
Clin Cancer Res. 2009 Dec 1;15(23):7381-8.
220. Cortes J, Baselga J. "How to treat hormone receptor positive, HER2 amplified breast cancer?".
J Clin Oncol. 2009 Nov 20;27(33):5492-4.
221. Taberero J, Ciardiello F, Rivera F, Rodriguez-Braun E, Ramos FJ, Martinelli E, Vega-Villegas ME, Roselló S, Liebscher S, Kisker O, Macarulla T, Baselga J, Cervantes A. "Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study".
Ann Oncol. 2009 Nov 25.
222. Ciruelos EM, Cortés J, Cortés-Funes H, Mayordomo JL, Bermejo B, Ojeda B, García E, Rodríguez CA, Muñoz M, Gómez P, Manso L, Andrés R, Lluch A, Saura C, Mendiola C, Baselga J. "Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial).
Ann Oncol. 2009 Nov 25.
223. Nemunaitis J, Clayman G, Agarwala S.S, Hrushesky W, Wells J.R, Moore C, Hamm J, Yoo G, Baselga J, Murphy B.A, Menander K.A, Licato LL, Chada S, Gibbons R.D, Hainaut P, Roth J.A, Sobol R.E, Goodwin W.J. "Biomarkers Predict p53 gene therapy efficacy in recurrent squamous cell carcinoma of the head and Neck".
Clin Cancer Res. 2009 Dec 15;15(24):7719-7725.
224. Gianni L, Lladò A, Bianchi G, Cortes J, Kellokumpu-Lehtinen P-L, Cameron David A, Miles D, Salvagni S, Wardley A, Goeminne J-C, Hersberger V, Baselga J. "Open-Label, Phase II, Multicenter, Randomized Study Of The Efficacy And Safety Of Two Dose Levels Of Pertuzumab, A Her2 Dimerization Inhibitor, In Patients With Her2-Negative Metastatic Breast Cancer".
J Clin Oncol. 2009. (In Press).
225. Baselga J, Gelmon K, Verma S, Wardley AM, Conte P, Miles DW, Bianchi GV, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L. "A Phase II Trial Of Pertuzumab And Trastuzumab In Patients With HER2-Positive Metastatic Breast Cancer That Had Progressed During Prior Trastuzumab Therapy".
J Clin Oncol. 2009. (In Press).
226. Taberero J, Cervantes A, Rivera F, Martinelli E, Rojo FG, Von Heydebreck A, Macarulla T, Rodriguez-Braun E, Vega-Villegas ME, Scheid S, Ramos FJ, Roselló S, Celik I, Stroh C, Baselga J, Ciardiello F. "Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation Study".
J Clin Oncol. 2009. (In Press).
227. O'Shaughnessy J, Blackwell KL, Burstein H, Storniolo AM, Sledge G, Baselga J, Koehler M, Laabs S, Florance A, Roychowdhury D. A randomized study of

- lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy .
J Clin Oncol. 2009. (In Press).
228. Beroukhi R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, McHenry KT, Pinchback R, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Taberero J, Baselga J, Tsao M, DeMichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. "The Landscape of copy number alterations across multiple human cancers".
Nature. 2009. (In Press).
229. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Bozhok A, Baronio R, Feyereislova A, Valagussa P, Baselga J. Neoadjuvant Trastuzumab in patients with HER2-positive locally advanced breast cancer: a randomized phase III trial with a parallel HER2-negative cohort (the NOAH trial)".
Lancet. 2009. (In Press)

Abstracts:

1. Baselga J, Kris MG, Gralla RJ, Cheng E, Potanovich LM, D'Aquisto RW, Fanucchi MP and Heelan RT. "Phase II studies of three new antifolates in non-small cell lung cancer".
Proc Am Soc Clin Oncol. Vol. 7, 1988: 853, 1988.
2. Baselga J, Gralla RJ, Kris MG, Houghton AN, Mendelsohn J and Cordon-Cardo C. "Cell surface antigens of human non-small cell lung cancer (NSCLC): expression of epidermal growth factor receptor (EGFr), GD2 and GD3 gangliosides (GANGL)".
AACR Meeting Abstracts 30: 1406 1989.
3. Baselga J, Magill GB, Curley T and Casper ES. "Phase II trial of PALA + dipyridamole in patients with metastatic soft tissue sarcoma".
AACR Meeting Abstracts 8841, 1990.
4. Kumar R, Mendelsohn J, Baselga J, Shieh J-H, Warren DJ and Moore M, "Interferon- γ mediated regulation of expression of interleukin-1 in human epidermoid A431 cells".
American Society of Hematology 1990. Abstract H-MD-0033.
5. Kumar R, Mendelsohn J, Baselga J, Shieh J, Warren DJ and Moore, M "Interferon- γ and interleukin 1 mediated growth regulation of human epidermoid A431 cells."
AACR Meeting Abstracts 32: 292, 1991.

6. Norton L, Baselga J, Masui H, Hyman J, Kumar R and Mendelsohn J. "Growth factor perturbation: A therapeutically exploitable mechanism for chemotherapy action". Proc Am Soc Clin Oncol. Vol. 10, 1991: 208.
7. Baselga J, Norton L, Miller W, Masui H and Mendelsohn J, "Synergistic antitumor effects of Adriamycin (ADR) and anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (Mab)". Proc Am Soc Clin Oncol. Vol. 11, 1992: 238.
8. Baselga J, Miller W, Norton L and Mendelsohn, J. "Modulation of epidermal growth factor receptor (EGFR)/ transforming growth factor- α (TGF- α) pathway by adriamycin (ADR)". AACR Meeting Abstracts 33: 2947, 1992.
9. Baselga J, Maerz WJ, Moy D, Miller WH, Castro L, Reuter VE, Masui H and Dmitrovsky E. "Transfection of a transforming growth factor cDNA overcomes anti-tumorigenic but not differentiation effects of retinoid acid in human teratocarcinomas". AACR Meeting Abstracts 34: 282, 1993.
10. Fan Z, Masui H, Baselga J and Mendelsohn J. "Anti-tumor effect of anti-EGF receptor monoclonal antibodies is enhanced by combination treatment with cisplatinum". AACR Meeting Abstracts 34: 2037, 1993.
11. Baselga J, Scott A, Pfister D, Kris M, Divgi C, Zhang Z, Larson S, Oettgen H and Mendelsohn J. "Comparative pharmacology in phase I and imaging trials utilizing anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MAbs) labeled with ^{131}I or ^{111}In ". Proc Am Soc Clin Oncol. Vol. 12, 1993: 368.
12. Scott AM, Baselga J, Divgi CR, Pfister D, Kris M, Zhang JJ, Daghihian F, Carmichael N, Oettgen HF, Mendelsohn J and Larson S. "Comparison of phase I trials of anti-epidermal growth factor receptor EGFR monoclonal antibodies MAbs 528 and 225 labelled with iodine-131 and indium-111". J Nucl Med 34, 5 Supplement: 213p. 1993.
13. Maerz WJ, Baselga J and Dmitrovsky E. "Over-expression of FGF4 promotes tumorigenicity without blocking retinoic acid-mediated human teratocarcinoma differentiation". AACR Meeting Abstracts 35: 3509, 1994.
14. Baselga J, Norton L, Coplan K, Shalaby R and Mendelsohn J. "Antitumor activity of paclitaxel in combination with anti-growth factor receptor monoclonal antibodies in breast cancer xenografts". AACR Meeting Abstracts 35: 2262, 1994.
15. Baselga J, Norton L, Coplan K, Shalaby R and Mendelsohn J. "Anti-HER2 humanized monoclonal antibody alone and in combination with chemotherapy against human breast carcinoma xenografts. Proc Am Soc Clin Oncol. Vol. 13, 1994: 53.
16. Hudis C, Seidman A, Baselga J, Raptis G, Lebwohl D, Gilewski T, Moynahan M, Sklarin N, Fennelly D, Crown J, Uhlenhopp M, Riedel E, Yao TJ and Norton L.

- “Sequential high dose adjuvant doxorubicin (A), paclitaxel (T) and cyclophosphamide (C) with G-CSF (G) is feasible for women (pts) with resected breast cancer (BC) and > 4(+) lymph nodes”.
Proc Am Soc Clin Oncol. Vol. 13, 1994: 62.
17. Seidman AD, Barrett S, Hudis C, Lepore J, Yao TY, Gilewski T, Currie V, Crown J, Hakes T, Moynahan ME, Baselga J, Sklarin N, Quinvilan S, Trochanoski B and Norton L. “Three hour taxol infusion as initial (I) and salvage (S) chemotherapy of metastatic breast cancer (MBC)”.
Proc Am Soc Clin Oncol. Vol. 13, 1994: 65.
 18. Anelli L, Sepp-Lorenzino L, Baselga J, Borgen P, Rosen N and Lebowitz DE. “Activation of wild-type ras is required for the malignant transformation of the human breast cancer cell line MDA MB-468”.
Proc Am Soc Clin Oncol. Vol. 13, 1994: 305.
 19. Baselga J, Tripathy D, Mendelsohn J, Benz C, Henderson IC, Twaddell T and Norton L. “Ongoing phase II study of intravenous recombinant human anti-p185 HER2 monoclonal antibody 4D5 (MAb 4D5) in patients with stage IV breast cancer overexpressing HER2”.
17th San Antonio Breast Cancer Symposium 1994.
 20. Baselga J, Norton L and Coplan K. et al. “Anti-growth factor-receptor monoclonal-antibodies enhance the antitumor effects of paclitaxel in breast-cancer xenografts”.
J Cell Biochem 250-250 Supplement 18p, 1994.
 21. Aghajanian C, Zhuo Y, Ho TY, Brown C, Zhen F, Baselga J and Mendelsohn J. “Spriggs DR. Anti-epidermal growth factor receptor monoclonal antibody treatment of A431 cells decreases cisplatin/DNA adduct repair in association with NF-KB induction”.
AACR Meeting Abstracts 36: 2545, 1995.
 22. Baselga J, Mendelsohn J, Kim YM and Pandiella A. “Transmembrane TGF- a precursor expression and release in human carcinoma cells”.
AACR Meeting Abstracts 36: 152 1995.
 23. Fennelly D, Gilewski T, Hudis C, Seidman A, Raptis G, Baselga J, Sklarin N. and Norton L. “Phase I trial of sequential edatrexate (etx) followed by paclitaxel (ptx); a design based on in vitro (IV) synergy in patients with advanced breast cancer”.
AACR Meeting Abstracts 36: 1470, 1995.
 24. Baselga J, Tripathy D, Mendelsohn D, Benz C, Dantis L, Moore J, Rosen PP, Henderson IC, Baughman S, Twaddell T and Norton T. “Phase II study of recombinant human anti-her2 monoclonal antibody (rhuMAb HER2) in stage IV breast cancer (BC): HER2-shedding dependent pharmacokinetics and antitumor activity”.
Proc Am Soc Clin Oncol. Vol. 14, 1995: 113.
 25. Pegram M, Lipton A, Pietras R, Hayes D, weber B, Baselga J, Tripathy D, Twadell T, Glaspy J and Slamon D. “Phase II study of intravenous recombinant humanized anti-p185 HER-2 monoclonal antibody (rhuMAb HER-2) plus Cisplatin in patients with HER-2/neu overexpressing metastatic breast cancer”.
Proc Am Soc Clin Oncol. Vol. 14, 1995: 124.

26. Theodoulou M, Baselga J, Scher H, Dantis L, Trainor K, Mendelsohn J, Howes L, Elledge R, Ravdin P, Bacha P, Brandt-Sarif T and Osborne K. "Phase I dose-escalation study of the safety, tolerability, pharmacokinetics and biologic effects of DAB389EGF in patients with solid malignancies that express EGF receptors" (EGFR).
Proc Am Soc Clin Oncol. Vol. 14, 1995: 1561.
27. Hudis C, Seidman A, Raptis G, Currie V, Baselga J, Sklarin N, Moynahan M, Lebwohl D, Gilewski T, Fennelly D, Riedel E, Uhlenhopp M, Yao TJ and Norton L. "Sequential doxorubicin (A) paclitaxel (T) and cyclophosphamide (C) in women (pts) with resected breast cancer (BC) and > 4 (+) lymph nodes (LN): Preliminary results".
Proc Am Soc Clin Oncol. Vol. 14, 1995: 152.
28. Fennelly D, Gilewski T, Hudis C, Seidman A, Hamilton N, Raptis G, Baselga J, Sklarin N and Norton L. "Phase I trial of sequential edatrexate (etx) followed by paclitaxel (ptx); a design based on in vitro (IV) synergy in patients with advanced breast cancer".
Proc Am Soc Clin Oncol. Vol. 14, 1995: 105.
29. Raptis G, Tiersten A, Hamilton N, Reich L, Rivera M, Fennelly D, Hudis C, Seidman A, Gilewski T, Sklarin N, Moynahan M, Theodoulou M, Baselga J, Currie V and Norton L. "Outpatient based, rapidly administered multi-cycle high dose chemotherapy (HDC) in patients with responding metastatic breast cancer (MBC)".
Proc Am Soc Clin Oncol. Vol. 14, 1995: 920.
30. Raptis G, Tiersten A, Shapiro F, Schneider J, Hamilton N, Reich L, Wuest D, Gucciardo A, Quiguyan L, Gilewski T, Baselga J, Theodoulou M, Hudis C, Surbone A, Moore M, Crown J and Norton L. "Rapid hematologic recovery following CD34+ selected versus unselected peripheral blood progenitor cell (PBPC) + filgrastim (G) rescue of sequential high dose chemotherapy (HDC) in patients (PTS) with metastatic breast cancer" (MBC).
Blood 86 (10):1601-1601 Supplement 1, Nov 15, 1995.
31. Bos M, Mendelsohn J, Bowden C, Pfister D, Cooper MR, Cohen R, Burtness B, D'Andrea G, Waksal H, Norton L and Baselga J. "Phase I Studies of Anti-Epidermal Growth Factor Receptor (EGFR) Chimeric Monoclonal Antibody C225 in Patients with EGFR Overexpressing Tumors".
Proc Am Soc Clin Oncol. Vol. 15, 1996: 443.
32. Park JW, Colbern G, Baselga J, Hong K, Shau Y, Kirpoten D, Nuijens A, Wood W, Papahadjopoulos D and Benz C. "Antitumor Efficacy of Anti-p185HER2 Immunoliposomes: Enhanced Therapeutic Index Due to Targeted Delivery".
Proc Am Soc Clin Oncol. Vol. 15, 1996: 501.
33. Seidman AD, Baselga J, Yao TJ, Gilewski T, Rosen PP and Norton L. "HER-2/neu Over-expressing and Clinical Taxane Sensitivity: A Multivariate Analysis in Patients with Metastatic Breast Cancer" (MBC).
Proc Am Soc Clin Oncol. Vol. 15, 1996: 104.
34. Hudis C, Seidman A, Raptis G, Baselga J, Fennelly D, Theodoulou M, Gilewski T, Currie V, Moynahan M, Surbone A, Sklarin N, Robles M, Yao TJ, Uhlenhopp M and Norton L. "Sequential Paclitaxel (T)->Cyclophosphamide(C) is Preferable to

- Concurrent T+C After Dose-Dense Doxorubicin (DD) as Adjuvant Therapy(RX) in Resected Node Positive (+) Breast Cancer (BC)".
Proc Am Soc Clin Oncol. Vol. 15, 1996: 119.
35. Riccio L, Hudis C, Holmes F, Seidman A, Raptis G, Baselga J, Fennelly, Theodoulou M, Gilewski T, Currie V, Moynahan M, Surbone A, Sklarin N, Maikel N, Usakewicz J, UhlenhoppM, Hortobagyi G and Norton L. "Phase II Study of Semisynthetic Paclitaxel (SSTAX) in Patients (pts) with Metastatic Breast Cancer (MBC) Previously Treated with One Chemotherapy Regimen".
Proc Am Soc Clin Oncol. Vol. 15, 1996: 119.
 36. Wu X, Rosen N, Fan Z, Baselga J, Fry DW and Mendelson A. "Blockade of epidermal growth factor receptor kinase activity and induction of p27 kip1".
AACR Meeting Abstracts 1996, 37: 42.
 37. Bos M, Mendelsohn J, Kim YM, Fry DW. and Baselga J. "A tyrosine inhibitor prevents ligand-induced receptor activation and inhibits growth of cancer cell lines expressing the epidermal growth factor receptor".
AACR Meeting Abstracts 1996, 37: 305.
 38. Sepp-Lorenzino L, Bos M, Ma Z, Baselga J, Rands E, Kohl NE, Oliff A, Mendelsohn J, Rosen P and Farnesyl N. "Protein transferase inhibitors (FTIs) block tyrosine kinase signal transduction and act in concert with an anti-EGF receptor antibody to inhibit cancer cell growth".
AACR Meeting Abstracts 1996, 37: 421.
 39. Tiersen A, Raptis G, Crown J, Hamilton N, Damaskos P, Vahdat L, Reich L, Fennelly D, Hudis C, Seidman A, Gilewski T, Moynahan M, Baselga J, Currie V, Sklarin N and Norton L. "Patterns of failure following high dose chemotherapy with peripheral blood progenitor cell support in patients with metastatic breast cancer".
Proc Am Soc Clin Oncol. Vol. 15, 1996: 338.
 40. Tiersen A, Raptis G, Yao TJ, Ren L, Hamilton N, Damaskos P, Kesselman E, Reich L, Vahdat L, Fennelly D, Hudis C, Seidman A, Gilewski T, Moynahan M, Baselga J, Sklarin N, Norton L and Crown J. "Factors predicting prolonged progression free and overall survival in metastatic breast cancer patients undergoing high dose chemotherapy with peripheral blood progenitor cell support".
Proc Am Soc Clin Oncol. Vol. 15, 1996: 339.
 41. Riccio L, Hudis C, Seidman A, Raptis G, Crown J, Baselga J, Lebwohl D, Theodoulou M, Gilewski T, Sklarin N, Surbone A, Currie V, Moynahan M, Reidel E, Tao Y, Yao TJ and Norton L. "Long-term distant disease-free survival (DFS) from two pilot studies of dose-dense sequential adjuvant chemotherapy (CRX) in womwn (pts) with resected breast cancer (BC) and > 3 postive nodes (+LN)".
Proc Am Soc Clin Oncol. Vol. 16, 1997: 507.
 42. Park JW, Colbern G, Nuijens A, Baselga J, Papahadjopoulos D and Benz CC. "Circulating HER2 extracelular domain (ECD) levels in multiple tumor xenograft models of HER-overexpressing bresat cancer".
Proc Am Soc Clin Oncol. Vol. 16, 1997: 652.
 43. Sole LA, Ribas A, Gallardo E, Almanza C, Carulla J, Albanell J, Vera R, Eres N, Bellmunt J and Baselga J. "A phase II study of paclitaxel and oral tegafur modulated

- by oral low-dose folinic acid in anthracyclin-resistant metastatic breast cancer (MBC)".
Proc Am Soc Clin Oncol. Vol. 16, 1997: 672.
44. Park JW, Colbern G, Hong K, Kirpotin D, Shao Y, Baselga J, Papahadjopoulos D and Benz CC. "Targeted intracellular drug delivery via anti-HER2 immunoliposomes yields superior antitumor efficacy".
Proc Am Soc Clin Oncol. Vol. 16, 1997: 1543.
45. Slamon B, Leyland-Jones S, Shak V, Paton A, Bajamonde T, Fleming W, Eiermann, Wolter J, Baselga J and Norton L. "Addition of Herceptin™ (humanized anti-HER2 Antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2 +/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial".
Proc Am Soc Clin Oncol. Vol. 17, 1998: 377.
46. Bellmunt L, Carles J, Climent MA, González Larriba JL, Banús JM, Gallardo E and Baselga J. "Phase I trial of paclitaxel, cisplatin and gemcitabine (TCG) in patients (pts) with advanced transitional cell carcinoma (TCC)".
Proc Am Soc Clin Oncol. Vol. 17, 1998: 1236.
47. Crown J, Baselga J, Leonard R, Perey L, Kozak J, Fennelly D, Maraninchi D, Marty M, Lind M, Howell A, Welch R, Gupta S, Cour-Chabernaud V, Byrnes J, King T and Luykx R. "European randomized breast cancer dose-intensity study (EBDIS): results of pilot evaluation".
Proc Am Soc Clin Oncol. Vol. 17, 1998: 514.
48. Baselga J, Miralles A and Arribas J. "Characterization of HER2 extracellular domain shedding in a panel of breast cancer cell lines".
Proc Am Soc Clin Oncol. Vol. 17, 1998: 2121.
49. Codony J, Albanell J, Arribas J and Baselga J. "Regulated shedding of the HER2 receptor ectodomain in human breast cancer cells".
AACR Meeting Abstracts 1999.
50. Norton L, Slamon D, Leyland-Jones B, Wolter J, Fleming T, Eiermann W, Baselga J, Mendelsohn A, Bajamonde M, Ash S and Shak. "Overall Survival (OS) Advantage to Simultaneous Chemotherapy (CRx) Plus the Humanized Anti-HER2 Monoclonal Antibody Herceptin (H) in HER2-Overexpressing (HER2+) Metastatic Breast Cancer (MBC)".
Proc Am Soc Clin Oncol. Vol. 18, 1999: 483.
51. Vera R, Albanell J, Lirola JL, Bermejo B, Soléa LA and Baselga J. "HER2 Overexpression as a Predictor of Survival in a Trial Comparing Adjuvant FAC and CMF in Breast Cancer".
Proc Am Soc Clin Oncol. Vol. 18, 1999: 265.
52. Lluch A, Sola C, Hornedo J, Germa JR, Benavides M, Baselga J, Guillen V, Cruz JJ, Alvarez I, Mayordomo JI, Prosper F, Ojeda B, Alonso S, Cortes H, López JJ and García-Conde J. "High Dose Chemotherapy (HDC) and Stem Cell Transplant (SCT) for High Risk Breast Cancer (HRBC): Results of 235 Transplants".
Proc Am Soc Clin Oncol. Vol. 18, 1999: 303.
53. Bellmunt J, Guillem V, Paz-Ares L, González-Larriba JL, Carles J, Batiste-Alentorn

- E, A. Sáenz, López-Brea M, Font A, Nogué M, Bastús R, Arnaiz A, Banus JM, Gallardo E and Baselga J. “A Phase II Trial of Paclitaxel, Cisplatin and Gemcitabine (TCG) in Patients (pts) with Advanced Transitional Cell Carcinoma (TCC) of the Urothelium”.
Proc Am Soc Clin Oncol. Vol. 18, 1999: 1279.
54. Albanell J, Codony J, Lopez-Talavera JC, Arribas J and Baselga J. “Inhibition of HER2 Extracellular Domain Shedding by Metalloprotease Inhibitors and by Herceptin® in Breast Cancer Cells”.
Proc Am Soc Clin Oncol. Vol. 18, 1999: 2381.
55. Gunneth K, Motzer R, Amato R, Todd M, Poo WJ, Cohen R, Baselga J, Cooper M, Robert F, Falcey J and Waksal H. “Phase II Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody C225 Alone in Patients (pts) with Metastatic Renal Cell Carcinoma (RCC)”.
Proc Am Soc Clin Oncol. Vol. 18, 1999: 1309.
56. Baselga J, Cañadas MA, Codony J, Huetto JA, Arcas A, Llado A, Puig X, Guix M, Raspall G and Albanell J. “Activated Epidermal Growth Factor Receptor: Studies in Head and Neck Tumors and Tumor Cell Lines After Exposure to Ligand and Receptor Tyrosine-Kinase Inhibitors”.
Proc Am Soc Clin Oncol. Vol. 18, 1999: 2392.
57. Baselga J, Llombart-Cussac A, Bellet M, Guillem-Porta V and Petruzella L. “Randomized Double-Blind Phase II study of a Selective Estrogen Receptor Modulator (SERM) LY353381 in Patients (Pts.) with Locally Advanced or Metastatic Breast Cancer (LAMBC)”.
Breast Cancer Research and Treatment 57: 25 1999.
58. Baselga J. “Safety profile of Herceptin (R) as a single agent and in combination with chemotherapy”.
Eur J Canc 35:S324-S324 1299 Supplement 4, Sep 1999.
59. Baselga J, Kerrigan M and Burchmore M, et al. “Health-related quality of life (HRQL) in women with HER2-overexpressing metastatic breast cancer (MBC) in a phase III study of Herceptin (R) plus chemotherapy versus chemotherapy alone”.
Eur J Cancer 35: S318-S318 1276 Supplement 4, Sep 1999
60. Bellmunt J and Baselga J. “Phase I trial of paclitaxel, cisplatin and gemcitabine (TCG) in patients (p) with advanced transitional cell carcinoma (TCC) of the urothelium”.
Semin Oncol 26 (1): 140-140 Supplement 2, Feb 1999.
61. Baselga J, LoRusso P and Herbst R, et al. “A pharmacokinetic/pharmacodynamic trial of ZD1839 (IRESSA (TM)), a novel oral epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitor, in patients with 5 selected tumor types (a phase I/II trial of continuous once-daily treatment)”.
Clin Cancer Res 5: 3735S-3735S 29 Supplement S, Nov 1999.
62. Baselga J, LoRusso P, Herbst R, Rischin D, Ransom M, Maddox AM and Averbuch S. “A pharmacokinetic/pharmacodynamic trial of ZD1839 (Iressa TM), a novel oral epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitor in patients with 5 selected tumor types (a phase I/II trial of continuous once-daily treatment)”.

- AACR-NCI-EORTC International Conference. Washington, DC, 1999
63. Codony-Servat J, Albanell J, Arribas J and Baselga J. et al. "Regulation of HER2 cleavage in breast cancer cells: activation by receptor ligands and inhibition by Herceptin".
AACR Meeting Abstracts 2000.
 64. Sola C, Hornedo J, Baselga J., Prosper F, Montes A, Climent MA, Cruz J, Benavides M, Solano C, Ojeda B, Cortés H and López JJ. "Consolidation Therapy with High-Dose Chemotherapy (HDCT) and Radiotherapy to Metastatic Breast Cancer in Complete Response".
Proc Am Soc Clin Oncol. Vol. 19, 2000: 566.
 65. Bellmunt J, De la Cruz J, Guillem V, Paz-Ares L, González-Larriba J, Carles J, Batiste-Alentorn E, Saenz A, López-Brea M, Font A, Nogue M and Baselga J. "Paclitaxel, Cisplatin and Gemcitabine (TCG), in Advanced Urothelial Tumors (AUT): Prognostic Factors for Survival".
Proc Am Soc Clin Oncol. Vol. 19, 2000: 1346.
 66. Prosper F, Sola C, Hornedo J, Climent MA, Montes A, Benavide M, Baselga J., Mayordomo J, Alvarez I, López JJ, Cortés H and García-Conde J. "Prognostic Factors for Relapse After High Dose Chemotherapy (HDC) and STEM Cell Transplant (SCT) in Patients with High Risk Breast Cancer (HRBC)".
Proc Am Soc Clin Oncol. Vol. 19, 2000: 581.
 67. Climent MA, Solà C, Lluch A, Ruiz A, Hornedo J, Benavides M, Montes A, Baselga J., López-López JJ, García-Conde J, Cortés-Funes H and Guillem V. "High-Dose Chemotherapy (CT) with Peripheral Stem-Cell Support (PSCS) Seems to Improve Disease-Free Survival (DFS) in Inflammatory Breast Cancer (IBC) Compared with an Historical Series of Patients (Pts)".
Proc Am Soc Clin Oncol. Vol. 19, 2000: 548.
 68. Rojo F, Albanell J, Del Campo JM, Sauleda S, Raspal GL, Giralt J and Baselga J. "Activation of Mitogen-Activated Protein Kinase (MAPK) Is Associated with Epidermal Growth Factor Receptor (EGFR), Transforming Growth Factor (TGF)? and HER2 Receptor Overexpression in Head and Neck Tumors".
Proc Am Soc Clin Oncol. Vol. 19, 2000: 2417.
 69. Albanell J, Molina MA, Codony-Servat J, Rojo F, Lluch A, Arribas J and Baselga J. "The Production of Cleaved Intracellular Truncated HER2 Fragment Is Inducible in Breast Cancer Cells and This Fragment Is Phosphorylated in Breast Tumors".
Proc Am Soc Clin Oncol. Vol. 19, 2000: 2458.
 70. Lladó A, Bellmunt J, Kaiser G, de Wit R, Gobartt E and Baselga J. "A Dose Finding Study of Carboplatin with Fixed Doses of Gemcitabine in ""Unfit"" Patients with Advanced Bladder Cancer".
Proc Am Soc Clin Oncol. Vol. 19, 2000: 1354.
 71. Díaz-Rubio E, Evans J, Tabernero J, Cassidy J, Sastre J, Lim JL, Bissett D, Baselga J. and Regueiro P. "Phase I Study of Capecitabine in Combination with Oxaliplatin in Patients with Advanced or Metastatic Solid Tumors".
Proc Am Soc Clin Oncol. Vol. 19, 2000: 772.
 72. Llombart-Cussac A, Bellet M, Guillem-Porta V, Petruzelka L, Enas N, Chick J,

- Dhingra K, Storniolo AM and Baselga J. "Efficacy and Safety of Two Doses of the Selective Estrogen Receptor Modulator (Serm) Ly353381 in Locally Advanced or Metastatic Breast Cancer (Lambc)- α Randomized Double Blind Phase 2 Study".
Proc Am Soc Clin Oncol. Vol. 19, 2000: 609.
73. Baselga J, Herbst R, LoRusso P, Rischin D, Ranson M, Plummer R, Raymond E, Maddox AM, Kaye SB, Kieback DG, Harris A and Ochs J. "Continuous Administration of ZD1839 (Iressa), a Novel Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), in Patients with Five Selected Tumor Types: Evidence of Activity and Good Tolerability".
Proc Am Soc Clin Oncol. Vol. 19, 2000: 686.
74. Felip E, Font A, Rosell R, Garrido P, Santom EL Carrato A, Terrasa S, Mane JM and Baselga J. "Preliminary results of sequential dose-dense paclitaxel followed by topotecan in extensive small-cell lung cancer (SCLC): A phase II study".
Ann Oncol 11: 120-120 548p Supplement 4, 2000.
75. Molina MA, Cordony-Servat J, Rojo F, Arribas J, Albanell J and Baselga J. "Cleavage of the HER2 ectodomain is a 4-aminophenylmercuric acetate-activable process that is inhibited by trastuzumab (Herceptin (R)) in breast cancer cells".
Ann Oncol 11: 132-133 605O Supplement 4, 2000.
76. Albanell A, Rojo F, Codony-Servat J, Hueto J, Sauleda S, Feyereislova A Averbuch S, Nicholson RI and Baselga J. "Pharmacodynamic effects of Iressa, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in skin biopsies from cancer patients participating in a phase I trial".
Clin Cancer Res 6: 4543S-4543S 383 Supplement S, Nov 2000.
77. Evans J, Tabernero J, Cassidy J, Sastre J, Eatock M, Baselga J, Bissett D, Requeiro P and Rubio ED. "Safety profile and preliminary efficacy of capecitabine (Xeloda (R)) in combination with oxaliplatin in patients with advanced or metastatic solid tumours: Results from a phase I study".
Ann oncol 11: 51-51 222p Supplement 4, 2000.
78. Tabernero J, Marimon I, Albanell J, Rojo F, Santome L, García M, Valverde S, Gadea N, Tuck D, Voi M, Van Vreckem A and Baselga J. "A phase I dose-escalation study of the farnesyltransferase (FT) inhibitor BMS-214662 administered as continuous weekly 1-hour infusion in patients with advanced solid tumors".
Clin Cancer Res 6: 4573s-4573s 532 Supplement S, Nov 2000.
79. Albanell J, Rojo F, Sonnichsen D, Manne V, Meeker J, Dendler R, Manning J, Tabernero J and Baselga J. "Elevated Farnesyltransferase Activity in Chemo-naive Breast Cancer Tissue as Compared to Normal Surrounding Tissue".
AACR Meeting Abstracts 2001, 42: 2634.
80. Green M, Koelbl H, Baselga J, Kubista E, Guillem V, Gascon P, Siena S, Lalisang R, Krippel P, Clemens M, Zani V, Bashir S, Renwick J, Liang B and Piccart M "Phase 3 Study Evaluating Fixed-Dose, One-Per-Cycle Pegylated Filgastrim (SD/01) vs daily Filgastrim to Support Chemotherapy for Breast Cancer".
Proc Am Soc Clin Oncol. Vol. 20, 2001: 90.
81. Saez R, Rojo F, Garcia-Barchino MJ, Molina MA, Marugan I, Sabadell D, Azagra P, Sauleda S, Lluch A, Garcia-Conde J, Baselga J and Albanell, J. "A truncated HER2

- Ectodomain is Inversely Associated to Lymph Node Metastasis in Human Breast Cancer".
Proc Am Soc Clin Oncol. Vol. 20, 2001: 139.
82. Gianni L, Albanell J, Eirmann W, Bianchi G, Bourquez D, Vigano L, Molina R, Raab G, Locatelli A, Vanhauwere B and Baselga J. "Feasibility, Pharmacology and Antitumor Activity of Herceptin with doxorubicin and Taxol followed by weekly Taxol (ATandT) in Women with HR-2 Positive Advance Breast Cancer".
Proc Am Soc Clin Oncol. Vol. 20, 2001: 174.
83. Tabernero J, Sonnichsen D, Albanell J, Damle B, Rojo F, Christofer L, Marimon I, Dendler R, Trigo JM, Manne S, Garcia M, Montoro JB and Baselga J. "A Phase I Pharmacokinetic (PK) and Serial Tumor and PBMC Pharmacodynamic (PD) Study of Weekly BMS-214662, a Farnesyltransferase (FT) Inhibitor, in Patients with Advanced Solid Tumors".
Proc Am Soc Clin Oncol. Vol. 20, 2001: 304.
84. Voi M, Tabernero J, Cooper MR, Marimon I, Van Vrekem A, Albanell J, Santome L, Valverde S, Carreras J and Baselga J. "A Phase I study of the Farnesyltransferase (FT) Inhibitor BMS-214662 Administered as a Weekly 1-Hour Infusion in Patients (Pts) with Advanced Solid Tumors: Clinical Findings".
Proc Am Soc Clin Oncol. Vol. 20, 2001: 312.
85. Felip E, Font A, Rosell R, Garrido P, Domine M, Santome L, Carrato A, Marimon I, Terrasa S, Vadell C, Mañe M and Baselga J. "Sequential Dose-Dense Paclitaxel Followed by Topotecan in Untreated Extensive Small-Cell Lung Cancer (SCLC): A Spanish Lung Cancr Group Phase II Study".
Proc Am Soc Clin Oncol. Vol. 20, 2001: 1271.
86. Anido J, Rojo F, Codony-Servat J, Arribas J and Baselga J. "Inhibition by ZD1839 (Iressa) of Epidermal Growth Factor (EGF) and Heregulin Inducing Signaling Pathways in Human Breast Cancer Cells".
Proc Am Soc Clin Oncol. Vol. 20, 2001: 1712.
87. Rojo F, Albanell J, Sauleda S and Baselga J. "Characterization of Epidermal Growth Factor (EGF) Receptor and Transforming Growth Factor (TGF) Alpha Expression in Gastric Cancer and its Association with Activation of Mitogen-Activated Protein Kinase (MAPK)".
Proc Am Soc Clin Oncol. Vol. 20, 2001: 1717.
88. Gonzalez S, Trigo J, Albanell J, Porta R, Santome L, Del Campo JM, Bellmunt J, Carulla J and Baselga J. "Five-Day Continous Infusion Fluorouracil (5-FU) Plus Vinorelbine (VNR) as Third Line Therapy in Metastatic Breast Cancer (MBC)".
Proc Am Soc Clin Oncol. Vol. 20, 2001: 1965.
89. Santome L, Tabernero J, Riofrio M, Gurpide A, Albanell J, Porta R, Gonzalez S, Garcia C, Van Vreckem A, Garrido C, Spielmann M, Muggia F, Voi M, Lebwahl D and Baselga J. "Continuing Improvement of Efficacy with Single-Agent Paclitaxel (T) After Discontinuation of Doxorubicin (A) in Patients (PTS) with Metastatic or Locally Advanced Breast Cancer (ABC) Treated with the AT combination".
Proc Am Soc Clin Oncol. Vol. 20, 2001: 1994.
90. Baselga J and Albanell J. "Mechanism of action anti-HER2 monoclonal antibodies".
Ann Oncol 12:35-41 Supplement 1, 2001.

91. Baselga J. "Phase I and II clinical trials of trastuzumab".
Ann Oncol 12:49-55 Supplement 1, 2001.
92. Fumoleau P, Trigo J, Campone M, Baselga J, Sistac F, Gimenez P, Manos L, Fontaine H, Semiond D, Sanderink G, Perard D and Besenval M. "Phase I and pharmacokinetics (PK) study of RPR 116258A given as a weekly 1-hour infusion at day 1, day 8, day 15, day 22 every 5 weeks in patients (pts) with advanced solid tumors".
Clin Cancer Res 7 (11): 3710S-3710S 282 Supplement S, Nov 2001.
93. Tabernero J, Albanell J, Rojo F, Christopher L, Dendler R, Damle B, Marimon I, Sonnichsen D, Guix M, Cooper M, Sauleda S, Van Vrechem A, Gadea N, Shaw PM, Voi M and Baselga J. "A phase I pharmacokinetic (PK) and serial tumor and PBMC pharmacodynamic (PD) study of weekly 24-hour (h) infusion BMS-214662, a farnesyltransferase (FT) inhibitor, in patients (p) with advanced solid tumors".
Clin Cancer Res 7 (11): 3775S-3775S 604 Supplement S, Nov 2001.
94. Baselga J, Yano S, Giaccone G, et al. "Initial results from a Phase II trial of ZD1839 (IRESSA) as second and third-line monotherapy for patients with advanced non-small-cell lung cancer (IDEAL 1)".
Clin Cancer Res 7 (11): 3780S-3780S 630a Supplement S, Nov 2001.
95. Baselga J, Trigo M, Bourthis J, Tortochaux J, Cortes-Funes H, Hitt R, Gascon P, Muesser M, Harstrick A and Eckardt A. "Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum based agent".
Proc Am Soc Clin Oncol. Vol. 21, 2002: 900.
96. Trigo J, Climent MA, Gil M, Lluch A, Hornedo J, Gascon P, V. Guillem V, Regueiro P and Baselga J. "Cardiac safety and activity of a phase I study of 3-weekly Myocet in combination with weekly herceptin and paclitaxel in HER2-positive (HER2+) locally advanced or metastatic breast cancer (LA/MBC)".
Proc Am Soc Clin Oncol. Vol. 21, 2002: 242.
97. Douillard Y.Y, Giaccone G, Horai T, Noda K, Vansteenkiste JF, Takata I, Gatzemeier U, Fukuoka M, Macleod A, Feyereislova A, Averbuch S, Nogi Y, Heyes A and Baselga J. "Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer (NSCLC) treated with ZD1839 (Iressa) (IDEAL 1)".
Proc Am Soc Clin Oncol. Vol. 21, 2002: 1195.
98. Grasselli G, Baselga J, Sessa C, Vigano L, Locatelli A, Trigo J, Llado A, Scigalla P, Kelsey S, Colombini S, Marsoni S and Gianni L. "Dose-escalation and pharmacologic study of oral SU-006668 in patients with advanced solid tumors."
Proc Am Soc Clin Oncol. Vol. 21, 2002: 67.
99. Sessa C, Hess D, Baselga J, Carminati P, Zanna C, Llado A, Cerny T, Gatti B, Liati P and Gianni L. "Concerted escalation of dose and dosing-duration in a phase i study of the oral camptothecin gimatecan (st 1481) in patients with advanced solid tumors".
Proc Am Soc Clin Oncol. Vol. 21, 2002: 386.
100. Fukuoka M, Yano S, Giaccone G.G., Tamura T, Nakagawa K, Douillard Y.I., Nishiwaki Y, Vansteenkiste J.F., Kudo S, Averbuch S, Macleod A, Feyereislova A

- and Baselga J. "Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1)".
Proc Am Soc Clin Oncol. Vol. 21, 2002: 1188.
101. Carbonell X, Castaneda-Soto N.J., Clemens M, Green M, Harvey V, Morales S, Barton C and Baselga J. "Efficacy and safety of 3-weekly herceptin (H) monotherapy in women with HER2-positive metastatic breast cancer (MBC): preliminary data from a phase II study".
Proc Am Soc Clin Oncol. Vol. 21, 2002: 73.
102. Gianni G, Baselga J., Eiermann W, Guillem Porta V, Semiglazov V, Garcia-Conde J, Zambetti M, Valagussa P and Bonadonna G. "First report of the European Cooperative Trial in operable breast cancer (ECTO): effects of primary systemic therapy (PST) on local-regional disease".
Proc Am Soc Clin Oncol. Vol. 21, 2002: 132.
103. Porta R, Carbonell X, del Campo J.M, Carulla J, Galtés S and Baselga J. "Phase I study of capecitabine in combination with cisplatin in patients (pts) with advanced and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)".
Proc Am Soc Clin Oncol. Vol. 21, 2002: 953.
104. Climent MA, Tabernero J, Albanell J, Lluch A, Vermorken J, Barnadas A, Anton A, Laurent C, Mayordomo J.I., Vazquez Estevez S, Constenla M, Dirix LY, Losa I, Tisaire JL, Guillem V, Garcia-Conde J and Baselga J. "Preliminary results of a phase II randomized trial of docetaxel (taxotere) as a single agent chemotherapy (CT) administered weekly or 3-weekly in patients (pts) with metastatic breast cancer (MBC)".
Proc Am Soc Clin Oncol. Vol. 21, 2002: 205.
105. Baselga J., Castaneda-Soto NJ, Clemens M, Green M, Harvey V, Barton C and Morales S. "Safety of Herceptin monotherapy administered on a 3-weekly schedule: preliminary data from a phase II study in women with HER2-positive metastatic breast cancer".
Eur J Cancer 38: S95-S95 213 Supplement 3, Mar 2002.
106. Madhusudan S, Baselga J., Conte PF, et al. "A multicentre phase II study of SU5416, a tyrosine kinase inhibitor, in locally advanced or metastatic melanoma".
Brit J Cancer 86: S114-S115 Supplement 1, Jun 2002.
107. Ghahramani P, Baselga J., Leyland-Jones B, et al. "Meta-analysis of the relationship between serum trastuzumab concentrations and shed HER2 extracellular domain (ECD)".
Breast Cancer Res Tr 76: S31-S31 10 Supplement 1, Dec 2002.
108. Tabernero J, Rojo F, Jimenez E, Montaner I, Santome L, Guix M, Rosen O, Kovar A, Viaplana I and Baselga J. "A phase I pharmacokinetic (PK) and serial tumor and skin pharmacodynamic (PD) study of weekly, every 2 weeks or every 3 weeks 1-hour (h) infusion EMD72000, an humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (p) with advanced tumors known to overexpress the EGFR".
Eur J Cancer. 38: S69-S70 216 Supplement 7, 2002.
109. Ramsey E, Saez R, Molina M, Garcia Barchino MJ, Lluch A, García-Conde J,

- Baselga J, Albanell, Keenan EJ and Clinton GM. “The truncated Her-2 product, p95HER-2, predicts worse outcome for breast cancer patients”.
AACR Meeting Abstracts Vol. 44, Abstract 2224, 2003.
110. Matar P, Rojo F, Guzman M, Rodriguez-Viltro I, Arribas J and Baselga J. “Combined anti-epidermal growth factor receptor (EGFR) treatment with a tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) and a monoclonal antibody (IMC-C225): Evidence of synergy”.
AACR Meeting Abstracts Vol. 44, Abstract 4007, 2003.
111. Baselga J Albanell, Ruiz A, Lluch A, Gascon P, Gonzalez S, Guillem V, Sauleda S, Averbuch S and Rojo F. “Phase II and tumor pharmacodynamic study of gefitinib (ZD1839) in patients with advanced breast cancer”.
Proc Am Soc Clin Oncol. Vol. 22, 2003: 24.
112. Eiermann W, Sabadell D, Baselga J, Vazquez C, Gillem Porta V, Semiglazov V, Garcia-Conde J, Zambetti M, Bonadonna G and Gianni L. “European cooperative trial in operable breast cancer (ECTO): no increased risk for local breast tumor recurrence (LBR) as first and only event after primary systemic therapy (PST)”.
Proc Am Soc Clin Oncol. Vol. 22, 2003: 37.
113. Trigo JM, Gil M, Miles D, Fornier M, Buzdar A.U., Barrett-Lee P, Dhingra K, Demario M and Baselga J. “A multicenter phase II study of the cell cycle inhibitor Ro 31-7453 in patients with metastatic breast cancer who have failed chemotherapy with an anthracycline and a taxane”.
Proc Am Soc Clin Oncol. Vol. 22, 2003: 62.
114. Albanell J, Baselga J, Guix M, Twelves CJ, Glasspool R, Awada A, Dodion P, Esseltine D, Werner MC and Piccart M. “Phase I Study of bortezomib in combination with docetaxel in antracycline-penetrated advanced breast cancer”.
Proc Am Soc Clin Oncol. Vol. 22, 2003: 63.
115. Marty M and Baselga J, Gatzemeier U, Leyland-Jones B, Suter T, C. Ward C, Barton C. “Changes in left ventricular ejection fraction (LVEF) during trastuzumab therapy: a pooled analysis of four trials”.
Proc Am Soc Clin Oncol. Vol. 22, 2003: 72.
116. Crown J, Perey L, Lind M, Guillem V, Efremedis A, Garcia-Conde J, Welch R, Montes A, Leonard R and Baselga J. “Superiority of tandem high-dose chemotherapy (HDC) versus optimized conventionally-dosed chemotherapy (CDC) in patients (pts) with metastatic breast cancer (MBC): The International Randomized Breast Cancer Dose Intensity Study (IBDIS 1)”.
Proc Am Soc Clin Oncol. Vol. 22, 2003: 88.
117. Jones RJ, Trigo J, Derosa F, Brennscheidt U, Rakhit A, Wright T, Carbonell X, Twelves C, and Baselga J. “A phase IB study of erlotinib plus capecitabine and docetaxel in metastatic breast cancer (MBC)”.
Proc Am Soc Clin Oncol. Vol. 22, 2003: 180.
118. Gianni L, Hess D, Baselga J, Malossi A, Cresta S, Zucchetti M, Zanna C, Gatti B, Zaniboni A and Sessa C. “A phase I study of the oral camptothecin gimatecan with a design of concerted dose escalation in three schedules of different dosing-duration”.
Proc Am Soc Clin Oncol. Vol. 22, 2003: 554.

119. Rojo F, Tabernero J, Van Cutsem E, Ohtsu A, Albanell J, Koizumi W, Peeters M, Averbuch S, Gallagher N and Baselga J. "Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with gefinitib (ZD1839)".
J Clin Oncol 21 (23):292S-292S Supplement S Dec 1 2003.
120. Tabernero J, Rojo F, Jimenez E, Montaner I, Santome L, Guix M, Rosen O, Kovar A, Salazar R and Baselga J. "A phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-week (2qw) or every 3-week (q3w) 1-hour (h) infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (pt) with advanced tumors".
Proc Am Soc Clin Oncol, Vol. 22, 2003: 770.
121. Del Campo J.M., Verges R, Gil A, Gonzalez S, Garcia A, Martinez-Palones J, Santome L, Felip E, Giralt J and Baselga J. "Prognostic factors (PF) in recurrent endometrial carcinoma (REC): A review of a single-centre experience".
Proc Am Soc Clin Oncol Vol. 22, 2003: 1947.
122. Salazar R, Koehne CH, Cortes-Funes H, Tabernero J, Folprecht G, Paz-Ares L, Baselga J, Quinn SE and Zacharchuk C. "Preliminary report of a phase 1/2A open-label study of EKB-569 in combination with 5-fluorouracil, leucovorin and irinotecan in patients with advanced colorectal cancer".
Clin Cancer Res 9 (16): 6099S-6100S part 2 Supplement S, Dec 1 2003.
123. Marty M, Baselga J, Gatzemeier U, et al. "Pooled analysis of six trials of trastuzumab (Herceptin (R)): exploratory analysis of changes in left ventricular ejection fraction (LVEF) as a surrogate for clinical cardiac events".
Breast Cancer Res Tr 82: S48-S48 218 Supplement 1, 2003.
124. Trigo J, Clement MA, Lluch A, Gascon P, Hornedo J, Gil M, Cirera L, Guillem V, Requeiro P and Baselga J. "Liposomal doxorubicin Myocet (R) in combination with Herceptin((R)) and paclitaxel is active and well tolerated in patients with HER2-positive locally advanced or metastatic breast cancer: a phase II study".
Breast Cancer Res Tr 82: S83-S83 351 Supplement 1, 2003.
125. Trigo J, Baselga J, De Rosa F, et al. "A phase IB study of Tarceva (TM) (erlotinib) plus capecitabine and docetaxel in metastatic breast cancer (MBC)".
Clin Cancer Res 9 (16): 6087S-6087S part 2 Supplement S, dec 1 2003.
126. Baselga J, Fumoleau P, Gil M, Colomer R, Roche H, Cortes-Funes H, Burstein H, Kaufman P, Kong S and Moore L. "Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results".
J Clin Oncol 22 (14): 13S-13S 544 Supplement S, Jul 15, 2004.
127. Leyland-Jones B, Marty M, Baselga J, Gatzemeier U, Barton C and Lennon S. "Effects of trastuzumab (H) and chemotherapy on circulating HER2 extracellular domain (ECD) in patients with metastatic breast cancer (MBC) and non-small cell lung cancer (NSCLC)".
J Clin Oncol 22 (14): 19S-19S 570 Supplement S Jul 15 2004.
128. Crown JP, Leyvraz S, Verill M, Guillem V, Efremidis A, Garcia-Conde Bru J, Welch R, Montes A, Leonard R and Baselga J. "Effect of tandem high.dose chemotherapy (HDC) on long-term complete remissions (LTCR) in metastatic breast cancer (MBC),

- compared to conventional dose (CDC) in patients (pts) who were not selected on the basis of response to prior C: Mature results of the IBDIS-I".
J Clin Oncol 22 (14): 35S-35S 631 Supplement S, Jul 15 2004 .
129. Salazar R, Tabernero J, Rojo F, Jimenez E, Montaner I, Casado E, Sala G, Tillner J, Malik R and Baselga J. "Dose-dependent inhibition of the EGFR and signaling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD)".
J Clin Oncol 22 (14): 127S-127S 2002 Supplement S, Jul 15 2004.
130. Graeven U, Vogel I, Killing B, Hinz S, Von Bernstorff W, Baselga J, Rojo F, Tillner J, P. Gropp and Schmiegel W. "Phase I study of humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 plus gemcitabine (Gem) in advanced pancreatic cancer".
J Clin Oncol 22 (14): 210S-210S 3061 Supplement S, Jul 15, 2004.
131. Di Cosimo S, Matar P, Rojo F, Guzman M, Rodriguez S, Jimenez J, Arribas J, Cognetti F, Lane H and Baselga J "Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001)".
J Clin Oncol 22 (14): 213S-213S 3074 Supplement S, Jul 15, 2004.
132. Casado E, Folprecht G, Paz-Ares L, Rojo F, Köhne C.H., Cortés-Funes H, Vauthier JM, Zacharchuk C, Baselga J and Tabernero J. "A phase I/IIa pharmacokinetic (PK) and serial skin and tumor pharmacodynamic (PD) study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) (FOLFIRI regimen) in patients (pts) with advanced colorectal cancer (ACC)".
J Clin Oncol 22 (14): 255S-255S 3543 Supplement S, Jul 15, 2004.
133. Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Bessa EH, Baselga J and Vermorken B. "Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study".
J Clin Oncol 22 (14): 488S-488S 5502 Supplement S, Jul 15, 2004.
134. Felip E, R. Rosell R, Taron M, Santome L, Mendez P, Sanchez M, Sanchez JJ, Queralt C, Baselga J and Majo J. "ERCC, RRM1 and XPD mRNA expression as a predictive marker of outcome in non-small-cell lung cancer (NSCLC) patients after platinum/gemcitabine induction chemotherapy followed by surgery".
J Clin Oncol 22 (14): 651S-651S 7142 Supplement S, Jul 15, 2004.
135. Rojo F, Iglesias C, Tabernero J, Jimenez J, Rodriguez S, Bellmunt J, Ramon S and Baselga J. "Molecular markers of the mTOR pathway activation in human tumors: a baseline analysis".
J Clin Oncol 22 (14): 841S-841S 9524 Supplement S, Jul 15, 2004.
136. Matar P, Moreno-Bueno G, Cassia R, Rojo F, Arribas J, Palacios J and Baselga J. "The anti-epidermal growth factor receptor (EGFR) monoclonal antibody Cetuximab and the EGFR tyrosine kinase inhibitor Gefitinib, alone and in combination, induce a differential gene expression profile by cDNA microarray analysis in A431 cells".

- AACR Meeting Abstracts vol. 45, Abstract 5335, 2004.
137. Crown JP, Leyraz S, Verrill M, et al. "Lessons from a positive randomized trial of high-dose chemotherapy in metastatic breast cancer: learn from our mistakes, build on our successes, drain the bathwater, hold the baby".
Biology of blood and marrow transplantation 10 (2): 29-30 62 Supplement 1, Feb 2004.
138. Bonner JA, Harari PM, Giralt J, Azarnia N, Cohen RB, Raben D, Jones C, Kies MS, Baselga J and Ang KK. "Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab".
J Clin Oncol 22 (14): 489S-489S 5507 Supplement S, Jul 15, 2004.
139. Di Cosimo S, Matar P, Rojo F, Guzman M, Rodriguez S, Jimenez J, Arribas J, Cognetti F, Baselga J. "The mTOR pathway inhibitor RAD001 induces activation of AKT which is completely abolished by Gefitinib, an anti-EGFR tyrosine kinase inhibitor and combined sequence specific treatment results in greater antitumor activity".
AACR Meeting Abstracts vol. 45, Abstract 5345, 2004.
140. Baselga J. "Pharmacodynamic endpoints in the clinical development of molecularly targeted agents".
Radiother Oncol 73: S65-S65 Supplement 1, Oct 2004.
141. Giralt J, Haran PM, Ang KK, et al. "A phase III study of high dose radiation therapy with or without cetuximab in patients with locoregionally advanced squamous cell carcinoma of the head and neck".
Radiother Oncol 73: S127-S127 Supplement 1, Oct 2004.
142. Gullo G, Leyvraz S, Verrill M, et al. "Evidence that durable complete remissions (DCR) of metastatic breast cancer (MBC) following high-dose chemotherapy (HDC) are not artefacts of selection by response: mature results of the International Breast Cancer Dose Intensity Randomised and Pilot Studies (IBDIS-I)".
Breast Cancer Res Tr 88: S103-S103 Supplement 1, 2004.
143. Cortes J, Climent M, Lluch A, et al. "Updated results of a phase II study (M77035) of Myocet (R) combined with weekly Herceptin (R) and paclitaxel in patients (pts) with HER2-positive locally advanced or metastatic breast cancer (LABC/MBC)".
Breast Cancer Res Tr 88: S125-S126 Supplement 1, 2004.
144. Baselga J, Carbonell X, Castaneda-Soto NJ, et al. "Updated efficacy and safety analyses of 3-weekly Herceptin (R) monotherapy in women with HER2-positive metastatic breast cancer: results from twelve months of follow-up to a phase II study".
Breast Cancer Res Tr 88: S126-S126 Supplement 1, 2004.
145. Miller KD, Trigo JM, Wheeler C, Barge A, Rowbottom J, Sledge G and Baselga J. "A phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer (MBC)".
Breast Cancer Res Tr 88: S240-S240 Supplement 1, 2004.
146. Ballot J, Doran Z, Leyvraz S, Verrill M, Guillem V, Efremidis A, Garcia-Conde Bru J, Welch R, Montes A, Rapoport B, Cameron D, Leonard R, Baselga J and Crown J.

- “Externally audited results of the international breast cancer dose-intensity study (IBDIS)”.
- Bone Marrow Trasplantation. 35: S51-S52 Supplement 2, Mar 2005.
147. Rojo F, Najera L, Lirola JL, et al. “Cell signaling phospho-proteins as a target of HER2/Neu activity and prognosis in breast cancer”.
- Modern Pathology 18: 49A-49A 212 Supplement 1, Jan 2005.
148. Cajal SRY, Iglesias C, Jimenez J, et al. “A distinctive association of activated mTOR pathway in human epithelial tumors: Akt&4EBP1 as targets of cell signaling”.
- Modern Pathology 18: 300A-300A 1389 Supplement 1, Jan 2005.
149. Val D, Majo J, Rojo F, et al. “Epidermal growth factor receptor (EGFR) enhanced expression in chemoresistant non-small-cell lung carcinoma (NSCLC) after platinum-based therapy”.
- Modern Pathology 18: 319A-319A 1483 Supplement 1, Jan 2005.
150. Cortes J, Baselga J, Kellkumpu-Lehtinen P, Bianchi G, Cameron D, Miles D, Salvagni S, Wardley A, Goeminne JC and Gianni L. “Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2”.
- J Clin Oncol 23 (16): 208S-208S part 1 Supplement S, Jun 1 2005.
151. Soria JC, Cortes J, Armand JP, Taleb A, Van Bree L, Lopez E, Song S, Zeradib K, Vazquez F, Martell RE and Baselga J. “Phase I pharmacokinetic profile and early clinical evaluation of the PAN-HER inhibitor BMS-599626”.
- J Clin Oncol 23 (16): 219S-219S part 1 Supplement S, Jun 1 2005.
152. Di Cosimo S, Seoane J, Guzman M, Rojo F, Jimenez J, Anido J, Arribas J, Cognetti F and Baselga J. “Combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus (E) with the insulin like growth factor-1-receptor (IGF-1-R) inhibitor NVP-AEW-541: a mechanistic based anti-tumor strategy”.
- J Clin Oncol 23 (16): 219S-219S part 1 Supplement S, Jun 1 2005.
153. Garrett C, Takimoto C, Wojtowicz M, Burris H, Hidalgo M, Tan B, S. Krishnamurthi S, Basik M, Baselga J and Mauro D. “Identification of a molecular signature of radiographic response to cetuximab in patients (pts) with advanced colorectal cancer”.
- J Clin Oncol 23 (16): 277S-277S part 1 Supplement S, Jun 1 2005.
154. Vermorken JB, Bourhis J, Trigo J, Kies M, Leon X, Mueser M, Amellal N, Schueler A and Baselga J. “Cetuximab in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies”.
- J Clin Oncol 23 (16): 501S-501S part 1 Supplement S, Jun 1 2005.
155. Bonner JA, Harari PM, Giralt J, Baselga J, Shin D, Cohen R, Jassem J, Azarnia N, Molloy P and Ang KK. “Improved preservation of larynx with the addition of cetuximab to radiation for cancers of the larynx and hypopharynx”.
- J Clin Oncol 23 (16): 508S-508S part 1 Supplement S, Jun 1 2005.
156. Carpenter JT, Roche H, Campone M, Colomer R, Jagiello-Gruszfeld A, Moore L, D’Amore M, Kong S, Boni J and Baselga J. “Randomized 3-arm, phase 2 study of ternsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer”.

- J Clin Oncol 23 (16): 19S-19S part 1 Supplement S, Jun 1 2005.
157. Cussac AL, Baselga J, Manikhas G, Kubista E, Steger G, Galbraith SM, Sullivan MA, Zerba K, Lee H and Gianni L. "Phase II genomics study in patients receiving ixabepilone as neoadjuvant treatment for breast cancer (BC): preliminary efficacy and safety data".
J Clin Oncol 23 (16): 25S-25S part 1 Supplement S, Jun 1 2005.
158. Leyland-Jones B, Baselga J, Latreille J, Wardley A and Lennon V. "A novel loading regimen for trastuzumab in MBC: boost serum levels in early cycles".
J Clin Oncol 23 (16): 27S-27S part 1 Supplement S, Jun 1 2005.
159. Bellmunt J, Trigo JM, Garcia-Ribas I, et al. "Phase I study of high-dose bi-weekly gemcitabine at a constant rate infusion (CRI) without growth factor support in advanced solid tumors, including prior standard gemcitabine treated patients".
J Clin Oncol 23 (16): 151S-151S part 1 Supplement S, Jun 1 2005.
160. Tabernero J, Rojo F, Burris H, et al. "A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor everolimus (RAD001) in patients (pts) with advanced solid tumors".
J Clin Oncol 23 (16):193S-193S part 1 Supplement S Jun 1 2005.
161. Gianni L, Baselga J, Eirmann W, et al. "European Cooperative Trial in Operable Breast Cancer (ECTO): improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF)".
J Clin Oncol 23 (16): 7S-7S part 1 Supplement S, Jun 1 2005.
162. Baselga J, Rojo F, Dumez H, et al. "Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: a pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen".
J Clin Oncol 23 (16): 198S-198S part 1 Supplement S, Jun 1 2005.
163. Felip E, Rojo F, Heller A, et al. "Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy".
Lung Cancer 49: S369-S369 Supplement 2, Jul 2005.
164. Funes HC, Lluch A, Climent M, et al. "SOLTI (Solid Tumor Intensification) Group experience with high-dose chemotherapy treatment for early breast carcinoma".
Breast Cancer Research 7: S15-S15 Supplement 1, 2005.
165. Baselga J, Gianni L, Llombart A, Manikhas G, Kubista E, Steger G, Lee H, Ronczka A, Xu L, Clark E, Galbraith S. (2005) "Predicting response to ixabepilone: genomics study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer (BC)".
28th San Antonio Breast Cancer Symposium, 2005.
166. Baselga J, Roché H, Fumoleau P, Campone M, Colomer R, Cortes-Funes H, Gil M, Chan S, Boni J, Kong S, Cincotta M, Moore L. (2005) "Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combination with temsirolimus: a randomized, 3-arm, phase 2 study".
28th San Antonio Breast Cancer Symposium, 2005.
167. Kathryn E. Oreilly, Qing Bai She, David Solit, Heidi Lane, Francesco Hofmann,

- Daniel J. Hicklin, Baselga J, Neal Rosen. (2005). "The IGF-1 dependent feedback activation of AKT".
AACR Meeting Abstracts. Vol 46, 2005:1689.
168. Anido J, Martánez-Arca S, Bech JJ, Roj F, Guzman M, Arribas J, Baselga J (2005). "Alternative initiation of HER2 translation produces active HER2 C-Terminal Fragments (CTFs)".
AACR Meeting Abstracts. Vol 46, 2005: 3677.
169. Di Cosimo S, Val D, Guzman M, Llonch ME, Rojo F, Seoane J, Lane H, Arribas J, Baselga J. (2005). "Schedule-dependent activity of combined epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) targeting in PTEN negative breast cancer xenografts".
AACR Meeting Abstracts. Vol 46, 2005: 4313.
170. Tabernero J, Baselga J. "Rapamycin analogs in cancer therapy".
ECCO 14. Eur J Cancer Supplement Volume 3, No. 2, October 2005, Page 5.
171. Baselga J, Burris H, Judson I, Hazell K, Rojo F, Jones S, Vidal L, Shand N, Macarulla T, J. Tabernero J. "Molecular pharmacodynamic (MPD) phase I study with serial tumor and skin biopsies of the oral mTOR inhibitor Everolimus (E, RAD001) at different doses and schedules in patients (pts) with advanced solid tumors".
ECCO 14. Eur J Cancer Supplements Volume 3, No. 2, October 2005, Page 419.
172. Soria J, Cortes J, Armand J, Ropert S, Van Bree L, Lopez S, Catteau A, Vasquez F, Martell R, Baselga J. "The Pan-HER inhibitor BMS-599626: biological effects, pharmacokinetic profile and early clinical evaluation of a phase I trial".
ECCO 14. Eur J Cancer Supplements Volume 3, No. 2, October 2005, Page 420.
173. Di Cosimo S, Scaltriti M, Rojo F, Val D, Guzman M, Seoane J, Jimenez J, Arribas J, Cognetti F, Baselga J. "Dual inhibition of mTOR and of the Insulin like Growth Factor Receptor1 completely blocks the PI3K/Akt/mTOR pathway and results in a supra-additive anti-tumor effect: a mechanistic-based combination approach".
ECCO 14. Eur J Cancer Supplements Volume 3, No. 2, October 2005, Page 428.
174. Baselga J. "Targeting the epidermal growth factor receptor family".
ECCO 14. Eur J Cancer Supplements Volume 3, No. 4, October 2005, Page 3.
175. Rojo F, Najera L, Lirola J, Baselga J, Jiménez J, Llonch E, Sabadell D and Cajal SRY, et al. "Hyperphosphorylation of translational repressor 4E-BP1 in human breast is a prognostic factor".
Laboratory Investigation 86: 41A-41A 175 Supplement 1 Jan 2006.
176. Cajal SR, Jiménez J, Lloch E, Cuatrecasas M, Iglesias C, Castellvi J, Garcia A, Baselga J and Allende H. "In search of a "Joker"factor in cell signalling pathway in human tumors. 4EBP1 as a very good candidate".
Laboratory Investigation 86: 293A-293A 1362 Supplement 1 Jan 2006.
Modern Pathology 19: 293A-293A 1362 Supplement 1 Jan 2006.
177. Rojo F, Najera L, Jiménez J, Rodríguez S, Llonch E, Sabadell D, Baselga J and Cajal SRY. "Hyperphosphorylation of translation repressor 4E-BP1 in human breast is a prognostic factor".
Modern Pathology 19: 41A-41A 175 Supplement 1 Jan 2006.
178. Tabernero J, Baselga J. "mTOR inhibitors".

- Annals of Oncology 17:24-24 Supplement 3 2006.
179. Baselga J, Rothenberg ML, Tabernero J, Seoane J, Daly TM, Cleverly A, Berry B, Kloeker S, Wallace LA, Yingling J, Lahn M, Arteaga C, M. Carducci M. "TGF- β 1, pSMAD and TGF β -related markers in Patients with advanced metastatic cancer". AACR Meeting Abstracts Vol 47, Apr. 2006: 854.
 180. Gomez, Vilar E, Saura C, Cortes J, Ocaña A, Bellet M, Carrera J, Baselga J. "Feasibility of Pegfilgrastim as haematopoietic support for Dose-Dense Every-2-Week Adjuvant Chemotherapy in Breast Cancer" J. Clin. Oncol. Vol 24, No. 18S (June 20 Supplement), 2006: 18606.
 181. Saura C, Vilar E, Cortes J, Bellet M, Ocaña A, Gomez P, Baselga J. "Pegfilgrastim induces elevation of serum CA 15-3 in breast carcinoma patients after receiving dose-dense adjuvant chemotherapy" J. Clin. Oncol. Vol 24, No. 18S (June 20 Supplement), 2006: 8595.
 182. Baselga J, Schöffski P, Rojo F, Dumez H, Ramos FJ, Macarulla T, Cajal R, Kisker O, Van Oosterom A, Tabernero J. "A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC)" J. Clin. Oncol. Vol 24, No. 18S (June 20 Supplement), 2006: 3006.
 183. Cortes J, Climent MA, Gomez P, Ruiz A, Calvo E, Zhang X, Perez ES, Demario M, Baselga J. "A phase I trial of weekly combination KOS-862 (Epothilone D) and trastuzumab in HER-2 overexpressing malignancies". J. Clin. Oncol. Vol 24, No. 18S (June 20 Supplement), 2006: 2028.
 184. Tabernero J, Cervantes A, Martinelli E, Vega E-Villegas, Rojo F, Pérez-Fidalgo A, E. Casado, Ciardiello F, Zubel A, Baselga J. "Optimal dose of cetuximab (C) given every 2 weeks (q2w): A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC)" J. Clin. Oncol. Vol 24, No. 18S (June 20 Supplement), 2006: 3085.
 185. Felip E, Rojo F, Reck M, Heller A, Klughammer B, Maacke H, Möcks J, Brennscheidt U, Gatzemeier U, Baselga J. "Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy: FISH results" J. Clin. Oncol. Vol 24, No. 18S (June 20 Supplement), 2006: 7160.
 186. Lee H, Xu L, Wu S, Paul B, Baselga J, Llombart A, Steger GG, Galbraith S, Clark E. "Predictive biomarker discovery and validation for the targeted chemotherapeutic ixabepilone". J. Clin. Oncol. Vol 24, No. 18S (June 20 Supplement), 2006: 3011.
 187. Porter L.L, Burris HA, Jones SF, Calvert S, Papadimitrakopoulou V, Hazell K, Shand N, Lebwohl D, Baselga J, Judson I. "Summary of results in patients with metastatic renal cell cancer (RCC) from phase I studies of RAD001 (everolimus)" J. Clin. Oncol. Vol 24, No. 18S (June 20 Supplement), 2006: 14599.

188. Bonner J A, Harari P M, Giralt J, Cohen R. B, Baselga J M, Spencer S A, Azarnia N, Rowinsky E K, Amellal N, Ang K K. “EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab”
J. Clin. Oncol. Vol 24, No 18S (June 20 Supplement), 2006: 5510.
189. Cristofanilli M, Boussen H, Baselga J., Lluch A, Ben Ayed F, Friaaha M, Ben Ahmed S, Hurley J, Johnston S, Kaufman B, Findlay M, Olopade O, Shannon C, Harris J, Stein S, Spector N. “A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC)”
29th Annual San Antonio Breast Cancer Symposium. Dec, 2006.
190. Chow LWC, Sun Y, Jassem J, Baselga J., Hayes DF, Wolff AC, Hachemi S, Cincotta M, Yu BW, Kong S, Moore L. “Phase 3 study of temsirolimus with letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer”
29th Annual San Antonio Breast Cancer Symposium. Dec, 2006.
191. Scaltriti M, Rojo F, Jimenez J, Guzman M, Arribas J, Baselga J. “Lapatinib, a HER2 tyrosine kinase inhibitor, causes accumulation of inactive HER2 receptors at the cell surface”
98th AACR Annual Meeting, April 2007: 5236.
192. Cervantes A, Ciardiello F, Rivera F, Rojo F, Casado E, Rodriguez-Braun E, Martinelli E, Kisker O, Baselga J., Tabernero J. “Optimal dose of cetuximab administered every 2 weeks (q2w): A phase I safety, pharmacokinetics (PK) and pharmacodynamics (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC)”
J. Clin. Oncol. Vol 24, No 18S (June 20 Supplement), 2006: 3085.
193. Khambata-Ford S, Garrett C R, Clark E A, Basik M, Harbison C T, Wong T W, Huang X, Wu S, Takimoto C H, Godwin A K, Hidalgo M, Baselga J., Meropol N J, Mauro D J. “Expression of epiregulin and amphiregulin and *K-RAS* mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab (Erbix[®])”
J. Clin. Oncol. Vol 25, No 22 (August 1) 2007: 3230 – 3237.
194. Prat A, Del Campo J, Peralta S, Cedres S, Perez A, Gil A, Martinez-Palones J, Garcia A and Baselga J. “Validation of CA-125 concentration nadir within the normal range following primary treatment as a predictor of survival for epithelial ovarian cancer (EOC)”
J Clin Oncol. Vol 25, No 18S (June 20 Supplement), 2007: 16007.
195. Di Cosimo S, Scaltriti M, Val D, Rojo F, Guzman M, Jimenez J, Seoane J, Arribas J and Baselga J. “The PI3-K/AKT/mTOR pathway as a target for breast cancer therapy”
J Clin Oncol. Vol 25, No. 18S (June 20 Supplement), 2007: 3511.
196. Tabernero J, Cervantes A, Hoekman K, Hurwitz HI, Jodrell DI, Hamberg P, Stuart M, Green TP, Iacona RB and Baselga J. “Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers”
J Clin Oncol. Vol 25, No 18S (June 20 Supplement), 2007: 3520.

197. Chandarlapaty S, Scaltriti M, Baselga J, Ye Q, Solit D, Norton L and Rosen N. "Extracellular cleaved HER2 (p95) confers partial resistance to trastuzumab but not HSP90 inhibitors in models of HER2 amplified breast cancer".
J Clin Oncol. Vol 25, No 18S (June 20 Supplement), 2007: 10515.
198. Gianni L, Semiglazov V, Manikhas GM, Eiermann W, Lluch A, Tjulandin S, Feyereislova A, Vanhauwere B, Valagussa P and Baselga J. "Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis".
J Clin Oncol. Vol 25, No 18S (June 20 Supplement), 2007: 532.
199. Baselga J, Cameron D, Miles D, Verma S, Climent M, Ross G, Gimenez V and Gelmon K. "Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T".
J Clin Oncol Vol 25, No. 18S (June 20 Supplement), 2007: 1004.
200. McLoughlin P, Delmar P, Akimov M, Lutz Verena, Essioux L , Ward C, Tan E-H, Baselga J, Klughammer B, Gutjahr T. "Pharmacogenomics of Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC): Results from the Merit Study
Joint Cold Spring Harbor Laboratory/Wellcome Trust Conference
Pharmacogenomics October 2007.
201. Gardner H, Bandaru R, Barrett C, Calcaterra M, Crowell T, Decker J, Dixon M, Fisch R, Fuchs M, Gelb A, Hanoteau N, Jonat W, Lane H, Lebwohl D, Liu W-H, Molloy B, Pena C, Phillips P, Rheinhardt J, Rugo H, Salesky S, Steinseifer J, Stumm M, Tokaji E, Voelker F, Yarbrough G, Yateman N, Yu Y, Zuber E, Baselga J. "Biomarker analysis of a phase II double-blind randomized trial of daily oral RAD001 (everolimus) plus letrozole or placebo plus letrozole as neoadjuvant therapy for patients with estrogen receptor positive breast cancer".
30th Annual San Antonio Breast Cancer Symposium. Dec, 2007.
202. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Dixon JM, Jonat W, Rugo HS. "Phase II double-blind randomized trial of daily oral RAD001 (everolimus) plus letrozole (LET) or placebo (P) plus LET as neoadjuvant therapy for ER+ breast cancer".
30th Annual San Antonio Breast Cancer Symposium. Dec, 2007.
203. Fumoleau P, Wardley A, Miles D, Verma S, Gelmon K, Cameron D, Gianni L, Conte PF, Ross G, McNally V, Baselga J. "Safety of pertuzumab plus trastuzumab in a phase II trial of patients with HER2-overexpressing metastatic breast cancer which had progressed during trastuzumab therapy".
30th Annual San Antonio Breast Cancer Symposium. Dec, 2007.
204. Serra V, Markman B, Scaltriti M, Eichhorn P, Valero V, Guzman M, Di Cosimo S, Maira M, Garcia-Echevarria C, Baselga J. "NVP-BEZ-235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits growth of cancer cells with activating PI3K mutations".
AACR Meeting Abstracts, Apr 2008; 2008: 1429.

205. Scaltriti M, Verma C, Guzman M, Jimenez J, Smith D.J, Landolfi S, Ramon y Cajal S, Arribas J, Baselga J. “Lapatinib induces HER2 stabilization and enhances the antitumor activity of trastuzumab in vivo”. AACR Meeting Abstracts, Apr 2008; 2008: 2559.
206. Green T.P, Jacobs V.M, Womack C, Fennell M, Jones R, Finkelman R, Elvin P, Stuart M, Smith I, Iacona R.B, Tabenero J, Baselga J. “First demonstration of the inhibition of Src signaling in tumor tissue in humans using the Src inhibitor AZD0530”. AACR Meeting Abstracts, Apr 2008; 2008: 4960.
207. Boccardo F, Kaufman B, Baselga J, Dieras V, Link J, Casey MA, Fittipaldo A, Oliva C, Zembryki D, Rubin SD. Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU) . J Clin Oncol Vol 26, No. 15S (May 20 Supplement), 2008: 1094.
208. O'Shaughnessy J, Blackwell KL, Burstein H, Storniolo AM, Sledge G, Baselga J, Koehler M, Laabs S, Florance A, Roychowdhury D. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy . J Clin Oncol Vol 26, No. 15S (May 20 Supplement), 2008: 1015.
209. Gelmon KA, Fumoleau P, Verma S, Wardley AM, Conte PF, Miles D, Gianni L, McNally VA, Ross G, Baselga J. Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy . J Clin Oncol Vol 26, No. 15S (May 20 Supplement), 2008: 1026.
210. Markman B, Serra V, Scaltriti M, Valero V, Guzman M, Garcia-Echevarria C, Maira M, Baselga J. Pharmacodynamic (PD) endpoints and cellular proliferation effects of NVP-BEZ235, a dual PI3K/mTOR inhibitor, in breast cancer cells and xenografts with wild-type (WT) and activating PI3K mutations . J Clin Oncol Vol 26, No. 15S (May 20 Supplement), 2008: 14508.
211. Calvo-Aller E, Baselga J, Glatt S, Cleverly A, Lahn M, Arteaga CL, Rothenberg ML, Carducci MA. First human dose escalation study in patients with metastatic malignancies to determine safety and pharmacokinetics of LY2157299, a small molecule inhibitor of the transforming growth factor-beta receptor I kinase . J Clin Oncol Vol 26, No. 15S (May 20 Supplement), 2008: 14554.
212. Prat A, Parera M, Peralta S, Martínez P, Adamo B, Pérez-Benavente M, Gil-Moreno A, Garcia A, Martínez- Palones J, Baselga J, Del Campo J. Prognostic significance of elevated pretreatment serum CA-125 in patients (pts) with epithelial ovarian cancer (CEO) treated with surgery and platinum/taxane-based chemotherapy . J Clin Oncol Vol 26, No. 15S (May 20 Supplement), 2008: 22011.
213. Cervantes A, Macarulla T, Martinelli E, Rodriguez-Braun E, Ciardiello F, Stroh C, Nippgen J, Baselga J, Taberner J. Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent

- followed by cetuximab + FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC)
J Clin Oncol Vol 26, No. 15S (May 20 Supplement), 2008: 4129.
214. Scaltriti M, Verma C, Guzman M, Jimenez J, Parra J, Pedersen K, Landolfi S, Ramon y Cajal S, Arribas J, Baselga J. Effect of lapatinib on accumulation of inactive HER2 at the cell membrane and on antibody-dependent cellular cytotoxicity (ADCC) mediated by trastuzumab: A novel mechanism for the enhanced effects of combined anti-HER2 therapy .
J Clin Oncol Vol 26, No. 15S (May 20 Supplement), 2008: 3594.
215. Atzori F, Tabernero J, Cervantes A, Botero M, Hsu K, Brown H, Hanley W, Macarulla T, Rosello S, Baselga J. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors .
J Clin Oncol Vol 26, No. 15S (May 20 Supplement), 2008: 3519.
216. Baselga J, Van Dam PA, Greil R, Gardner H, Bandaru R, Molloy B, Steinseifer J, Phillips P, Dixon JM, Rugo HS. Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase II neoadjuvant trial in ER+ breast cancer .
J Clin Oncol Vol 26, No. 15S (May 20 Supplement), 2008: 530.
217. Delmar P, Tan EH, Pluzanska AG, Ramlau R, Reck M, McLoughlin P, Baselga J, on behalf of the MERIT investigators. MERIT: Analysis of differential gene expression in patients (pts) with advanced non-small-cell lung cancer (NSCLC) treated with erlotinib .
J Clin Oncol Vol 26, No. 15S (May 20 Supplement), 2008: 8046.
218. Saura C, Fortuny D, Ramon y Cajal T, Torres A, Graña B, Darder E, Sanz J, Brunet J, Baselga J, Balmaña J, IMASS Collaborative Group. Cancer screening practices (CSP) among women at risk of hereditary breast and ovarian cancer syndrome (HBOS) before genetic testing in Spain .
J Clin Oncol Vol 26, No. 15S (May 20 Supplement), 2008: 1538.
219. Quispe IR, Navalpotro B, Capdevila J, Ramos FJ, Macarulla T, Elez ME, Casado E, Baselga J, Giralt J, Tabernero J. Neoadjuvant chemoradiotherapy (CT-RT) in patients (pts) with stage II-IVA esophageal cancer (EC): Retrospective analysis of a Spanish single institution .
J Clin Oncol Vol 26, No. 15S (May 20 Supplement), 2008: 15635.
220. Cedrés Pérez S, Prat A, Felip E, Peralta S, Perez J, Del Campo J, Sala G, Andreu J, Pallisa E, Baselga J. Cutaneous rash as a surrogate marker of time to tumor progression 221. (TTP) with erlotinib in previously treated advanced non- small cell lung cancer (NSCLC) .
J Clin Oncol Vol 26, No. 15S (May 20 Supplement), 2008: 19125.
221. Gianni L, Eiermann W, Pusztai L, Semiglazov VF, Hoegel B, Koehler A, Manikhas G, Bates M, Valagussa P, Baselga J. Biomarkers as potential predictors of pathologic complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab

- in patients (pts) with HER2-positive locally advanced breast cancer (LABC) .
J Clin Oncol Vol 26, No. 15S (May 20 Supplement), 2008: 504.
222. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Baselga J, O Shaughnessy J. A randomized study of the efficacy and safety of lapatinib in combination with trastuzumab and as monotherapy after progression on trastuzumab in heavily pretreated ERBB2+metastatic breast cancer (MBC) .
Annals of Oncology 19(Supplement 8): viii137, 2008.
223. Burstein HJ, Wu Y, Blackwell K, Storniolo AM, Rugo H, Amonkar M, Ellis C, Sledge G, Baselga J, O Shaughnessy J. Lapatinib plus trastuzumab versus lapatinib monotherapy in trastuzumab-refractory ERBB2+ metastatic breast cancer (MBC) patients (PTS): Quality of life (QOL) assessment .
Annals of Oncology 19(Supplement 8): viii138, 2008.
224. Tabernero J, Hitt R, Cervantes A, Rolland F, Valverde C, Lalami Y, Baselga J, Shepherd S, Gansert J, Vermorken J. "Panitumumab (PMAB) administered with chemoradiotherapy (CRT) following induction chemotherapy (IC) in the treatment of patients (PTS) with loco-regionally advanced squamous cell carcinoma of the head and neck (SCCHN)".
Annals of Oncology 19(Supplement 8): viii690, 2008.
225. Klughammer B, Akimov M, Delmar PD, Gutjahr T, McLoughlin P, Rohr K, Ward C, Ramlau R, Tan E, Baselga J. "Merieda: Exploratory analysis of the tumor gene expression dataset from MERIT, a phase II study in advanced NSCLC patients treated with erlotinib".
Annals of Oncology 19(Supplement 8): viii228, 2008.
226. Baselga J, Di Cosimo S, Cortes J. "Emerging molecular therapies in breast cancer".
31st Annual San Antonio Breast Cancer Symposium. Dec, 2008.
227. Gianni L, Eiermann W, Semiglazov V, Manikhas GM, Lluch A, Tjulandin S, Feyereislova A, Valagussa P, Baselga J. "Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial".
31st Annual San Antonio Breast Cancer Symposium. Dec, 2008.
228. Guix M, Aura CM, Jimenez J, Scaltriti M, Gomez HL, Doval DC, Ellis C, Gagnon R, Liu Y, Koehler M, Baselga J. "Lapatinib is active in patients with HER2-amplified breast tumors expressing p95HER2".
31st Annual San Antonio Breast Cancer Symposium. Dec, 2008.
229. Baselga J, Imadalou K, Paton V, Gray D, Swain S. "Efficacy, safety and tolerability of dual monoclonal antibody therapy with pertuzumab + trastuzumab in HER2+ metastatic breast cancer patients previously treated with trastuzumab".
31st Annual San Antonio Breast Cancer Symposium. Dec, 2008.
230. Ellis MJ, Lin L, Crowder R, Tao Y, Evans DB, Steinseifer J, Bandaru R, Liu WH, Gardner H, Semiglazov V, Baselga J. "Phosphatidylinositol-3-kinase Alpha catalytic subunit kinase domain mutations impart a favorable prognosis on estrogen receptor positive breast cancer through a mechanism that is independent of responsiveness to endocrine treatment".

- 31st Annual San Antonio Breast Cancer Symposium. Dec, 2008.
231. Muehlbauer S, Revil C, Leyland-Jones B, Bell R, Baselga J, Marty M, Jones A, Feyereislova A. "Pooled cardiac safety analysis of patients with HER2-positive metastatic breast cancer receiving trastuzumab."
31st Annual San Antonio Breast Cancer Symposium. Dec, 2008.
232. Gianni L, Goldhirsch A, Gelber RD, Azambuja E, Procter M, Untch M, Smith I, Jackisch C, Cameron D, Muehlbauer S, Leyland-Jones B, Piccart-Gebhart M, Baselga J, Bell R, for the HERA study team. "Update of the HERA trial and the role of 1 year trastuzumab as adjuvant therapy for breast cancer."
The Breast, Volume 8, Supplement 1, March 2009, page S11, abstract S25.
233. Serra V, Eichhorn P, Scaltriti M, Prudkin L, Rodriguez O, Guzman M, Baselga J. "NVP-BEZ235, a dual inhibitor of PI3K and mTOR, induces MAPK phosphorylation in HER2 positive cells."
100th AACR Annual Meeting. April 2009.
234. Scaltriti M, Guzman M, Normant E, Jimenez J, Prudkin L, Aura C, Baselga J. "The Hsp90 inhibitor IPI-504 inhibits proliferation and tumor growth of HER2 overexpressing breast cancer cells with acquired trastuzumab resistance."
100th AACR Annual Meeting. April 2009.
235. Arts J, Smans K, Andries L, Floren W, King P, Van Nuffel L, Goris I, Goehlmann H, Rooney B, Palmer P, De Bie L, Bol K, Kraljevic S, Zhuang SH, Page M, Tabernero J, Baselga J, Dirix L, Schöffski P, Winkler H. "Preclinical and clinical pharmacodynamic activity of JNJ-26854165: A novel hdm2 antagonist in clinical development."
100th AACR Annual Meeting. April 2009.
236. Sobol RE, Nemunaitis J, Clayman G, Roth JA, Olivier M, Hainaut P, Agarwala S, Hrushesky W, Wells JR, Moore C, Hamm J, Yoo G, Baselga J, Murphy BA, Menander KA, Chada S, Licato L, Gibbons R, Goodwin WJ. "Biomarkers predict p53 gene therapy efficacy in recurrent squamous cell carcinoma of the head and neck (SCCHN)."
100th AACR Annual Meeting. April 2009.
237. Perez Garcia JM, Saura C, Muñoz E, Sanchez-Olle G, Gomez P, Di Cosimo S, Sabadell D, Cortes J, Baselga J, Bellet M. "Progesterone receptor (PR) negativity predicts pathological complete response (PCR) after neoadjuvant chemotherapy (NACT) in breast cancer (BC) patients (PTS).
Annals of Oncology 20(Supplement 2), May 2009: 53-54.
238. Perez Garcia JM, Saura C, Muñoz E, Sanchez-Olle G, Gomez P, Peg V, Sabadell D, Cortes J, Baselga J, Bellet M. "Role of progesterone receptor status (PR) as predictive factor of pathological complete response (pCR) to neoadjuvant chemotherapy (NACT) in breast cancer (BC) patients (pts)".
J Clin Oncol Vol 27, No. 15S (May 20 Supplement), 2009: 637.
239. Cortes J, Baselga J, Petrella T, Gelmon K, Fumoleau P, Verma S, Pivot X, Ross G, Szado T, Gianni L. "Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER2- positive breast cancer".

- J Clin Oncol Vol 27, No. 15S (May 20 Supplement), 2009: 1022.
240. Prudkin L, Aura CM, Jimenez J, Scaltriti M, Ellis C, Gagnon R, Arbushites M, Liu Y, Koehler M, Baselga J. “Clinical benefit of lapatinib-based therapy in patients with HER2-positive breast tumors expressing p95HER2”. J Clin Oncol Vol 27, No. 15S (May 20 Supplement), 2009: 1048.
241. Capdevila J, Clive S, Tabernero J, Lardelli P, Soto-Matos A, Baselga J, Piera A, Pardos I, Rye R, Smyth JF. “Phase I study of the novel anticancer drug PM00104 as a 24-hour IV infusion every 3 weeks (q3w) in patients (pts) with advanced solid tumors or lymphoma”. J Clin Oncol Vol 27, No. 15S (May 20 Supplement), 2009: 2568.
242. Macarulla T, Rodríguez-Braun E, Tabernero J, Roselló S, Baselga J, Lee Y, Manfredi M, Liu H, Fingert H, Cervantes A. “Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of the selective aurora A kinase (AAK) inhibitor MLN8054 in patients (pts) with advanced solid tumors”. J Clin Oncol Vol 27, No. 15S (May 20 Supplement), 2009: 2578.
243. Shapiro G, Kwak E, Baselga J, Rodon J, Scheffold C, Laird AD, Bedell C, Edelman G. “Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors”. J Clin Oncol Vol 27, No. 15S (May 20 Supplement), 2009: 3500.
244. Eskens FA, Ramos FJ, Burger H, de Jonge MJ, Wanders J, Lopez-Anaya A, Baselga J, Tabernero J. “First-in-human clinical, pharmacokinetic (PK), and pharmacodynamic (PD) phase I study of the first-in-class spliceosome inhibitor E7107 administered IV (bolus) on days 1, 8, and 15 every 28 days to patients with solid tumors”. J Clin Oncol Vol 27, No. 15S (May 20 Supplement), 2009: 3508.
245. Tabernero J, Dirix L, Schoffski P, Cervantes A, Capdevila J, Baselga J, Van Beijsterveldt L, Winkler H, Kraljevic S, Zhuang SH. “Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of HDM-2 antagonist JNJ-26854165 in patients with advanced refractory solid tumors”. J Clin Oncol Vol 27, No. 15S (May 20 Supplement), 2009: 3514.
246. Horak CE, Lee FY, Xu L, Galbraith S, Baselga J. “High β -III tubulin expression in triple-negative (TN) breast cancer (BC) subtype and correlation to ixabepilone response: A retrospective analysis.” J Clin Oncol Vol 27, No. 15S (May 20 Supplement), 2009: 3587
247. Saura C, Baselga J, Herbst R, del Campo J, Marotti M, Tessier J, Collins B, Heymach J. “Antitumor activity of cediranib in patients with metastatic or recurrent head and neck cancer (HNC) or recurrent non-small cell lung cancer (NSCLC): An open-label exploratory study.” J Clin Oncol Vol 27, No. 15S (May 20 Supplement), 2009: 6023.
248. Baselga J, Gianni L, Gradishar WJ, Hudis C, Perez EA, Piccart-Gebhart M, Schwartzberg LS, Sledge G, Fleming TR. “Phase IIb double-blind, randomized, placebo-controlled trials for the efficacy and safety of sorafenib in patients (pts) with metastatic or locally advanced breast cancer (BC): Review of the Trials to Investigate the Effects of Sorafenib in BC (TIES) program.”

- J Clin Oncol Vol 27, No. 15S (May 20 Supplement), 2009: e12000.
249. Serrano C, Cortes J, Bellet M, Gómez P, Saura C, Martínez P, Pérez J, Atzori F, Baselga J, Di Cosimo S. “Trastuzumab in the elderly: Is it age or cardiovascular risk profile that really matters?”. J Clin Oncol Vol 27, No. 15S (May 20 Supplement), 2009: e20527.
250. Donovan MJ, Puig P, Erill N, Clayton M, Hamann S, Khan F, Powell D, Costa J, Cordon-Cardo C, Baselga J. “Employing multiplex immunofluorescence to quantify Her2 and phosphorylated Her2 in formalin-fixed, paraffin-embedded breast tumor specimens.” Breast Cancer Res, Volume 11, Supplement 1, 2009, page S19.
251. Baselga J, Segalla GM, Roché H, del Giglio A, Ciruelos EM, Filho SC, Gomez P, Lluch A, Llombart A, Costa F. “SOLTI-0701: A double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with capecitabine (CAP) in patients (pts) with locally advanced”. Eur J Cancer Supplements, Vol. 7, No 3, September 2009, Page 3: 3LBA.
252. Badve S, Shen C, Thorat M, Li L, Gagnon R, Koehler M, Ellis C, O'Shaughnessy J, Baselga J, Sledge G. “Identification of gene expression profiles that predict response to HER2-targeted therapy”. Eur J Cancer Supplements, Vol. 7, No 3, September 2009, Page 5: 5BA.
253. Serrano C, Cortes J, Russillo M, Bellet M, Gómez P, Saura C, Pérez J, Carreras MJ, Baselga J, Di Cosimo S. “Trastuzumab-related cardiotoxicity in the elderly: which role for cardiovascular risk factors?”. Eur J Cancer Supplements, Vol. 7, No 2, September 2009, Page 216: O-4005.
254. Serrano C, Cortes J, Russillo M, Bellet M, Gomez P, Saura C, Perez J, Farriols A, Baselga J, Di Cosimo S. “Adjuvant docetaxel and cyclofosfamide in breast cancer patients over 65 years: compliance and toxicity”. Eur J Cancer Supplements, Vol. 7, No 2, September 2009, Page 218: P-4012.
255. Martinez P, Valverde C, Morales R, Rodon J, Suarez C, Baselga J, Carles J. “Docetaxel activity in second line treatment for urothelial carcinoma: a retrospective analysis”. Eur J Cancer Supplements, Vol. 7, No 2, September 2009, Page 448: P-7184.
256. Jerusalem G, Ellard S.L, Fasolo A, Awada A, Manlius C, Vittori L, Massacesi C, Sahnoud T, Moldovan C, Baselga J. “Non-Infectious pneumonitis in breast cancer patients treated with everolimus containing therapy: Analysis of five studies”. San Antonio Breast Cancer Symposium, December 10, 2009.
257. Baselga J, Grupo Español de estudio tratamiento y otras estrategias experimentales en tumores sólidos, Roché H, Costa F, Getúlio Martins Segalla J, Pinczowski H, Ma Ciruelos E, Cabral Filho S, Gómez P, Van Eyll B. “SOLTI-0701: A multinational double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with Capecitabine in patients with locally advanced or metastatic breast cancer”. San Antonio Breast Cancer Symposium, December 11, 2009.

258. Ma X-J, Bandaru R, Letzkus M, Philips P, Barrett JC, Erlander M, Goetz M, Sgroi D, Gardner H, Baselga J. “HOXB13 May predict response to neoadjuvant Letrozole in patients with estrogen receptor-positive breast cancer”.
San Antonio Breast Cancer Symposium, December 11, 2009.
259. Baselga J, Cortés J, Fumoleau P, Petrella T, Gelmon K, Verma S, Pivot X, Ross G, Szado T, Gianni L. “Pertuzumab and Trastuzumab: Re-responses to 2 biological agents in patients with HER2 – positive breast cancer which had previously progressed during therapy with each agent given separately: A new biological and clinical observation”.
San Anotnio Beast Cancer Symposium, December 12, 2009.
260. Blackwell K.L, Burstein H.J, Sledge G.W, Stein S, Ellis C, Casey M, Baselga J, O’Shaughnessy J. “Updated survival analysis of a randomized study of Lapatinib alone or in combination with Trastuzumab in women with HER2-positive metastatic breast cancer progressing on Trastuzumab therapy”.
San Antonio Breast Cancer Symposium, December 12, 2009.

Book Chapters:

1. Kemeny N, Baselga J Regional chemotherapy of colorectal cancer. In: Abad A. Ed. *Medical Treatment of Colorectal Cancer*. Monterrey , Madrid, 1991, pp. 175-206.
2. Baselga J, Dmitrovsky E. Retinoids in Teratocarcinoma. In: Hong WK and Lotan R. Ed. *Retinoids in Oncology*. New York: Marcel Dekker Inc. 1993.
3. Baselga J, Mendelsohn J. Interaction of biologic agents with chemotherapy. In: DeVita Jr. VT, Hellman S, Rosenberg SA, Ed. *Biologic Therapy of Cancer*. 2nd ed. JB Lippincott, Philadelphia, 1995: 863-876.
4. Mendelsohn J, Baselga J Antibodies to Growth Factors and Receptors. In: DeVita Jr. VT, Hellman S, Rosenberg SA, Ed. *Biologic Therapy of Cancer*. JB Lippincott, Philadelphia, 1995:607-624.
5. Baselga J, Mendelsohn J. Monoclonal Antibodies Directed Against Growth Factor Receptors. In: Rosenberg SA, Ed. *Principles and Practice of the Biologic Therapy of Cancer*. 3rd ed. Lippincott Williams & Wilkins, Philadelphia, 2000: 475-489.
6. Baselga J, Albanell J. Epitelial growth factor receptor interacting agents. In: Hidalgo M, Ed. *Hematology /Oncology Clinics of North America. Targeted Theraphies*. W.B.Saunders Company, Volumen 16, Number 5, 2002:1041-1063.
7. Baselga J Treatment of Breast Cancer with Trastuzumab (Herceptin). Anti-EGFR family tyrosine kinase inhibitors. In: Baselga J, Hudis C. A. Ed. *Breast Cancer Therapy*. Martin Dunitz, Taylor & Francis Group, 2003:107-125; 195-202 .
8. Felip E, Baselga J. Receptor Tyrosine Kinase Abnormalities in Lung Cancer. In: Harvey I.Pass, David P.Carbone, David H.Johnson, John D.Minna, Andrew

- T.Turrisi, III, Ed. *Lung Cancer*. 3rd Edition. Lippincott Williams & Wilkins, Philadelphia, 2005:147-159.
9. Baselga J Targeting of the EGFR As a Modulator of Cancer Chemotherapy. In: Gary K. Schwartz, Ed. *Combination Cancer Therapy*. Humana Press Inc. New Jersey, 2005:1-26.
10. Baselga J, Cortes J. Epidermal growth factor receptor pathway inhibitors. In: Giaccone G. Schilsky R. Sondel P. Ed. *Cancer Chemotherapy and Biological Response Modifiers*. Elsevier, Amsterdam, 2005:205-223.
11. Baselga J. Newer Targeted Therapy in Breast Cancer. In: Harris JR, Lippman, ME, Morrow M, Osborne CK. Ed. *Diseases of the Breast*. 4th Edition. Lippincott Williams & Wilkins, Philadelphia, 2010:971-979.

Laboratory Research Funding:

Completed Research Support:

- **Genentech Inc.**
“Inhibition of HER2 Ectodomain Cleavage by Herceptin”
DATE: 1999-2001
MAIN INVESTIGATOR: Dr. José Baselga
- **FIS 01/0040-02**
“Caracterización de la expresión y activación de Akt en pacientes con cáncer de mama: Asociación con las formas completa y truncada de HER2”
DATE: 2001-2004
MAIN INVESTIGATOR: Dr. José Baselga
- **Bristol-Myers Squibb Pharmaceutical Research Institute**
” Estudios Farmacogenómicos en cáncer de mama”
DATE: 2002- 2006
MAIN INVESTIGATOR: Dr. José Baselga
- **Red Temática de Cáncer (C03/10)**
Instituto Carlos III
DATE: 2003- 2004
MAIN INVESTIGATOR: Dr. José Baselga y Dr. Joaquín Arribas
- **SAF2003-03818 (MCyT)**
“Optimización del tratamiento anti-tumoral con inhibidores del Receptor del Factor de Crecimiento Epidérmico (EGFR) y sus vías de señalización mediante uso”
DATE: 2003-2005
MAIN INVESTIGATOR: Dr. José Baselga
- **Bristol-Myers Squibb Foundation, Inc**
“Extracellular remodelling and angiogenesis”
DATE: 2002-2006
MAIN INVESTIGATOR: Dr. José Baselga

- **The Breast Cancer Research Foundation**
“The PI3-K/ Akt/mTOR pathway. A novel target for breast cancer therapy”
DATE: 2003-2004
MAIN INVESTIGATOR: Dr. José Baselga
- **The Breast Cancer Research Foundation**
“The PI3-K/ Akt/mTOR pathway. A novel target for breast cancer therapy”
DATE: 2004-2005
MAIN INVESTIGATOR: Dr. José Baselga
- **The Breast Cancer Research Foundation**
“Truncated intracellular HER-2 C-terminal fragments and trastuzumab resistance”
DATE: 2005-2006
MAIN INVESTIGATOR: Dr. José Baselga
- **The Breast Cancer Research Foundation**
“Mechanisms of resistance to anti-HER2 therapies in HER2 positive breast tumors”
DATE: 2006-2007
MAIN INVESTIGATOR: Dr. José Baselga
- **The Breast Cancer Research Foundation**
“Mechanisms of resistance to Anti-HER2 and downstream signalling pathways therapies in Breast Cancer”
DATE: 2007-2008
MAIN INVESTIGATOR: Dr. José Baselga
- **Ref. C03/10**
“Red de Centros “Genómica del Cáncer. Genotipado de tumores. Mecanismos moleculares en el desarrollo y progresión del cáncer. Nuevas estrategias diagnósticas y terapéuticas”
DATE: 2003 - 2006
MAIN INVESTIGATOR: Dr. Joaquín Arribas y Dr. José Baselga
- **Ref. 2005SGR 00439**
“SGR Suport a Grups de Investigació de Qualitat”
DATE: 2005 - 2007
MAIN INVESTIGATOR: Dr. José Baselga
- **Ref. Lapatinib Her2 (p95)**
“Análisis de la sensibilidad a lapatinib del cáncer de mama Her2 positivo cuyas células expresan las formas truncadas del dominio intracelular C-terminal de los receptores Her2 (p95)”
DATE: 2006-2007
MAIN INVESTIGATOR: Dr. José Baselga

Ongoing Research Support:

- **Ref. PI061647**
“Truncated intracelular HER2 C-terminal fragments and trastuzumab resistance”
DATE: 2006-2009
MAIN INVESTIGATOR: Dr. José Baselga

- **Ref. IST-2004-027265 (SIMAP)**
“Simulation modelling of the MAP kinase pathway”
DATE: 2006- 2009
MAIN INVESTIGATOR: Dr. José Baselga
- **Ref. RD06/0020/0075. ISCIII.**
Red Temática de Investigación Cooperativa en Cáncer (RTICC) del Instituto de Salud Carlos III, MSC
DATE: 2006- 2008
MAIN INVESTIGATOR: Dr. José Baselga
- **LSHC-CT-2004-503426**
“TRANSBIG”
DATE: 2005-2011
MAIN INVESTIGATOR: Dr. José Baselga
- **FIS Grant Award Ref. PI061647. ISCIII.**
“Truncated intracellular HER2 C-terminal fragments and trastuzumab resistance”
DATE: 2007- 2009
MAIN INVESTIGATOR: Dr. José Baselga
- **The Breast Cancer Research Foundation**
“Overcoming resistance to Anti-HER2 and PI3K inhibitors therapies in breast cancer”
DATE: 2008-2009
MAIN INVESTIGATOR: Dr. José Baselga
- **The Breast Cancer Research Foundation**
“Novel Cancer Therapies to overcome resistance to anti-HER2 and PI3K inhibitor in breast cancer”
DATE: 2009- 2010
MAIN INVESTIGATOR: Dr. José Baselga
- **Eurosalud Ref. AI0790045. ISCIII.**
“Simulation modelling of the MAP Kinase Pathway”
DATE: 2007- 2010
MAIN INVESTIGATOR: Dr. José Baselga
- **SU2C: Dream Team Translational Cancer Research Grant**
“Targeting PI3K in Women’s Cancer”
DATE: 2009-2012
MAIN INVESTIGATOR: Dr. José Baselga
- **Novartis Ref. CIBOT**
“Overcoming resistance to anti-HER2 therapy with PI3K inhibitors “
“Anticipating emerging resistance to PI3K pathway inhibition”
DATE: 2009- 2011
MAIN INVESTIGATOR: Dr. José Baselga
- **Genentech, Inc**
“In vitro and in vivo activity of the AKT inhibitor GDC-0068 in breast cancer cells”
DATE: 2009-2009
MAIN INVESTIGATOR: Dr. José Baselga

- **Breast International Group (BIG) NEO ALTTO**
“Neo-adjuvant lapatinib and/ or Trastuzumab Treatment Optimisation Study”
DATE: 2009-2012
MAIN INVESTIGATOR: Dr. José Baselga
- **Ref. 2009SGR 00342**
“SGR Suport a Grups d’Investigació de Qualitat”
DATE: 2009- 2011
MAIN INVESTIGATOR: Dr. José Baselga
- **Fidelity UK Foundation**
“Towards Personalized Medicine in Cancer: Acquisition of a Sequenom MassARRAY Platform to match the right patient with the right anti-cancer therapy“
DATE: 2009- 2010
MAIN INVESTIGATOR: Dr. José Baselga